Conclusions: 1. Regardless of the scoring system used, there was a trend towards higher expression of HER2 in HGUC compared to LGUC, and in MPUC compared to both HGUC and LGUC. In addition, overexpression of HER2 is seen in higher stage MPUC. These data suggest that HER2 overexpression may be prognostically signifi cant. 2. The GC scoring system appears to correlate better with tumor stage grade than the BC system. The true prognostic and therapeutic relevance of this fi nding, however, will be dependent upon further studies comparing IHC scoring systems in conjunction with gene amplifi cation studies and the potential clinical trial of HER2-target therapy. B Zhu, X Lin, S Rohan, M Zhong, R Goyal, E Gersbach, X Yang. Northwestern University, Chicago. Background: In normal human tissues strong nuclear p63 protein expression is present in the basal layer of stratified squamous and transitional epithelia. Immunohistochemistry (IHC) for p63 is frequently used in clinical practice to aid in diagnosing urothelial carcinoma (UC). However, loss of p63 expression has been described in high stage UC. Micropapillary urothelial carcinoma (MPUC) is a variant of bladder cancer with an aggressive behavior that frequently presents at an advanced stage. The aim of our study was to investigate p63 IHC in MPUC in comparison to conventional UC of different grades and stages. Design: IHC for p63 expression was performed on paraffi n embedded tissue sections of 23 cases of HGUC, 20 cases of low grade urothelial carcinoma (LGUC) and 20 cases of MPUC. IHC staining was scored semiquantitatively as follows: 0 (no reactivity); 1+ (< 10% cells labeling); 2+ (10 -50% cells labeling); 3+ (50 -75% positive); 4+ (75-90% positive); and 5+ (> 90% positive). Only nuclear labeling was considered positive. Results: p63 expression was identifi ed in non-neoplastic surface urothelium in all MPUC cases, however, the MPUC tumor cells were negative for p63 (Table 1) . 22% of high stage (pT2 or pT3) HGUC were also negative for p63. Additionally, 22% of pT2 or pT3 HGUC showed only 1+ labeling. In contrast, 60% of low stage (pTis or pT1) HGUC exhibited more than 3+ labeling. Finally, 70% of LGUC exhibited 5+ (more than 90% tumor cells) labeling for p63. Conclusions: Our study indicates that p63 IHC is negative in the majority of MPUC cases. Additionally, 44% of high stage (≥ pT2) HGUC exhibited no more than focal (<10% of cells) labeling for p63. All of our LGUCs were positive for p63. Our fi ndings suggest that decreased p63 expression in UC is more common in tumors with aggressive features. Future studies evaluating the utility of p63 as a prognostic marker in UC are warranted. 
Decreased p63 Expression Is Common in Micropapillary Urothelial Carcinoma (MPUC) and High Grade Urothelial Carcinoma (HGUC)

Conclusions:
Tumor size showed signifi cant association with prognostic variables such as LVI, MI and recurrence in USC. Based on this preliminary data, larger studies would be useful in testing the validity of this variable as an independent prognostic indicator for these tumors. (n=26) 10 (38) 23 (88) 20 (77) 22 (85) Grade 2 EMC (n=12) 8 (67) 12 (100) 12 (100) 12 (100) Grade 3 EMC (n=11) 10 (91) 11 (100) 10 (91) 10 (91) Non-endometrioid Carcinoma (n=6) 5 (83) 6 (100) 6 (100) n sign * not available in exophytic tumors; +ve: positive; -ve: negative n sign -not signifi cant DR was statistically correlated with TS>4cm(p=0.008), LNM(p=0.023) and RM≤1mm(p=0.014) . No correlation was found regarding VI, ICW and VM and disease recurrence. TS and LNM were not statistically associated between themselves but RM was signifi cantly correlated with TS(p=0.014), LNM(p=0.007) and ICW(p=0.0001). VI was associated with the presence of LNM and deep ICW (p=0.0009 and p=0.0001, respectively) . Conclusions: In our series of cervical SCC, the tumor size, lymph node metastases and distance to radial margin were signifi cantly associated with disease recurrence. Distance to radial margin is a useful marker of disease recurrence in radical hysterectomies, however this parameter was signifi cantly associated with TS and LN status.
Levels and P16 Are Valuable Adjuncts in the Evaluation of Cervical Cone or Loop Electrosurgical Excision Procedure (LEEP) Specimens
Initially Considered Negative for Dysplasia AB Carrigg, N Weidner, G Lin, M Peterson, F Hasteh . University of California San Diego Medical Center, San Diego, CA. Background: At University of California San Diego Medical Center an average of 19% of the cervical cone biopsies are negative for dysplasia or malignancy. In order to identify sources of misdiagnosis and error, we evaluated the cause and outcomes of these cervical conization specimens. Design: Fifty one cone biopsies with an original negative diagnosis were selected at UCSDMC. These specimens and the presurgical Pap smears, biopsies and endocervical curettages (ECC) were reviewed by up to 6 surgical pathologists in order to obtain a consensus diagnosis. Deeper levels and then p16 immunostains were performed on all the cone cases and select biopsy sections. Results: Please see fi gure 1.
Conclusions:
Our results suggest four categories of cases. MISSED DYSPLASIA IN CONE SPECIMEN: In 35.3% of cases the original cone diagnosis was overturned to positive (SIL, LSIL or HSIL). SAMPLING ERROR: For cases with confi rmed pre-surgical diagnosis of HSIL but negative cone specimen, 6 of the original 51 cases (11.8%) were found to have dysplasia or even invasive squamous cell carcinoma on subsequent follow-up, suggesting that the conization sampling may have been incomplete due to factors that complicated the surgical procedure. PRESURGICAL SPECIMEN OVERCALLED AS HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION (HSIL): In 29.4%, conization was not clinically indicated, due to an overcall of HSIL on the preceding Pap smear, cervical biopsy, or ECC. PRESURGICAL MATERIAL CONFIRMED AS HSIL, WITH NEGATIVE CONE AND NEGATIVE FOLLOWUP: In 17.6% of cases, no errors were detected in either pre-surgical or conization diagnosis and the patient had negative subsequent follow-up. The implications of this category are unclear, but could result from either incomplete tissue examination, regression of the lesion, or possibly complete excision of small foci of HSIL by biopsy. Our results, taken as a whole, emphasize the necessity for close clinical follow up, liberal use of p16 immunohistochemistry, examination of deeper level sections, review of prior material, and consensus group review to reduce errors in the pathologic workup of cervical dysplasia.
Results: 55 patients with early invasive cervical adenocarcinoma were identifi ed. 50 patients (91%) had FIGO 1A1 tumors and 5 patients (9%) had FIGO 1A2 tumors. 46 (84%) of the patients had radical surgery consisting of radical hysterectomy with pelvic lymph node dissection (PLND) (44 patients) or radical trachelectomy with PLND (2 patients). 9 patients (16%) received conservative surgery consisting of simple hysterectomy (4 patients) or cervical conization (5 patients). No lymphovascular space invasion was identifi ed, fi nal margins were clear in all cases and no lymph node metastases were identifi ed in the patients who underwent PLND. Follow up information was available for 54 of 55 patients with a mean follow of 7 years. 21 of 46 patients (46%) who underwent radical surgery experienced complications --5 cases of lymphedema (of which one case resolved), 1 case of severe peripheral neuropathy, and 16 cases of transient bladder or sexual dysfunction. In the conservatively managed patients, 1 patient (11%) experienced a post conization infection. No recurrences have been reported to date. Conclusions: This is the largest reported case series of FIGO 1A1 and 1A2 cervical adenocarcinoma. No lymph node metastases nor recurrences were identifi ed in this cohort of 55 patients, yet 5 of 46 patients (11%) who underwent radical surgery experienced signifi cant long term complications. Conservative surgery should be considered in this low risk patient population.
STMN1 Expression Is Associated with FIGO Grade and Presence of Cervical Involvement in Uterine Endometrioid
Carcinoma JSY Chan, LH Ellenson. NYP-Weill Cornell Medical Center, New York City, NY. Background: Endometrial carcinoma is the most common cancer of the female genital tract in the US. Currently, there are few molecular prognostic markers. Our previous research has shown that while PTEN and PI3KCA mutations are common in uterine endometrioid carcinoma (UEC), they do not correlate with FIGO grade. Stathmin (STMN1) regulates microtubule dynamics in cell proliferation. Its expression is associated with activation of the phosphatidylinositol 3-kinase (PI3K) pathway, and its expression has been shown to correlate with grade and other clinicopathologic features in UEC. In this study, we evaluated UEC for expression of STMN1 as a possible prognostic marker. Design: A tissue microarray was constructed using tumor tissue from 68 cases of UEC grade 1, 66 cases of UEC grade II, and 20 cases of UEC grade III. Samples of proliferative and secretory endometrium were also included in the analysis. STMN1 expression was detected using standard immunohistochemical staining with polyclonal STMN1 antibody (#3352, Cell Signaling). STMN1 expression was scored by extent of staining (0=absent, 1=<10%, 2=10-50%, 3=>50%). Institutional IRB approval was obtained for this study. Results: The average STMN1 staining score for grade I tumors was 0.6 (σ=0.13), grade II was 1.01 (σ=0.16), and grade III was 2. 36 (σ=0.25) . Tumors that invaded the cervix had an average STMN1 score of 1.5 (σ=0.13) while tumors without cervical involvement had an average STMN1 expression of 0.9 (σ=0.13), p=.025. There was no statistically signifi cant correlation between STMN1 staining and other histological/ clinical tumor attributes including depth of invasion, lymph node metastasis, or mucinous tumor phenotype. Conclusions: In this study, we demonstrate that STMN1 expression is signifi cantly different between FIGO grades in UEC with increased mean levels of expression in higher FIGO grades. Additionally, tumors with cervical involvement have statistically signifi cant levels of STMN1 staining. The association between STMN1 expression and FIGO grade suggests that alterations in the PI3K pathway downstream of PI3K activation could correlate to increasingly aggressive tumor phenotype. Given the association between STMN1 expression and cervical invasion, STMN1 may serve as a molecular marker of direct local extension rather than distant metastatic spread. Future directions include examining STMN1 expression as a predictive marker of response to microtubule inhibitors in endometrial carcinoma.
mTOR and STMN1 Expression Is Associated with Type I Endometrial Carcinoma
JSY Chan, LH Ellenson. NYP-Weill Cornell Medical Center, New York City, NY. Background: Endometrial carcinoma is the most common cancer of the female genital tract in the US. Endometrial carcinoma is broadly classifi ed as Type 1 (low grade carcinoma with endometrioid histology with good prognosis) and Type 2 (high grade carcinoma with serous or clear cell histology with aggressive behavior), which also have different molecular genetic profi les. Our previous research has shown that Type 1 cancers have gene mutations in both PTEN and PIK3CA, however Type 2 cancers are associated with only PIK3CA gene mutations. Mammalian target of rapamycin (mTOR) and stathmin (STMN1) expression are associated with activation of the phosphoinositide 3-kinase (PI3K) pathway. In this study, we evaluated Type 1 and Type 2 endometrial carcinomas for expression of mTOR and STMN1 for use as possible prognostic markers. Design: A tissue microarray was constructed using tumor tissue from 153 cases of Type 1 carcinoma (FIGO 1=68, FIGO 2=65, FIGO 3=20) and 34 cases of Type 2 carcinoma (serous type). Samples of proliferative and secretory endometrium were also included in the analysis. mTOR and STMN1 expression were detected using standard immunohistochemical staining with rabbit monoclonal mTOR antibody (clone 49F9, Cell Signaling) and polyclonal STMN1 antibody (#3352, Cell Signaling). Expression was scored by extent of staining (0=absent, 1=<10%, 2=10-50%, 3=>50%). Institutional IRB approval was obtained for this study. Results: The average mTOR staining score for Type 1 tumors was 2.1(σ=0.17), while the average mTOR score for Type 2 tumors was 1.7(σ=0.10). The average STMN1 staining score for Type 1 FIGO 3 tumors was 2.4 (σ=0.3), while the average STMN1 score for Type 2 tumors was 0. 94 (σ=0.24) . This difference in staining score between Type 1 and Type 2 endometrial tumors was statistically signifi cant with p < 0.05. Neither STMN1 nor mTOR staining scores were signifi cantly different when samples were evaluated for other tumor characteristics including depth of invasion or lymph node involvement. Conclusions: Type 1 endometrial carcinoma revealed higher mTOR and STMN1 staining scores than Type 2. In STMN1 staining, this difference is only seen in Type 1 FIGO grade 3 tumors; however, the association between mTOR staining and Type 1 carcinoma was independent of FIGO grade. The increased mTOR and STMN1 expression may be a refl ection of underlying PTEN mutations. Further studies are necessary to address this possibility. mTOR and STMN1 may be useful molecular markers in distinguishing Type 1 versus Type 2 endometrial carcinoma regardless of other confounding factors. Background: Endometrial stromal sarcomas (ESSs) were historically divided into low-and high-grade based on mitotic index (MI), with brisk MI (>10/10 HPF) being considered a poor prognostic factor. Since then, there have been confl icting studies regarding the prognostic value of MI in these tumors. The presence of tumor cell necrosis (TCN) in ESSs has also been recently reported to correlate with aggressive behavior in tumors confi ned to the uterus. The aim of this study is to evaluate the utility of MI and TCN in primary uterine low-grade ESSs in predicting patient outcome. Design: We reviewed all available slides of primary uterine low-grade ESS from 33 patients with clinical follow-up from 3 institutions. MI, as determined by number of mitoses/10 HPF averaged over 100 HPF, and presence or absence of TCN and infarcttype necrosis (ITN) were recorded. Progression-free and overall survival probability based on MI, TCN, and ITN was estimated by the Kaplan-Meier method. Results: Twenty-one patients presented with stage I tumors, while 3, 4, and 5 patients had stage II, III, and IV disease, respectively. MI ranged from <1 to 22, <1 to 5, <1 to 26, and <1 to 5 per 10 HPF for stage I, II, III, and IV tumors, respectively. Sixteen tumors, including 10 stage I ESSs, showed MI <1/10 HPF, and in this group, 3 patients (stages I, II, and IV) experienced one or more relapses, and 2 died of disease (stages I and II) . Of the 17 tumors with MI ≥1/10 HPF, 6 patients relapsed (4 stage I with MI ranging from 4 to 22/10 HPF, 1 stage III, 1 stage IV), and 1 died of disease (stage I with 22 mitoses/10 HPF). ITN was present in 12 ESS (9 stage I), and 5 of them also showed juxtaposed focal TCN. Among patients with tumors exhibiting TCN, only 2 had relapses (stage II and IV, both with MI <1/10 HPF) of whom 1 died of disease. Among patients with tumors showing either ITN or TCN, only 3 relapsed of whom 2 died of disease. Progression-free and overall survival data based on MI, TCN, and TCN or ITN were not statistically signifi cant for tumors confi ned to the uterus or the entire cohort. Conclusions: Although the number of patients is limited in this study, MI, TCN, and ITN do not appear to be predictive of tumor progression or outcome in patients with low-grade ESS, including those with stage I tumors. Conclusions: Our data, the largest study size to date, shows a very low incidence of CIN2/3 among women in this subgroup. Females with ASC-H Pap tests and negative hrHPV testing may be more effi ciently managed by regular Pap and hrHPV testing rather than universal colposcopy. Additional long term follow-up studies are needed on patients with hrHPV testing and divergent cytology results utilizing new methods of cytology screening. are aggressive malignant tumors with moderate to marked cytological atypia and little resemblance to proliferative-phase endometrial stroma. Unlike ESS, U-ESS doesn't generally harbor a JAZF1/JJAZ1 chromosomal rearrangement. Recently, a rearrangement of (WYHAE) on 17p13 with FAM 22 A-B on chromosome (Chr) arm 10q has been described in U-ESS. The aim of our study was to evaluate the frequency of WYHAE rearrangement and to look for a correlation with morphology. Design: We collected 29 cases of U-ESS from our Department diagnosed between 1995 and 2011. At the morphological level, we distinguished the U-ESS Uniform (U-ESS-U) and pleiomorphic (U-ESS-P) types according to Kurihara S et al criteria. An immunohistochemical study including CD10, H-caldesmon and desmin was performed. FISH analysis using break-apart probes targeting the WYHAE gene on chr17p13 and JAZF1gene on chr7p15 was performed on paraffi n-embedded tissue sections. In-house FISH probes were selected and validated on chromosome spreads. Results: Mean age at diagnosis was 58.6 years (31 to 93). 22/29 (76%) tumors expressed CD10 marker. Only 2/29(7%) and 2/29(7%) cases showed a weak and heterogeneous positivity for desmin and H-caldesmon, respectively. The tumors expressed estrogen and progesterone receptors in 6/27 (22%) and 8/28 (28%) respectively. FISH was interpretable in 22/29 cases. 9/22 (41%) cases showed a WYHAE chromosomal rearrangement of which 8/9 (89%) showed a uniform morphology (U-ESS-U): 2 with fi bromyxoid features, 3 with spindle morphology and 1 with spindle and epithelioid appearance. Only one case (1/9) (11%) showed a pleomorphic morphology (U-ESS-P).
Do Mitotic Index and Tumor Cell Necrosis Predict
YWHAE Rearrangement Identified by FISH in a Series
No chromosomal rearrangement for JAZF1-JJAZ was detected. Three hybridization profi les were observed: 1 chromosomal rearrangement for YWHAE and 1 normal Chr 17; 1 chromosomal rearrangement for YWHAE and the loss of other Chr 17 and 1 chromosomal rearrangement for YWHAE and a gain of the non-rearranged Chr 17. Never less these tumors showed a very unstable chromosomal profi le with loss or gain of part of chromosomes. Conclusions: YWHAE t(10;17) rearrangement was found in 41% U-ESS in our series and correlated with the uniform, spindle and fi bro-myxoid variant. Background: Small cell carcinoma hypercalcemic type (SCC-HT) is a unique ovarian cancer of unknown histogenesis with highly consistent clinicopathologic features and aggressive behaviour. Consistent immunohistochemical markers, other than weak expression of cytokeratins and a strong vimentin immunoreaction, are lacking. We tried to identify genetic alterations in 21 of these rare neoplasms. Design: Twenty cases were seen in consultation over a 19-years period and one was from the hospital fi les. Twenty juvenile granulosa cell tumors (JGCT) were used as controls. A tissue microarray (TMA) was stained with AE1/AE3, vimentin, p53, WT1, and FOXL2. We also investigated mutation of the TP53 gene (exons 5-8) and the KRAS gene (exon 2, codons 12 and 13) by direct sequencing.
Results:
The mean age of the patients was 22 years (range 10-39) and the tumor size 15 cm (range 7-20 cm). Nine cases were confi ned to the ovary (stage I) and 12 had widespread tumor (stage III). Necrosis was found in 14 cases and the average mitotic rate was 15 (range: 4-27 MF x 10HPF). Twelve patients died of their disease within 2 years, and 5 were alive with disease 1-2 postoperatively. Three patients were alive and well at 2, 4, and 6 years. Tumor stage was a strong prognostic factor. All 21 tumors were focally immunoreactive for cytokeratins AE1/AE3, and 14 tumors exhibited diffuse immunoreaction for vimentin. Tumor cells showed low to moderate immunohistochemical expression of p53 in a mean of 36.25% of cells (range 5-68%). Eighteen cases exhibited WT1 positivity, 9 with 3+ intensity. FOXL2 immunostaining was expressed in 14 of 19 JGCTs, but in none of the SCC-HTs. Neither p53 nor K-RAS mutations were found in any case.
Conclusions:
Although the diagnosis of SCC-HT was easily made by H&E stained sections, there was a striking lack of reliable molecular markers. Focal positivity with AE1/AE3 and diffuse WT1 immunoreaction suggests an epithelial origin. In diffi cult cases, negative staining with FOXL2 may aid in the differential diagnosis with JGCT. p53 immunoreaction was not supported by p53 gene mutation. The absence of both, p53 and K-RAS mutations, suggest that SCC-HT follow alternative carcinogenic pathways. Background: Glandular lesions of the endocervix can be diagnostically challenging and occasionally the differential diagnosis includes both endocervical (ECA) and endometrial adenocarcinomas (EmCA). PAX8 expression has been recently described in the normal endocervix, but there is limited literature evaluating its expression in benign and malignant endocervical lesions, particularly in the context of currently utilized IHC markers such as p16, Ki-67 and CEA. We wanted to evaluate the potential utility of PAX8 to this IHC panel.
PAX8 Immunohistochemical (IHC) Expression in Endocervical Glandular Lesions
Design:
We searched our pathology fi les for benign cervical lesions including: microglandular hyperplasia (MGH), endocervical laminar hyperplasia (ELH), tuboendometrioid metaplasia (TEM), cervical endometriosis (CEM), and tunnel clusters (TC). Premalignant and malignant cohort included: endocervical adenocarcinoma in situ (EC AIS), invasive endocervical adenocarcinoma (ECA), and mucinous/ MGH variants of endometrial adenocarcinoma (EmCA). An IHC panel of CEA, p16 and PAX8 was performed on all cases. Immunoreactivity was scored on degree of positivity (S0 -no staining, S1-up to 10% cells staining, S2-between 10-50% cells staining, S3->50% cells staining) and intensity (I1-mild, I2-moderate, I3-strong). Conclusions: 1. PAX8 shows diffuse positivity with at least moderate intensity in a spectrum of benign endocervical glandular lesions. 2. PAX8 intensity and extent of staining progressively decreased from benign lesions to EC AIS to ECA with ECA showing only focal/ rare staining with mild intensity. This alteration raises possible role of PAX8 in ECA. 3. Variants of EmCA (mucinous/ MGH) show diffuse PAX8 positivity with variable intensity. 4. PAX8 IHC could be added to a panel of other IHC markers in distinguishing benign endocervical lesions from ECA and extent of PAX8 staining could help in separation of ECA from EmCA. Background: Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) are the two most common uterine sarcomas, but both are rare cancers. The aim of the present study was to compare the global gene expression patterns of LMS and ESS, in order to expand and improve the panel of biomarkers currently available for their diagnosis, as well as to defi ne type-specifi c biological targets. Design: Gene expression profi les of 7 ESS and 13 LMS were analyzed using the HumanRef-8 BeadChip from Illumina. Differentially expressed candidate genes were validated using quantitative real-time PCR and immunohistochemistry. Results: Unsupervised hierarchical clustering using all 54,675 genes in the array separated ESS from LMS samples. We identified 549 unique probes that were signifi cantly differentially expressed in the two cancers by greater than 2-fold with 1% FDR cutoff using one-way ANOVA with Benjamini-Hochberg correction, of which 336 and 213 were overexpressed in ESS and LMS, respectively. Genes overexpressed in ESS included SLC7A10, IGDCC3, EFNB3, CCND2, ECEL1, ITM2A, NPW, PLAG1 and GCGR. Genes overexpressed in LMS included CDKN2A, FABP3, TAGLN, JPH2, GEM, NAV2, RAB23 . The top 100 differentiators for each entity included the MYLK and CALD1 genes, coding for myosin light chain and caldesmon, respectively, both overexpressed in LMS, but not the genes coding for CD10, desmin or actin. Results for selected genes were validated by quantitative real-time PCR and immunohistochemistry. Conclusions: We present the fi rst study in which gene expression profi ling was shown to distinguish between ESS and LMS. The molecular signatures unique to each of these cancers may aid in expanding the diagnostic battery for their differentiation, and may provide a molecular basis for prognostic studies and therapeutic target discovery. KJ Dedes, P Wilkerson, D Wetterskog, MB Lambros, R Natrajan, DS Tan, A CampionFlora, DN Rodrigues, A Gauthier, F Daley, CJ Lord, SB Kaye, A Ashworth, JS ReisFilho . The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom; Institut Curie, Paris, France. Background: Ovarian clear cell carcinoma (OCCC) is an aggressive histological subtype of epithelial ovarian cancer (EOC). A potent poly(ADP) ribose polymerase (PARP)-inhibitor, olaparib, has been shown to be active in cancers with dysfunctional homologous recombination (HR) DNA repair, including tumours with loss of BRCA1, BRCA2 or PTEN function. The aims of this study were to determine whether a subset of OCCC cell lines would be sensitive to PARP inhibition and to identify potential mechanisms of loss of competent HR in OCCCs. Design: The ability of 12 OCCC cell lines to elicit HR DNA repair in the presence of DNA double stand breaks was determined using the γH2AX (a surrogate marker for DNA double strand breaks) and RAD51 (a surrogate of marker HR repair) foci formation assay following irradiation or treatment with cisplatin or olaparib. Cell viability was assessed following treatment with cisplatin and olaparib using Celltitre Glo, BRCA1, BRCA2 and PTEN expression by western blotting. Co-treatment of cells with olaparib and verapamil (a p-glycoprotein inhibitor) was performed to evaluate the role of MDR1 expression on olaparib resistance. A tissue microarray containing 50 OCCC primary tumours was assessed for the expression of PTEN and MDR1. Results: Of the 12 OCCC cell lines, TOV-21 and KOC-7c cells lacked PTEN expression, and none showed loss of BRCA1 or BRCA2 expression. Five of the 12 OCCC cell lines (KOC-7c, TOV-21, KK, RMG-1, and SMOV-2) were unable to elicit HR in the presence of DNA double strand breaks induced by radiation. These cells, with the exception of KOC-7c, had signifi cantly higher sensitivity to cisplatin and olaparib than HR-competent OCCC cells. Upon treatment with cisplatin or olaparib, however, KOC-7c cells did not form γH2AX foci and RAD51 foci, but expressed high levels of MDR1. Treatment of KOC-7c with the MDR1 inhibitor verapamil sensitised these cells to olaparib. Loss of PTEN expression was noted in 8% (4/49) primary OCCCs, of which 3 expressed moderate-to-high levels of MDR1. Conclusions: A subgroup of OCCC cells are sensitive to PARP inhibitors in vitro, and this sensitivity can be predicted by a γH2AX/RAD51 foci formation assay. PTEN loss of function was associated with a defect in HR repair in OCCCs. Expression of known drug effl ux pumps (e.g. MDR1) may cause resistance to olaparib. These results provide a rationale for the testing of PARP inhibitors as a targeted therapy in a subset of OCCCs. Background: Wolffi an tumors of the female genital tract (FGT), including mesonephric adenocarcinoma (MA) and female adnexal tumor of probable Wolffi an origin (FATWO), arise from remnants of the mesonephric (Wolffi an) system. Their diagnosis is often problematic due to their low frequency as well as overlapping histologic features with other FGT tumors. Behavior is also not well known as only small series have been reported. Design: Files of 2 institutions were searched, including Dr. R. Scully's consultation fi les. Glass slides and medical records were reviewed and relevant clinicopathologic features were recorded. Results: A total of 32 tumors were identifi ed, including 26 FATWOs and 6 MAs. Average patient age was 45 years. FATWOs originated from ovary (n=16), fallopian tube (n=9), and pelvis/retroperitoneum (n=1). All MAs arose in the cervix (n=6). FIGO stage at presentation was as follows: I:23, II:4, III:2, and IV:3. Average tumor diameter was 7.6 cm and average mitotic index (MI) was 4.65 /10 high power fi elds (HPF). Mesonephric rests were identifi ed in all 6 MAs and 6 FATWOs. Eosinophilic secretions and necrosis were present in 20 and 12 tumors respectively. One FATWO had focal sarcomatous transformation. Almost all of both FATWOs and MAs (29/32) had more than one growth pattern, the most common being tubular, cystic, or sieve-like. Other growth patterns included solid, spindled, sertoliform, retiform, and pseudoendometrioid. Two MA and one FATWO had only tubular growth. The stroma was frequently hyalinized. FATWOs in the ovary usually had a multinodular growth pattern compared to other locations. Immunohistochemical studies were available in selected cases with the following positive results: inhibin 4/6, calretinin 8/11, (both usually focal) ER 1/11 (focally), PR 0/11, CD10 10/10, CK7 5/5, PAX8 5/5, EMA 3/4, p16 0/7, CEA 0/3, p53 0/5, HNF1-β 2/6, FOXL2 1/1. Follow-up was available for 23/32 patients (average 73 months); 16 had no evidence of disease, 5 are alive with disease (AWD), 1 died of disease (DOD), and 1 died of another cause. Patients DOD or AWD presented at advanced stage and had an average MI of 14/10 HPF, these included 4 FATWOs from the ovary (including the tumor with sarcomatous transformation) and 2 MAs. IIIc2  61  DOD  2  --I a  6 5  N E D  3  --I c  7 3  N E D  4  --I b  8 3  D O D  5  --I a  5 1  D O D  6  --I a  5 5  N E D  7  --IIIc1  75  AWD  8  --IIIc2  56  NED All patients whose tumors showed aberrant p53 presented at advanced stage due to peritoneal metastases and are either dead of disease (DOD) or alive with disease (AWD) on follow-up. PIK3CA, KRAS, NRAS  +  +  --LTF  EC  KRAS  +  +  --DOD  EC  PIK3R1  -+  --DOD  EC  PTEN  -+  +  -LTF  EC  PIK3CA  -+  --DOD  EC  PIK3R1, KRAS  -+  --DOD  SC  PIK3CA  -+  --DOD  SC  PIK3R1  -+  --NED  SC  PIK3CA  -+  +  +  A W D  SC  PIK3R1  -+  -+  LTF  SC  PIK3CA  -+  -+  NED  SC  KRAS  -+  +  - Background: PAX8, a transcription factor involved in organogenesis, is expressed in tumors of the thyroid gland, kidney, and Mullerian system. Recent data suggests PAX8 is useful in distinguishing mucinous tumors of the ovary from the GI tract, but this has not been confi rmed; in addition, PAX8 expression in mucinous carcinomas arising from ovarian teratomas has not been studied. We examined PAX8 expression in a large series of primary GI carcinomas, primary ovarian mucinous tumors, and mucinous carcinomas arising from ovarian teratomas to determine the utility of PAX8 in distinguishing these lesions. Design: Tissue microarrays (TMAs) containing 174 colorectal adenocarcinomas, 103 gastric adenocarcinomas, and 30 pancreatic ductal adenocarcinomas were stained for PAX8. TMAs and whole sections comprising 20 primary ovarian mucinous tumors (16 carcinomas, 4 borderline tumors) and whole sections of 10 mucinous carcinomas arising in ovarian teratomas were also stained for PAX8. 
Results:
Gene Expression Signatures Differentiate Uterine Leiomyosarcoma and Endometrial Stromal Sarcoma
PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance
Wolffi an Tumors of the Female Genital
Conclusions
- - - D O D CC PIK3R1 - - - - D O D CC KRAS - - - - D O D EC
Results:
The results are summarized in the Table. The rates of grade 1 and 2 carcinoma were comparable between the two groups. The rates of outer MI and LVI were signifi cantly higher in the LN positive group on FS and PS. However, FS underestimated the number of cases with FIGO grade 2, outer MI and particularly LVI. At time of FS, LVI was either not reported or accurately perceived in a large proportion of cases.
Using a decision tree model, MI and LVI status at FS could discriminate between LN positive and LN negative cases with an overall performance of only 75%.
Conclusions: While outer MI invasion and LVI are more frequent in cases with positive LNs, inability to reliably recognize LVI in a large proportion of cases on FS renders FS a relatively inaccurate method for predicting LN involvement in low risk endometrial adenocarcinoma. Background: Cervical neuroendocrine tumors are a rare, aggressive subtype of cervical cancer, but their immunohistochemical features and relationship to coexisting tumors are incompletely described in the medical literature. Expression of TTF1, c-kit (a potential marker or therapeutic sensitivity), and CD44 (a tumor stem cell marker) by extrapulmonary small cell carcinomas has been recently reported. Cervical neuroendocrine tumors are known to be related to high risk human papillomavirus and p16 immunohistochemical expression is expected. Design: A search for a 22 year period was performed for all available cervical neuroendocrine tumors. Immunohistochemical staining for synaptophysin, chromogranin A, TTF1, c-kit, CD44, and p16 was performed. Loss of heterozygosity (LOH) analysis for fi ve polymorphic microsatellite markers (D3S1300, D9S171, D11S914, D13S319, and TP53) and X chromosome inactivation analysis were performed. Results: Twenty-nine cases were identifi ed (17 small cell, 10 large cell, and 2 mixed). The mean patient age was 44 years (range: 18-82 years). There was coexisting adenocarcinoma in 7 cases, squamous cell carcinoma in 2 cases, adenosquamous carcinoma in 1 case, adenocarcinoma in situ in 1 case, and squamous cell carcinoma in situ in 1 case. Of 18 cases with available blocks, 13 (72%) were synaptophysin+, 8 were chromogranin A+ (44%), 9 (50%) were TTF1+, 8 (44%) were c-kit+, and 7 (39%) were CD44+. Strong patchy or strong diffuse p16 staining was seen in all cases. LOH and X chromosome inactivation analysis were performed for 17 cases, 8 of which had a coexisting squamous or adenocarcinoma component. Five of the eight (63%) cases with two components showed allelic loss in both components. All fi ve of these cases demonstrated identical LOH between the neuroendocrine and squamous or adenocarcinoma components. Nonrandom X chromosome inactivation was seen in the neuroendocrine and other components in 4 of the 8 cases. In all 4 cases the pattern of inactivation was identical between the two components. Conclusions: Cervical neuroendocrine carcinomas have immunophenotypic features similar to other extrapulmonary neuroendocrine carcinomas, including frequent expression of TTF1, c-kit, and CD44. Consistent staining for p16 is also seen. Concordant genetic alterations in X inactivation patterns support common clonal origin for neuroendocrine carcinomas with a coexisting squamous or adenocarcinoma component. N Eritja, C Mirantes, D Llobet, G Masip, J Pallares, X Dolcet, X Matias-Guiu. Hospital Universitari Arnau de Vilanova , University of Lleida, Irblleida, Lleida, Spain. Background: Development of three dimensional (3D) epithelial culture systems has emerged as a good approach to study the genes involved in the disruption of gland architecture, loss of epithelial polarity and increase of proliferation. We describe a novel 3D culture system of primary mouse endometrial epithelial cells which could be used to investigate the frequent alterations found in the endometrial carcinogenesis at the light of morphology, such as decreased E-Cadherin or PTEN expression or the effects of estrogenic stimulation. Design: Epithelial cells from uterus were obtained after a mechanical and enzymatic digestion. After 24 hours of platting in plastic, cells were grown in a medium containing EGF plus Insulin and 3% of a reconstituted extracellular matrix (Matrigel).
Validation of 3D Glandular Cultures To Investigate Endometrial Carcinogenesis
Matrigel allows cells to display a 3D organization comparable to that observed in vivo endometrium. We analyzed glandular polarity by immunofl uorescense staining for different polarity markers. We inhibited E-Cadherin and PTEN expression by lentivirus-delivered shRNAs. We also exposed these cultures to a situation mimicking hyperestrogenism and we studied its effects on cell proliferation.
Results:
The endometrial glands developed in our in vitro system conserved cytokeratin expression and were negative staining for vimentin, indicating its epithelial origin. Staining with phalloidin and GM130 indicated correct positioning of actin cytoskeleton and Golgi apparatus respectively. E-Cadherin and β-Catenin staining demonstrated stable cell-to-cell contacts. To validate our 3D culture for the study of disorders associated with tumor formation we infected epithelial cells with PTEN or E-Cadherin shRNAs. PTEN knock-down resulted in consistent increase of proliferation, measured by BrdU incorporation and Ciclin D1 expression. In cultures infected with E-Cadherin shRNA, cells were unable to form glandular structures and caused a complete loss of cell polarity accompanied by the acquisition of features associated with a malignant/ migratory phenotype such as β-Catenin translocation, Golgi delocalization and polymerization of stress fi bers. An excessive stimulation of estrogen caused an increase of proliferation and an enhanced gland size, but structures retained a correct architecture.
Conclusions:
The results confi rmed that glandular structures displayed the characteristic apicobasal polarity of glandular tissues, as well as the appropriate formation of cellto-cell and cell-to-extracellular matrix contact, with patterns similar to those observed in intact endometrium. ER level of LGSC are signifi cantly lower than FT and SBOT but higher than HGSC, a fi nding only seen in the HistoRX analysis.
LGSC and HGSC do not differ with respect to PR expression; both show a signifi cantly lower PR expression than FT and SBOT.
Nonparametric bivariate density analysis ( Figure) revealed two populations with respect to hormone receptor expression within LGSC only when using the ER and PR AQUA data. Conclusions: Immunohistochemical assays do not distinguish the hormone receptor expression level between LGSC and HGSC, while the HistoRx AQUAnalysis platform showed a signifi cant higher ER expression in LGSC. HistoRx AQUAnalysis reveals two distinct populations with respect to hormone receptor expression within LGSC, which may be useful as a predictive marker for hormonal therapy, assuming that only double high expressors benefi t from hormonal treatment. Background: The pattern of myometrial invasion in endometrioid carcinomas varies considerably; i.e., from widely scattered glands and cell nests, often associated with stromal desmoplasia, to invasive glands with little or no stromal response. Recently, two distinct stromal signatures, derived from a macrophage-response (CSF1) and a fi broblastic-response (DTF), were identifi ed in breast carcinomas and correlated with clinicopathologic features including outcome. In this study, we explored whether these stromal signatures also apply to endometrioid carcinomas and if the aforementioned expression patterns correlated with morphologic changes. Design: Stromal signatures were studied by immunohistochemistry on a tissue microarray of 88 endometrioid carcinomas. A case was considered to carry the CSF1-response signature if it showed coordinate expression of CD163, CD16, and CD32. Similarly, co-expression of SPARC and MMP11 was required for inclusion in the DTF-stromal signature group.
Stromal Signatures in Endometrioid Endometrial
Results: Desmoplasia correlated positively with DTF expression signature. Likewise, CSF1 expression signature correlated strongly with the presence of mononuclear infi ltrate. The DTF and CSF1 groups accounted for 17 % each of the total (15 of 88). Another 12 cases were positive for both DTF and CSF1 signatures (12/88; 13% The macrophage response (CSF1) was associated with higher tumor grade and PIK3CA mutations (P =0.000). In contrast, tumors that evoked little or no infl ammatory stromal response were low-grade and had a low rate of vascular invasion and PIK3CA mutations (P =0.000).
Conclusions:
This study is the first characterization of stromal signatures in endometrioid carcinomas. Our fi ndings shed new light on the relationhip between genetically different endometrioid carcinomas and various types of stromal response. Conclusions: Tu size ≥2 cm, %PA, MELF, SCI, LVI, LUS and CX involvement, MI>50% and number of PALNs sampled were found to be signifi cant predictors of the odds of LNM or ED.Presence of PA and %solid >20% also suggest increased odds (p=0.0658, 0.0527 respectively). Age, FIGO grade 2 vs 1 and number of PLNs sampled were not signifi cant predictors. This multi institutional study validates MI and LVI as predictors of LNM and ED. Additionally, MELF and SCI invasion patterns as predictors of LNM and ED. Attention to pattern of invasion during frozen section may identify pts who could benefi t from LND. Further study is required to determine a multivariate model to predict advanced stage and to study whether these features could also be predictors of recurrence. Background: Vulvar cysts are known to be uncommon, but a systematic analysis of their full clinicopathologic spectrum as seen in a routine pathology practice is lacking. To facilitate patient counselling in patients presenting with a vulvar cyst, we conducted a study designed to defi ne 1) the spectrum, frequency and proportional distribution of pathologic entities that are seen in patients presenting with a vulvar cyst, and 2) the proportion of those cases that are malignant neoplasms. Design: An institutional database was queried for all vulvar cases that were designated as cystic in the clinical history or specimen description sections in a 10-year period (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . All cases (n=83, table 1) were reviewed and classifi ed by gynecologic pathologists. Results: The average patient age was 46.3 years and the mean aggregate size of submitted tissues was 2.05 cm. The most common cysts were follicular cysts (39.75%) and Bartholin cysts (22.9%). Only 3 cases were malignant (squamous cell carcinomas, SCC), but all 3 cases were recurrences in patients with known vulvar SCC. Specifi c clinical impressions were stated in 40 cases, and this matched the fi nal pathologic diagnoses in 28. For the groups with ≥3 cases, the highest clinical/pathologic concordance rates were in Bartholin cysts and SCC (100%) whereas the lowest was in pseudocysts, granulation tissue and abscesses (25%). 7% (6/83) of these clinically cystic lesions were entirely solid pathologically. 
Clinically cystic vulvar lesions encompass a wide spectrum of pathologic lesions, data on which are outlined, which may be useful in the counselling of patients presenting with a vulvar cyst. Vulvar cysts are only rarely malignant (3.6%), and such lesions are typically recurrences of known malignancies. In this series, there were no patients without a history of malignant vulvar neoplasia presenting with a vulvar cyst that ultimately proved to be malignant. Design: 11 gynecologic pathologists (median experience: 10 years) from 11 institutions in the US and Canada rendered diagnoses on glass slides from 35 endometrial neoplasms in a blinded fashion and without predetermined diagnostic criteria. (TP, 4/12) . Cases diagnosed as CC by at least 1 (9%) but <80% of observers (Group 2; n=13) displayed some of the same features but less frequently: clear cells in ≥33% of tumor (6/13), HP (3/13), HC (2/13), SP (6/13), TP (0/13). The groups did not signifi cantly differ in lesional size, mitotic index, or predominant nuclear grade. EC and mixed ca were the most common non-CC diagnoses in Group 2. 44 semi-quantifi ed morphologic variables were analyzed in a logistic regression model, and some traditionally CC-associated features, including hyaline globules and hobnails, were not predictive of confi rmed CC from the overall group of 35 cases. The presence of a nested pattern on reticulum had a sensitivity of 78% and specifi city of 74 % for detection of a FOXL2 mutation.
Conclusions
Conclusions: These data demonstrate the diffi culty in establishing a diagnosis of diffuse or sarcomatoid GCT. Neither the presence of the FOXL2 mutation, calretinin or inhibin immunostaining or the presence of nests on reticulum stain easily confi rmed the morphologic consensus diagnosis. Distinguishing between spindled sex cord stromal tumors remains diffi cult. Perhaps determining the best methods for their diagnosis may be established only by correlation with biologic behavior in long tern follow-up studies. Background: APA has been regarded as a benign tumor; however, it is often associated with endometrioid adenocarcinoma and its histologic diagnosis and biologic potential have been controversial. Design: A multicentric study was carried out involving 15 institutions in Japan. Clinicopathologic features, morphology, and the effects of hormonal (medroxyprogesterone acetate) therapy and biologic behavior were studied in 50 APA cases.
Results:
The patients' ages ranged from 22 to 66 (mean: 30) years. All but three of the patients were premenopausal. Histologically, the lesions were composed of a biphasic proliferation of architecturally complex and cytologically atypical endometrial glands with a myomatous or myofi bromatous stroma. Squamous metaplasia or morules were observed in 37 cases. Eleven had evidence of background endometrial hyperplasia and 15 had endometrioid carcinoma (12 in APA and 3 in the adjacent endometrium). All 6 patients who were initially treated with curettage or polypectomy followed by hormonal therapy had residual or recurrent APA. Cases treated with hormonal therapy exhibited a decreased N/C ratio of epithelial cells, persistent atypical glandular structures, and a markedly edematous stroma. Hysterectomy was performed in 13 cases because a defi nite diagnosis could not be made preoperatively, the curettages raised the possibility of adenocarcinoma, or because there was a high possibility of residual or recurrent lesions. All showed residual or recurrent APA in hysterectomy specimens. Two showed superfi cial myometrial invasion, and two showed APA in a focus of adenomyosis. The overall residual or recurrent lesion rate was high (19/50, 38% Of the 89 STIC cases associated with HGSC, 51 (57%) were attributed to be of FT origin, 26 (29%) to be of ovarian origin, 9 (10%) of peritoneal origin, and 3 (4%) of endometrial origin based on the presence of the bulk of the tumor. Most of these tumors were widely disseminated at presentation with omental/peritoneal involvement seen in 92% cases, and lymph node and lymphovascular involvement in 49% and 48% cases, respectively. The age, race, and FIGO stage showed no signifi cant difference among the four groups of HGSC. Conclusions: To our knowledge, this is the largest study evaluating distribution of carcinomas associated with STIC. Although STIC is considered a precursor for most ovarian and primary peritoneal HGSC, the primary tubal cancers are still far more common in presence of a STIC compared with ovarian HGSC. Most ovarian HGSC might originate from the epithelium of the fallopian tube, but substantial percentage of the cases may not be related to STIC. The high percentage of omental involvement (92%) in these tumors suggests direct extension of the tumor cells due to associated STIC.
Proliferation in the Normal Tubal Epithelium Is a Hallmark of the Follicular Phase Not BRCA1 Mutation Status
SHL George, A Milea, PA Shaw. University Health Network, University of Toronto, Toronto, Canada. Background: BRCA1/2 mutation carriers are at increased risk of ovarian/tubal high grade serous carcinoma. We recently demonstrated that the fallopian tube epithelium (FTE) of BRCA1 mutation carriers have altered signaling pathways compared to controls. We sought to determine whether these differences give a proliferative advantage to the epithelial cells in this high-risk patient population and whether the differences are also due to intraepithelial immune infi ltrating cells. Design: Immunohistochemistry for Ki67 and p53 were performed on histologically normal tubal epithelium (ampulla, TMA n=76, BRCA1/2 versus non-BRCA1/2) and histologically normal fi mbria (whole sections, n=18) with known ovarian cycle status at the time of surgery. To determine whether fi mbria with cancer precursor lesions have an overall increased proliferative index, we analyzed precursor lesions (n=44) from women with and without BRCA1/2 mutations who underwent risk-reducing salpingooophorectomy. We determined the contribution of CD3 + , CD8 + , CD20 + and CD68 + cells within the tube epithelium in the TMA and fi mbria and in 15 cases of Serous Tubal Intraepithelial Carcinoma (STIC). Analysis of the Ki67 stain was performed by 3 independent observers (blinded) using digital slides, where 0 < 1%, 1 = 1%, 2 = 2-4%, 3 = 5-15% and 4 > 4% positive FTE cells.
Results: There was no signifi cant difference (p=0.5711, p=0.7577) in Ki67 positivity between BRCA1/2 (n=42) vs nonBRCA (n=34). A signifi cant increase in CD68 + cells, intercalated in the FTE, was observed in the luteal (n=32) compared to the follicular phase (n=44); (p=0.0027). No signifi cant differences were observed by ovarian cycle or mutational status for CD3 + CD8 + or CD20 + cells. As demonstrated by gene expression profi ling (previously published), the FTE-BRCA cases have a higher immune signature particularly in the luteal phase (GO terms: MHC class II p=0.0055, MHC protein complex p=0.021 and chemokine receptor binding p=0.014) than FTE-nonBRCA in either phase of the menstrual cycle. Conclusions: BRCA1/2 mutation carriers exhibited no significant increase in proliferation of the tube epithelial cells in either the ampulla or fi mbriated ends. There was a signifi cant increase in proliferation as measured by Ki67 staining in follicular phase epithelium. A subset of immune cells within the epithelium are increased during the luteal phase. We also demonstrated a marked increase in lymphocytes invading cancer precursor lesions, suggesting lymphocytes may have a role early in tumor formation.
P16/MIB-1 Immunoreactivity and HPV DNA Status in Tubal
Metaplasia of Endocervical Epithelium: Is There Any Correlation? JC Gomez-Gelvez, Z Zhang, M Raoufi , TE Buekers. Henry Ford Hospital, Detroit, MI. Background: Studies have shown that p16 over-expression occurs in more than half of endocervical tubal metaplasia (TM) and as a result, it is speculated that TM may be a precursor of endocervical glandular neoplasm. In addition, it has been shown that most cases of endocervical glandular neoplasm are associated with HPV infection. In this study, we evaluate p16 over-expression and HPV status in TM to investigate any correlation between these potential neoplastic markers.
Design: From June 2005 to September 2011, all cases diagnosed as AGUS on liquid based cytology with concurrent high-risk HPV DNA testing and subsequent biopsy proven TM were selected. Biopsies containing concurrent squamous dysplasia were excluded due to potential confounding by HPV positivity in dysplastic squamous epithelium. A total of 26 patients with an age range of 21-49 were identifi ed. HPV DNA test results were collected. P16 and MIB-1 immunostains were performed on 17 cases for which the pathology materials were available. MIB-1 stain was scored as <10%, 10-30%, >30% nuclear staining. P16 stain was graded as negative, focal+ (<50% cytoplasmic and nuclear stain) and diffuse+ (>50% cytoplasmic and nuclear stain). Results: Eight out of 17 cases were negative for p16 stain, 5/17 were focally and 4/17 were diffusely positive. Cases with negative p16 stain demonstrated minimal nuclear changes and architecturally benign endocervical glands lined by cilia. However, cases with focal or diffuse p16 positivity showed signifi cant nuclear atypia including nuclear enlargement, hyperchromasia, and pseudostratifi cation. In all cases, MIB-1 stain was either negative or showed <10% of nuclear staining. Of particular interest, high-risk HPV DNA test was negative in all cases.
Conclusions: This is the fi rst study to evaluate the pattern of p16 over-expression in endocervical TM and its correlation with HPV status. The distribution and intensity of p16 over-expression in TM tended to directly correlate with the degree of nuclear atypia. More importantly, no correlation was found between p16 over-expression and HPV status in TM. The association between p16 over-expression and premalignant potential of TM warrants further investigation.
Does GVHD Involve the Gyn Tract? Immunohistochemical Expression of Elafin as a Marker of Graft-Versus-Host Disease in Gynecological Biopsies
GS Gomez-Macias, P Stratton, BA Walter Rodriguez, MJ Merino. NCI, NIH, Bethesda; NICHD, NIH, Bethesda. Background: Graft-versus-Host Disease (GVHD) is a common complication of allogenic bone marrow transplant affecting frequently skin, liver and gastrointestinal tract. Involvement of the gyn tract, particularly vulva and vagina has not been well characterized, and the diagnosis depends on clinical criteria that is sometimes unspecifi c. Recently, Elafi n, an elastase inhibitor secreted in response to cytokines (IL-1 and TNF alpha) has been proposed as a good biomarker to recognize GVHD in skin biopsies. In this study, we describe the morphological fi ndings of 16 patients with GVHD and gynecologic lesions and the use of IHC for Elafi n in patients with GVHD. Design: 30 biopsies (vulva (11), cervix (7), vagina (5), endometrium (3), endocervix(2); 1 areola and 1 perianal region were obtained from 16 patients with lesions suspicious of GVHD, reviewed and stained by IHC with the Elafi n antibody. Ten skin biopsies with known GVHD were used as control. A positive Elafi n expression was defi ned as a staining that extend to a depth of >50% of the mucosa or epidermis. Results: Patients mean age was 35.8 y. Most frequent symptoms included vaginal dryness and discharge, dyspareunia, vulvar discomfort and vaginal scarring. Nine cases had GVHD in the eye, skin, mouth, GI, lung and liver. Morphologically, the vulvar biopsies showed changes similar to GVHD in the skin with occasional ulceration, apoptotic bodies in the basal layer of the epidermis, and chronic infl ammatory cells predominantly lymphocytes. The vaginal biopsies showed increased fi brosis, infl ammation and variable degrees of VIN and condyloma. Rare apoptotic bodies were also seen. The cervical biopsies had marked acute and chronic cervicitis. One case was involved by leukemia and in another an abnormal lymphoid infi ltrate was present. The mucosa had occasional apoptotic bodies. Rare apoptotic bodies were also found in the endometrial glands. HPV was identifi ed in 8 patients. For the Elafi n marker, 11 biopsies were interpreted as positive. These biopsies corresponded to those highly suspected of GVHD. Patients received treatment with topical steroids, topical estrogens and dilators. Conclusions: Our results suggest that the gynecologic tract is affected by GVHD with vulva and vagina being the areas more frequently affected. Morphologic changes are similar to those occurring in the skin and other organs. Elafi n over expression was found in cases with histological changes of GVHD and suggest its potential usefulness to diagnosis GVHD in patients that are clinically suspicious.
Expression of Stem Cell Marker ALDH1 in Cervical Intraepithelial
Neoplasia P Gong, J Palazzo. Thomas Jefferson University Hospital, Philadelphia, PA. Background: Cervical cancer is the second most common type of cancer in women worldwide. The human papilloma virus (HPV) has recently been shown to specifi cally target cervical cancer stem cell (CSC) s. The ability to identify and characterize CSCs is crucial for understanding cervical cancer. Aldehyde degydrogenase (ALDH) 1, a detoxifying enzyme responsible for the oxidation of intracellular aldehydes, has been shown to be a stem cell marker in several tissue types and tumors. We investigated the expression pattern of ALDH1 in cervical intraepithelial neoplasia (CIN) and its possible role in carcinogenesis. Design: Fifty-six cervical biopsy specimens with the diagnoses of normal cervical mucosa, koilocytosis, CIN1, CIN2, and CIN3 were collected from the pathology fi les at Thomas Jefferson University Hospital. All diagnoses were confi rmed by at least two experienced pathologists. Immunohistochemical staining for ALDH1 was performed following a previously published protocol. Any cytoplasmic staining of ALDH1 in the epithelial cells was considered positive. Positive and negative controls were used in each study. Results: Normal cervical mucosa had no ALDH1 expression. In koilocytosis, 2 of 7 cases showed ALDH1+ cells limited to the basal layer. In CIN1, 11 of 20 cases showed ALDH1+ cells limited to the lower 1/3 of epithelium and the other 9 cases were negative for ALDH1. In CIN2, 7 of the 13 cases showed positive cells limited to the basal layer, 4 cases showed positive cells extending to the mid and upper 1/3 of the mucosa. Two cases were negative for ALDH1. All CIN3/carcinoma in situ (CIS) cases were positive for ALDH1. Three of 6 cases show positive cells extending up to mid 1/3 of mucosa and the other three cases show positive cells extending up to the upper 1/3 of mucosa. Conclusions: Cervical dysplasias show positive staining for ALDH1 compared to normal cervical mucosa. ALDH1 expression and distribution parallels the degree of cervical dysplasia. CSCs, as detected by ALDH1 expression, may play a role in the progression of cervical intraepithelial neoplasia and carcinogenesis.
Oncofetal Protein IMP3, a Molecular Marker for the Malignant Progression of Ovarian Serous Neoplasm
The aim of this study was to establish the expression pattern and diagnostic value of IMP3 in benign serous cystadenomas, borderline cystadenomas, and serous carcinomas of the ovary. Design: A total of 108 cases (oopherectomy specimens) (serous cystadenoma, n=15; borderline cystadenoma; n=17, serous carcinoma; n=74) obtained from the surgical pathology fi les of the Umass Medical Center were examined by immunohistochemistry for IMP3 expression. The epithelial/tumor cell staining with IMP3 was recorded by percentage for each lesion. Positive staining in greater than 15% of tumor cells is a positive result. Results: IMP3 demonstrated dark brown cytoplasmic staining(See Figure 1) . IMP3 expression averaged 5% in cystadenomas (range 0-25%, median 5%), 12% in borderline tumors (range 0-75%, median 5%), and 64% in serous carcinomas (range 5-100%, median 80%)(See Figure 2) .
Conclusions: IMP3 is highly expressed in malignant serous tumors of the ovary but not, or rarely in benign or borderline tumors. The data suggest that IMP3 may play an important role in malignant transformation in serous ovarian cancer. Negative staining for IMP3 can increase the level of confi dence in establishing a defi nitive diagnosis of a benign or borderline tumor, and positive IMP3 staining for a malignancy.
IMP3 Expression Differentiates Ovarian Serous from Endometrioid
Carcinoma S Goodman, D Lu. Umass Memorial Medical Center, Worcester, MA. Background: Ovarian carcinoma is characterized by a wide range of tumors. Histologically, differentiation of serous from endometrioid carcinoma can sometimes be diffi cult, and so far there is no reliable biomarker available. The aim of this study was to compare the expression pattern and diagnostic value of IMP3 in endometrioid and serous carcinomas of the ovary. Design: A total of 84 cases (endometrioid carcinoma, n=10; serous carcinoma, n=74) obtained from the surgical pathology fi les of Umass Memorial Medical center were examined by immunohistochemistry for IMP3 expression. The epithelial/tumor cell staining with IMP3 was recorded by percentage for each lesion. Expression in more than 15% of tumor cells is a positive result. Results: IMP3 showed dark brown cytoplasmic staining (see fi gure 1). IMP3 expression was positive in 1/10 (10%, median 5% staining) of endometrioid carcinoma cases, and positive in 57/74 (77%, median 80% staining) of serous carcinomas (see fi gure 2).
Conclusions: IMP3 is expressed in majority of serous carcinoma but only rarely in endometrioid carcinoma. Positive IMP3 staining can increase the level of confi dence in differential diagnosis of endometrioid vs. serous carcinoma. Little is known about their molecular pathogenesis. Fluorescent in-situ hybridization (FISH) has been proven to be useful as a molecular tool for the diagnosis of testicular GCT, and the presence of isochromosome 12 (i(12p)) has been demonstrated in dysgerminoma, the most common malignant ovarian GCT. Design: Cases of primary ovarian GCT were retrieved: 59 cases, including 4 gonadoblastomas (GNB), 2 embryonal carcinomas (EC), 6 immature teratomas (IT), 2 struma ovarii (SO), 21 yolk sac tumors (YST) and 24 dysgerminomas (DYS), were obtained. Interphase FISH was performed on formalin-fi xed paraffi n embedded tissue as previously described, using the following probes: spectrum orange centromeric (CEP) 12, spectrum green subtelomeric (Tel12p), spectrum orange CEP 9, and spectrum acqua CEP X (Vysis, Abbott Molecular). We also used a homemade probe for the DMRT1 gene. Results: FISH detected several chromosomal abnormalities: all cases of GNB, SO, and the majority of IT lacked i(12p) or 12p overrepresentation. Monosomy X was seen in 50% of GNB and 20% of IT. Polysomy X and 9 was seen in 25% of GNB and 33% of IT. YST had i(12p) or 12p overrepresentation in 28% of cases. 30% had polysomy X and 15% monosomy X. 15% showed either polysomy or monosomy 9. Among DYS, 59% showed 12p overrepresentation (fi g.1a) and 29% had i(12p). 27% had either monosomy or polysomy X. 18% showed polysomy 9 and 9% monosomy 9. Two cases (1 YST and 1 DYS) showed DMRT1 deletion (fi g.1b). In the 2 cases of EC, one show numerical chromosomal gains, and the other was normal. The 2 cases of SO had normal cytogenetic fi ndings. 12p overrepresentation was more common in YST and DYS, compared to GNB, SO and IT (50% vs 9%, p=0.02). 52% of GCT showed numerical changes of chromosomes X and 9, and DMRT1 amplifi cation was not present. Conclusions: Contrary to the preexisting evidence, i(12p) or 12p overrepresentation has a relatively low sensitivity (59%) for dysgerminoma diagnosis but a good specifi city (83%). Numerical changes in chromosomes X and 9 are very frequent in ovarian GCTs and may be important in their pathogenesis.
Utility of FISH in the Molecular
Endometrial Glands with Mucinous Metaplasia in the Setting of Chronic Endometritis: A Newly Described Finding
PY Gulavita, B Djordjevic. University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada. Background: Mucinous metaplasia is a rare phenomenon in non-neoplastic endometrium. For the fi rst time, we present a case series of mucinous endometrial metaplasia in the setting of chronic endometritis. Design: We reviewed 77 endometrial biopsies and curettings with chronic endometritis from our institution over a period of 4 years. The histological diagnosis of endometritis was made by establishing the presence of infl ammatory cells in the endometrial stroma including plasma cells and any lymphocytes, eosinophils or neutrophils. Presence of endometrial stroma was confi rmed with CD10 staining. Mucinous metaplasia in the involved endometrial glands was confi rmed with mucicarmine and Alcian blue (pH2.5) staining. Results: Endometritis was diagnosed in a number of clinical settings, including 44 cases of recent pregnancy with retained products of conception, 28 cases of intrauterine contraceptive device use, 3 cases of uterine leiomyomata, 1 case of uterovaginal prolapse, and 1 case of endometrial hyperplasia. Of these cases, we identifi ed 3 with mucinous metaplasia of endocervical type. Two of these cases were in the setting of dilation and curettage for retained products of conception, and 1 in the setting of intrauterine contraceptive device use. In all 3 cases, mucinous metaplasia was a focal fi nding.
Conclusions: Mucinous endometrial metaplasia is uncommonly seen in endometritis.
In endometrial biopsies, it may be confused with endocervical glands. As diagnosis of endometritis often relies on identifi cation of plasma cells, which may be diffi cult to detect, awareness of the possibility of mucinous endometrial metaplasia in endometritis may be a useful diagnostic aid. K Gwin, R Buell-Gutbrod, N Lee, E Lengyel, A Montag, MK Mirza . University of Chicago, Chicago, IL. Background: The high mobility group transcription factor SOX2 is essential for preservation of embryonic stem cell pluripotency and self-renewal of tissue specifi c adult stem cells. Similar to other solid tumors, cervical carcinoma contains a heterogeneous population of cancer cells. Recent studies identifi ed and characterized a cancer stem-like population from primary carcinomas of the cervix uteri by RT-PCR, and demonstrated the expression of adult stemness-related genes, including Sox2. In this study, we assed the expression of SOX2 in cervical intraepithelial neoplasia (CIN) grade I-III and invasive squamous cell carcinoma.
The Stem Cell Associated Transcription Factor Sox2 as a Diagnostic Marker of Cervical Neoplasia
Design: Tissue microarrays were constructed with tissue cores from paraffi n embedded biopsy material of 54 patients. Included were cases of CIN I (n=12), CIN II (n=14), CIN III (n=9), invasive squamous cell carcinoma (n=14) and normal cervix as control. The tissue microarrays were examined using immunohistochemistry for the expression and localization of Sox2. Expression of SOX2 was semi-quantitatively scored by intensity (0-3) and percentage of cells staining. Results: In normal cervix, Sox2 was negative or expression confi ned to the basal cell layer of the epithelium. In low-grade dysplasia (CIN I), Sox2 positivity was seen in the basal 1/3 of the epithelium (100% of cells), mostly of moderate intensity. Cell revealing HPV associated changes usually expressed SOX2. In high-grade dysplasia, moderate to strong SOX2 expression was confi ned to the basal 2/3 of the epithelium in CIN II (100% of cells), and full thickness expression was seen in CIN III (100% of cells). In invasive squamous cell carcinoma, moderate to strong SOX2 expression was present in 13/14 cases (93%) in 40-100% of tumor cells. One case was negative for SOX2 expression. Squamous metaplasia and endocervical glands were devoid of SOX2 expression in all cases where they were present. Conclusions: These fi ndings suggest that reactivation of SOX2 is involved in the progression of cervical neoplasia and is an early step in cervical carcinogenesis. SOX2 is a useful marker for detecting cervical dysplasia on biopsy specimens. In addition, SOX2 is helpful for accurate grading of the dysplastic changes. All cases included in this study could be classifi ed, without diffi culty, as high-grade or low grade dysplasia based on the staining pattern. SOX2 however is not a suitable marker to distinguish high-grade dysplasia from invasive squamous cell carcinoma, as both reveal strong expression of this marker.
Survey of Mammaglobin Expression by Immunohistochemistry in Gynecologic Carcinomas
IS Hagemann, JD Pfeifer, D Cao. Washington University School of Medicine, St. Louis, MO. Background: Mammaglobin-A (MGA) has been proposed as a sensitive and specifi c immunohistochemical marker for breast carcinoma. The extent to which MGA immunoreactivity differs between breast and gynecologic lesions is not known, although the differential diagnosis of breast carcinoma versus a gynecologic primary arises frequently. Design: We performed a survey of MGA immunoreactivity in 221 gynecologic samples from 191 patients, including 27 benign gynecologic tissues (6 ectocervix, 9 endocervix, 12 endometrium), 13 endocervical adenocarcinomas, 72 endometrial adenocarcinomas, and 88 ovarian adenocarcinomas. Staining intensity was scored as weak (1+), moderate (2+), or strong (3+). The extent of staining was scored as focal (<10% of cells), patchy (10-50%), and diffuse (>50%). Results: Gynecologic specimens often showed weak (1+) diffuse MGA staining, which we interpreted as being nonspecifi c. For analysis we thus considered only 2+ or 3+ staining as being signifi cant. In benign tissues, MGA was detected in 0/6 ectocervices, 5/9 endocervices, and 8/12 endometria. Among malignancies, MGA was detected in 1 of 13 endocervical adenocarcinomas (8%; patchy distribution), 12 of 21 endometrial endometrioid carcinomas (57%; 4 focal, 8 patchy), but only 1 of 18 endometrial clear cell carcinomas (5%; focal) and 5 of 31 endometrial serous carcinomas (16%; focal). MGA was present in 6 of 15 ovarian endometrioid carcinomas (40%; 2 focal, 3 patchy, 1 diffuse), 4 of 19 ovarian clear cell carcinomas (21%; 2 focal, 2 diffuse), 1 of 16 ovarian mucinous carcinomas (6%; focal) and 12 of 36 ovarian serous carcinomas (33%; 5 focal, 6 patchy, 1 diffuse). The 3 tumors with the strongest MGA reactivity were all serous carcinomas (ovarian, focal 3+; endometrial, focal 3+; endometrial, patchy 3+). Considering all cases with 2+ or 3+ MGA reactivity, the distribution of this reactivity was focal or patchy (i.e., not diffuse) in 52 of 60 cases. There were no cases with diffuse 3+ MGA expression, as is seen in many breast carcinomas. On the other hand, diffuse 2+ MGA was seen in 4 cases including one endometrioid carcinoma of ovary, one serous carcinoma of ovary, and two clear cell carcinomas of ovary. Conclusions: A signifi cant proportion of gynecologic carcinomas are immunoreactive for MGA. MGA expression is not specifi c for breast carcinoma, and gynecologic carcinomas should be considered in the differential diagnosis of MGA-positive malignancies.
Sarcoma Histology, Percentage of Sarcoma, and Tumor Necrosis Are Prognostically Neutral in Uterine Carcinosarcoma
IS Hagemann, D Cao. Washington University School of Medicine, St. Louis, MO. Background: Uterine carcinosarcoma (malignant mixed Mullerian tumor) is an aggressive variant of endometrial carcinoma which often presents as a necrotic mass, with variable histologies and percentages of sarcoma. The prognostic signifi cance of these factors is uncertain. Design: We reviewed all uterine carcinosarcomas resected at our institution from 1991 to 2009 for which complete records were available. Reports and slides were reviewed to extract clinicopathologic data including patient demographics, staging, and the histology, relative abundance, and percent necrosis of both carcinoma and sarcoma components. Patient outcomes were retrieved from clinical and public records, with overall survival used as the primary endpoint. Results: A total of 94 cases were available for inclusion (FIGO stage I, 53 cases; stage III, 27 cases; stage IV, 13 cases), with a mean follow-up interval of 32.7 months. Univariate analysis confi rmed the prognostic signifi cance of tumor stage (p=0.0006, logrank test), of lymphovascular invasion within stage I tumors (p=0.0058), and of depth of myometrial invasion (p=0.0016). Homologous vs. heterologous sarcoma histology was not, overall, prognostically signifi cant, although in patients surviving more than 40 months, homologous differentiation became a favorable indicator. Upon review of intrauterine tumor histology, necrosis was present in the carcinoma component of 49% of cases and, in these cases, averaged 10% in extent. The sarcomatous component showed necrosis in 65% of cases and, in these, averaged 13% in extent. Cases with and without necrosis of either component did not signifi cantly differ in stage (p>0.05, Student's t), nor did they differ in overall survival when compared stage for stage. The percentage of sarcoma ranged from 1% to 99% (mean 54%), but this factor was also not signifi cantly associated with overall survival. Conclusions: The presence of tumor necrosis, while dramatic, is not prognostically signifi cant in uterine carcinosarcoma. Likewise, the relative percentage of sarcoma and carcinoma does not predict survival. Homologous differentiation, historically considered favorable, appears in this series to be favorable only in long-term survivors. 
Lower Uterine Segment Involvement in Low Grade
Background:
The clinicopathologic signifi cance of lower uterine segment involvement (LUSi) in management of patients with endometrial adenocarcinoma remains controversial. Although the presence of LUSi is not incorporated into the FIGO staging system as an independent criterion, recent studies have found signifi cant associations with other FIGO prognostic factors. However, an association with adverse clinical outcomes has yet to be elucidated. We investigated the prognostic signifi cance of LUSi in patients with low grade endometrioid endometrial adenocarcinoma, focusing on its association with staging criteria and clinical outcomes, specifi cally recurrence-free survival (RFS) and overall survival (OS). Design: Surgical pathology archives of endometrial adenocarcinoma from 2004-2009 were reviewed. Of 417 patients, 294 met inclusion criteria and 130 were excluded due to high grade/aggressive histologic subtypes; synchronous gynecological carcinomas; neoadjuvant therapy. Prognostic data including tumor histology, myometrial invasion, LUSi, lymphovascular invasion (LVI), nodal metastasis, and FIGO stage were recorded. Fisher's exact, Chi-square, and rank-sum tests were used to evaluate the association of LUSi with other prognostic data. Kaplan Meier analysis was used to assess the relationship of LUSi with OS and RFS. Results: LUSi was present in 95 patients (32.3%) with low grade endometrioid adenocarcinoma. LUSi was associated with presence of LVI (p <0.0001), >50% myometrial invasion (p <0.0001), and grade 2 tumors (p =0.0056). There were 12 local recurrences and no disease-related deaths. Nine patients (10.23%) with LUSi had local recurrence compared with 3 patients (1.79%) without LUSi (p=0.004). RFS at 5 years was 69.5% for patients with LUSi compared with 98.9% for patients without LUSi (p=0.0022).
Conclusions:
The presence of LUSi in patients with low grade endometrioid endometrial adenocarcinoma is associated with signifi cantly decreased RFS and is signifi cantly associated with lymphovascular invasion. Lower uterine segment involvement should be considered a poor prognostic indicator in operative management with regard to surgical staging and clinical treatment. MBTs were classifi ed into IMBTs and EMBTs, based on the review of hematoxylin and eosin stained slides of all the cases. The MBT tissues were arranged in tissue microarrays (TMAs) with duplicate 2 mm tissue cores obtained from the tumor area in each MBT. Immunohistochemistry for Claudins (CLDN1, 3, 4, 7 and 18), MUCs (MUC1, 2, 5AC and 6), CK7, CK20, CA125, ER, PgR and vimentin were performed on the TMAs. Results: CLDN18 expression was observed in all IMBTs, whereas only one EMBT was CLDN18-positive. There was no signifi cant difference in the expression of CLDNs 1, 3, 4, and 7 between IMBTs and EMBTs. With regards to MUCs, MUC1 was more frequently expressed in EMBTs than in IMBTs. Positive immunoreactivity for MUC2 and MUC5AC were observed more often in the IMBTs. ER, PgR, and vimentin expression were seen almost exclusively in the EMBTs. Conclusions: Frequent expression of CLDN18, MUC2, and MUC5AC by IMBTs supports a "gastrointestinal" phenotype of the IMBT tumor cells, since CLDN18 and MUC5AC are known gastric epithelial markers and MUC2 is a colonic marker. Furthermore, our study indicates that ER, PgR, vimentin, and CA125 can be used as endocervical-type markers, and CLDN18 and CK20 can be used as intestinal-type markers, for classifying ovarian mucinous tumors into two subsets. 
B-RAF V600E Mutations in Endometrial Adenocarcinoma
Background:
The EGFR-KRAS-BRAF pathway plays a critical role in the development of many types of malignancies including lung, colon and ovarian cancers. Previous studies have only reported the detection of B-RAF mutations other than the V600E mutation in endometrial adenocarcinoma. Our current study aims to investigate the prevalence of B-RAF V600E mutations in endometrial adenocarcinoma in our patient population. Design: With IRB approval, nineteen (19) endometrial adenocarcinoma cases were selected for this study. Genomic DNA was extracted from formalin-fi xed paraffi nembedded tissue sections that were microdissected to ensure more than 80% tumor cells. B-RAF V600E mutations were fi rst screened using mutant allele-specifi c real-time PCR. Positive cases were then verifi ed by direct sequencing using capillary electrophoresis. B-RAF V600E mutation results were also compared to the K-RAS results obtained from our previously reported study. All are uncommon, collectively comprising less than 2% of ovarian tumors. They histologically resemble urothelial neoplasms of the urinary tract, potentially posing diagnostic pitfalls. PAX8 is a developmental transcription factor and a diagnostic and histogenetic marker for Müllerian epithelial tumors. Its expression has not been fully examined in OTCT. In this study, we investigate the expression of PAX8 in OTCT utilizing immunohistochemistry(IHC) and provide additional information regarding the histogenesis and differential diagnosis of these intriguing tumors. Design: 25 benign BT, 1 malignant BT, and 23 OTCC were retrieved, and a tissue microarray(TMA) was assembled with 3 cores from each case. Walthard rests(WR) from 5 salpingectomy specimens and TMA containing 41 invasive TCCs of the urinary bladder(UTCC) from radical cystectomy specimens were also examined. IHC with PAX8, p63, and CD44 was performed. Only distinct nuclear staining was considered to be positive for PAX8 and p63. The staining intensity was graded as negative, weak(1+), moderate(2+) and strong(3+).
Results: B-RAF
Results: All of the WR and benign BT were strongly positive for p63, while all of the OTCC were negative. All WR and benign BT were negative for PAX8, while all of the OTCC and the 1 malignant BT were strongly and diffusely positive for PAX8. In addition, all of the WR and benign BT were 2+ for CD44, while OTCC showed variable staining for CD44(negative in 5, 1+ in 9, 2+ in 8, and 3+ in 1 case(s)). All of the UTCC were consistently negative for PAX8, but had variable staining for p63(negative in 13, 1+ in 25, 2+ in 2, 3+ in 1 case(s)). Staining of CD44 in UTCC was also variable(negative in 9, 1+ in 9, 2+ in 13, and 3+ in 10 cases Background: K-ras mutations are often seen in malignancies of lung, pancreas, colon or ovary displaying mucinous differentiation. Our previous study showed that K-ras mutation can be found in approximately 70% of mucinous carcinoma and endometrioid carcinoma with signifi cant mucinous differentiation (MC&ECMD), signifi cantly higher than other types of endometrioid carcinoma (EC). Current study expanded the mutation study to the mucinous lesions of uterus in order to gain further understanding of the molecular nature and characteristics of these lesions. Design: With IRB approval, seven "atypical mucinous (endometrial) hyperplasia (AMH)", six "mucinous (endometrial) metaplasia (MM)" and nine "microglandular hyperplasia of cervix" were obtained from the archival fi les of the Department of Pathology. Previous MC cases with mutations served as positive control. Six normal cervical biopsy materials were used as negative control. Genomic DNA was extracted from formalin-fi xed paraffi n-embedded tissue sections that were microdissected to ensure more than 80% of lesional cells. PCR amplifi cation for K-ras codons 12 and 13 were performed and followed by sequencing using capillary electrophoresis. The sequencing results were analyzed by "Sequence Scanner v1.0" program. Background: Carcinomas of the lower uterine segment (LUS) with prominent cervical involvement need to be distinguished from primary cervical adenocarcinoma (PCAC) because of differences in behavior and treatment. Furthermore, an association of carcinoma arising in the LUS with impaired DNA mismatch repair protein (MMRP) expression predictive for Lynch syndrome has been described, while MMRP expression in PCAC is not well characterized. Design: H&E slides and pathological reports from 42 hysterectomy specimens of cases originally classifi ed as PCAC, were reevaluated for cervical and endometrial precursor lesions and LUS involvement. Cases with LUS involvement (LUS+) in the absence of cervical precursor lesions (CPL-) were subjected to PCR analysis for HPV-DNA. LUS+/CPL-/HPV-cases were reclassifi ed as LUS carcinoma (LUSC). All cases were analyzed immunohistochemically for expression of the MMRP proteins MLH1, MSH2, MSH6, PMS2 as well as for expression of ER, vimentin, CEA, and p16 expression. Immunohistochemical expression patterns of PCAC were compared to LUSC using Fisher's exact test.
Results: A total of fi ve cases with a LUS+/CPL-/HPV-status were reclassifi ed as LUSC (5/42, 11.9%). Of the remaining 37 PCAC, 25 (67%) had an IHC-pattern typical for cervical adenocarcinomas (ER-, Vimentin-, CEA+) and 35 (94%) stained moderately to strongly positive for p16. None of the LUSC cases had an IHC pattern typical for cervical adenocarcinomas and none was diffusely positive for p16. All PCAC had retained MMRP expression, but loss of MMRP expression was found in 4/5 LUSC (p< 0.005). One mixed type serous/ endometrioid and one undifferentiated LUSC had loss of MSH2 and MSH6 (suggestive for MSH2 germline mutation). One mucinous LUSC showed isolated loss of PMS2 (suggestive for PMS2 germline mutation), one mixed type serous/ endometrioid LUSC showed loss of PMS2 and MLH1. One LUSC of endometrioid subtype had retained MMRP expression. Conclusions: Impaired MMRP expression, predictive for Lynch syndrome, is frequent in LUSC and uncommon in genuine PCAC, therefore LUSC should be screened for MMRP expression. As LUSCs with involvement of the uterine cervix are liable to be misclassifi ed as PCAC, uterine carcinoma ambiguous for site of origin need to be subjected to ancillary studies including MMRP expression. . A second population of low grade CINs were identifi ed that arose caudal to the SCJ. This group was negative for the SCJ-specifi c biomarkers. New SCJs following LEEP/ conization did not display the immunophenotype of the SCJ cells. Conclusions: This study establishes, for the fi rst time, the presence of a unique cell population in the cervix that is selectively retained at the SCJ at birth, possesses an immunophenotype identical to carcinogenic HPV-associated neoplasms, and may be lost or reduced following surgical excision of the SCJ. Moreover, it suggests that low grade CINs can be subdivided immunophenotypically into putative ectocervical and SCJ origins. The attributes of the junctional epithelium described above are consistent with a cell of origin for cervical cancer at the SCJ. Background: Endometrial Intraepithelial Neoplasia (EIN) is a recently described, alternative staging system for endometrial hyperplasia that has been cited as a discerning and reproducible means of predicting the development of endometrial adenocarcinoma. In this study we compare the WHO and EIN classifi cations using lesions previously classifi ed as hyperplasia, and correlated them with clinical outcome in a patient population treated with hormone therapy. Design: Seventy-seven WHO classifi ed hyperplasias (all types) from 2004 to 2011 were analyzed. The reviewers were unaware of the initial diagnosis. EIN criteria were applied (gland to stroma ratio at least 55%, cytologic alteration, size > 1mm, exclusion of mimics/cancer). Reclassifi ed cases were compared to the WHO classifi cation, and correlated with clinical treatment and pathologic follow up. Results: 77 cases (70 with follow up) were available for review; 38 (49%) met criteria for EIN. These 38 were originally classifi ed as complex atypical hyperplasia (CAH) (14, 37%), complex hyperplasia (CH) (23, 60%) and simple atypical hyperplasia (1, 3%). The 39 cases that did not meet EIN criteria consisted of polyps (10, 26%), subdiagnostic atypical or crowded glands (13, 33%), benign hyperplasia (3, 8%) and benign endometrium (13, 33%). Of the 70 patients with available follow-up, 33 (47%) were treated with hormones. Of these, 15 patients (45%) had negative follow up biopsies. 2 patients (6%) went to hysterectomy and were diagnosed with carcinoma (5 & 11 months), and 1 (4%) had residual EIN on follow up. 15 patients (45%) had no biopsy follow up (12 had no evidence of disease clinically, 2 had persistent bleeding but were not re-biopsied, and 1 was lost to follow up). Clinical follow up ranged from 1-83 months with a mean of 16 months. None of the patients who did not meet EIN criteria developed endometrial carcinoma, and all patients who developed endometrial carcinoma were reclassifi ed as EIN during the review. Conclusions: EIN criteria is sensitive (100%), has an excellent negative predictive value (100%) in that none of the cases that did not meet EIN criteria developed carcinoma, and provides an objective approach to endometrial biopsy interpretation. Medical management of EIN is a viable alternative to surgical therapy in the proper clinical setting, with only 6% progressing to carcinoma over our follow up period. Due to the high negative predictive value of the EIN criteria, patients without EIN may be conservatively managed. Background: Mullerian adenosarcoma (MA) is a rare mixed tumor composed of benign glands with papillary (leaf-like) or dilated glands and frequent polypoid intraluminal projections of neoplastic stroma; however, the diagnosis is challenging because many lesions are subtle. We examined the clinicopathologic features and outcome of patients who had uterine polyps that raised the possibility of, but were not diagnostic for, MA. Design: A search of institutional archives for biopsies diagnosed as atypical endometrial or endocervical polyps that had some, but not all, features of MA was performed and 28 cases were retrieved. The frequency of the diagnosis of benign uterine polyp in this time frame was also determined. All 28 cases were evaluated for presence/absence and distribution (focal vs diffuse) of stromal cellularity, altered periglandular stroma, stromal atypia, mitoses, phyllodes-like architecture, intraluminal polypoid projections, and rigid cysts. Partial involvement of the polyp was also recorded. Clinical followup data was obtained when possible. Results: The diagnosis of atypical endometrial polyp was made in < 0.2% of all uterine polyps diagnosed at our institution. 27/28 (96%) cases had followup (f/u) information; 15 (56%) had f/u biopsy(ies) only, 9 (32%) had TAH +/-BSO, and 3 (11%) had clinical f/u without further pathologic sampling. 1 patient died of pancreatic cancer, but all other patients are alive with NED (range in f/u 5.8-236 mo; mean 142.6 mo). 1 case was reclassifi ed as MA on our review; this patient had benign f/u biopsy and is disease free at 82 mo. 23 (82%) cases showed partial involvement of the polyp. The most common fi ndings were: periglandular stromal alteration (86%; 4 focal, 2 vague); phyllodes-like architecture (79%; 8 focal, 1 multifocal); and rigid cysts (46%). Intraluminal polypoid projections in the absence of phyllodes architecture were uncommon. Stromal atypia was rare (2 cases; 1 focal, 1 multifocal). Mitoses ranged from 0-11/10 HPF; and were not seen in 8 cases. The case with the highest mitotic count had partial involvement of the polyp, focal phyllodes-like architectural changes, and diffuse periglandular stromal alteration. Background: A fundamental controversy in using biomarkers to diagnose cervical precursors (ie, cervical intraepithelial neoplasia, CIN) is their specifi city for CIN2/3. Stathmin (STMN), a microtubule destabilizingprotein important in mitosis, is overexpressed in a variety of malignancies, and may be associated with poor outcome. STMN expression in cervical neoplasia has never been explored. Design: Cervical samples (N=191) of non-neoplastic (N=25), non-invasive neoplasia (N=82 CIN, N=19 AIS), invasive squamous cell carcinoma (SCC) (N=31), and invasive adenocarcinoma (ACA) (N=34) were evaluated for STMN, p16, and Ki67 expression by immunohistochemistry (IHC). H&E stained cervical biopsies were independently scored by 3 expert gynecologic pathologists. Squamous lesions were classifi ed as benign, CIN1, CIN2, or CIN3 based on a majority diagnosis (≥2/3 agreeing); cases without agreement were reviewed together and majority opinion was obtained. Each diagnosis was correlated with STMN, p16, and Ki67 expression. IHC interpretation was blindly performed by 2 pathologists. Results: A majority diagnosis was obtained in 187/191 cases on initial review. Squamous epithelia were classifi ed as benign, CIN1, CIN2, and CIN3 in 25, 56, 11 and 15 cases, respectively. STMN was normally expressed in ectocervical basal cells and was absent in benign endocervix. Positive STMN staining was defi ned as immunoreactivity in at least 2/3 of the epithelial thickness. STMN was positive in 5/56 (9%) CIN1, 5/11 (45%) CIN2, and 14/15 (93%) CIN3 (p <0.001), and all cases of AIS, SCC, and ACA. In contrast, 25/56 (45%) CIN1, 11/11 (100%) CIN2, and 14/15 (93%) CIN3 lesions were p16 positive. p16 was also expressed in 5 (20%) benign biopsies. All 30 p16 positive benign and CIN1 biopsies were STMN negative. Ki67 was increased in all neoplastic and some non-neoplastic epithelia. Conclusions: STMN is overexpressed in virtually all cervical carcinomas and CIN3 lesions. In contrast to p16, which can stain CIN1 and reactive epithelia, STMN has greater specifi city for CIN3, and will distinguish these lesions from the majority of low grade precursors and negative cervical biopsies. STMN overexpression appears independent of proliferation, maturation, and HPV cytopathic effect, and may be useful in identifying higher grade CIN at greater risk for progression (CIN3). STMN can also be used to confi rm AIS or invasive carcinoma. Further studies correlating STMN staining with lesion persistence or morphologic progression, in the context of CIN grade, are warranted.
EGFR Protein Expression and Genetic Amplifi cation in High-Grade
Pleomorphic Uterine Sarcomas J Huang, A Smith, C-H Lee. University of British Columbia, Vancouver, BC, Canada; BC Cancer Agency, Vancouver, BC, Canada. Background: Epidermal growth factor receptor (EGFR) is known to be frequently expressed in undifferentiated endometrial sarcomas (UES) and the sarcomatous component of malignant mixed mullerian tumors (MMMT or carcinosarcoma), but little is known regarding its genetic basis. Only a single case of UES with EGFR amplifi cation which showed a signifi cant but temporary response to imatinib has been previously reported (Ann Diagn Pathol. 2007; 11(1):49-54) . The aim of the current study is to evaluate EGFR copy number and amplifi cation status in a series of non-smooth muscle high-grade pleomorphic uterine sarcomas. Design: We identifi ed a series of 14 high-grade non-smooth muscle primary uterine sarcomas (hysterectomy specimens) through retrospective review of pathology archive at Vancouver General Hospital since 2000. All cases demonstrated highgrade nuclear features with diffuse and marked nuclear pleomorphism and none showed features of endometrial stromal sarcoma. These included 8 UES, 4 uterine sarcomas with rhabdomyosarcomatous differentiation (US-RMS), 1 uterine sarcoma with osteosarcomatous differentiation (US-OSA) and 1 adenosarcoma that is nearly completely overgrown by high-grade undifferentiated sarcomas (US-AD). EGFR (Dako) immunostaining was performed on representative whole sections and scored using Her-2/neu scoring criteria for breast cancer. Fluorescence in situ hybridization (FISH) for EGFR and CEP7 (LSI EGFR/CEP7, Abbott Molecular, 40 tumor nuclei evaluated) was performed in cases that showed 3+ EGFR protein expression. Results: Seven of the 14 cases showed 3+ EGFR protein expression (4 UES, 2 US-AD, 1 US-RMS and 1 US-OSA). Interpretable FISH was obtained in fi ve cases with 3+ EGFR staining with the remaining two cases to be repeated (data pending). Among these 5 cases, one case (US-OSA) showed EGFR amplifi cation (EGFR/CEP7 ratio 2.07) while the 3 other cases (1 UES, 1 US-RMS and 1 US-AD) showed increased EGFR copy numbers in >50% of the nuclei evaluated with similar corresponding increase in CEP7 signals. Conclusions: A signifi cant subset of non-smooth muscle high-grade uterine sarcomas strongly expresses EGFR and the data here suggest that EGFR amplifi cation or increased copy number appear to be the underlying genetic mechanism for the observed protein expression. These fi ndings, together with the prior reported case of EGFR-amplifi ed UES provide a compelling rationale for therapeutic targeting of EGFR in these highgrade uterine sarcomas. 2001; 25:1347-1354 ) is uncommon and has been the subject of only a few studies. Histologically, it ranges from simple papillae with fi brovascular cores, typically involving endometrial polyps, to complex intracystic proliferations. Some consider the latter appearance nonatypical complex hyperplasia. Design: To further characterize PPE, with emphasis on the risk of and features associated with underlying neoplasia, the clinicopathologic features of 56 cases of PPE without cytologic atypia were studied. The architectural complexity, extent of the proliferation, and any co-existent hyperplasia of conventional type (WHO classifi cation) were recorded. Results: The age of patients ranged from 23 to 82 years (median, 53); thirty-six (64%) were postmenopausal. The majority presented with abnormal bleeding. Thirteen patients (23%) were receiving hormonal preparations. The diagnosis of PPE was made in 47 biopsies and in 9 hysterectomies. In 46 cases (82%), there was an endometrial polyp. Fifty (89%) had epithelial metaplasias, most commonly mucinous (39 cases, 78%). Co-existent non-atypical and atypical hyperplasia was found in 8 and 5 cases, respectively. In 7 cases (12.5%) a low-grade endometrioid carcinoma was found either in the follow-up sample or hysterectomy specimen. We looked whether the genomic rearrangement secondary to the clonal integration of HPV DNA sequences into the host genome may be used as a highly specifi c marker to detect ct DNA in patients with HPV-associated cervical carcinoma. Design: Nine cases of HPV16-associated invasive cervical carcinoma, corresponding to stage I (2 cases) to stage IV (one case) were analyzed. HPV integration locus was characterized using the Detection of Integrated Papillomavirus Sequenced (DIPS-PCR) method. Cell free circulating DNA was isolated from serum specimens taken before treatment in each case. Sequential serum specimens taken during the course of the disease were also available for 2 of these 9 cases. A PCR-assay was designed to specifi cally amplify the cell-viral DNA junctions and the minimal amount of tumour DNA detectable with this assay was determined in reconstruction experiments using serial dilutions of tumour DNA into Tris-EDTA buffer.
Results: HPV integration sites were located at different loci in the 9 cases. According to reconstruction experiments, the PCR-assay was able to detect a concentration as low as 0.5 pg/ml of tumour DNA in Tris-EDTA buffer. Using the 9 specifi c assays, ct DNA was detected in 7 of the 9 serum specimens with concentrations ranging from 0.03 to 42 pg/200 μl. Comparison with clinical data showed that two of the three negative cases corresponded to stage I carcinoma with tumor size ≤ 15 mm. In both cases with sequential specimens, a dynamic of ct DNA according to the tumor mass was observed during treatment and at time of relapse. Conclusions: HPV insertional mutations can be used to detect ct DNA with a high level of specifi city in patients with HPV-associated carcinoma. We investigated the clinicopathologic features of 10 mesonephric adenocarcinomas including 7 of the cervix and 3 of the uterine corpus. Design: Clinical information and follow-up data was obtained from physicians and medical records. The gross pathologic fi ndings were abstracted from pathology reports. Microscopic and immunohistochemical features were evaluated in the tumors and in adjacent mesonephric hyperplasia.
Results:
The mean age was 52 years. Nine women had a hysterectomy, with bilateral salpingo-oophorectomy in 3, 5 had lymph-node dissections; 2 pelvic radiation. All patients with cervical MA were stage 1B while 2/3 with corpus MA were stage IIIC or higher. Average follow-up was 5 years. Microscopically, tubular, glandular, retiform, sieve-like, spindle cell and solid growth patterns were observed. Tumor cells were low columnar to cuboidal, had scant cytoplasm and moderately atypical hyperchromatic nuclei. The mean mitotic index was 16/10 HPFs. 30% of tumors were associated with diffuse mesonephric hyperplasia. Immunohistochemical fi ndings are presented in Table 1 . The mean Ki-67 index was 25% in tumor, 11% in atypical hyperplasia and 5% in remnants. 
Conclusions:
The presence of a desmoplastic stromal response as identifi ed by increased periglandular staining for α-SMA is useful in identifying invasive glandular lesions of the endocervix. Further studies are necessary to confi rm these fi ndings and to establish biologically relevant cut-off values for α-SMA staining. Conclusions: Overall, the immunostaining patterns within the imNE of teratomas were similar to those of oPNETs, with the exception of p53 which consistently showed more expression in oPNETs, and Oct4, which was focally expressed within imNE in 45% of cases, but not within the oPNETs. The increased p53 expression in oPNETs may indicate tumor progression. The focal Oct4 expression within immature teratomas appeared mainly in occult foci of embryonal carcinoma in these tumors. Both tumor types showed strong staining for CD56, nestin, vimentin, Sox2, Pax8, and Bcl2. Unlike pPNETs, imNE and oPNETs were negative for CD99 and only weakly positive for Fli1. Unlike cPNETs, expression of chromogranin and synaptophysin was negative to focal in both oPNETs and imNE. oPNETs expressed Sall4 (40% positive) and Sox2 (100% positive), which represent diagnostic pitfalls as these markers are commonly used to diagnose other germ cell tumors. FISH testing for nMYC and cMYC amplifi cation and EWSR1 translocation was negative in all oPNETs and imNEs suggesting that the molecular mechanisms of oPNETs do not mimic either central or peripheral PNETs. EnCa and 10 PSCa were tested by immunohistochemistry (IHC) with a monoclonal antibody to napsin A (IP64, Leica), comparing results with antibodies to another lung-restricted marker, TTF-1 (SPT24, Leica), and a GYNrestricted marker, PAX8 (BC12, Biocare). The following scoring criteria were employed: 0 = negative, <1% = rare cell, 1-25% = focal, 26-75% = variable, and >75% = uniform.
Characterization and Comparison of Ovarian
Results: All 12 of 12 (100%) of CCCas were napsin A-positive, with all 12 cases showing variable to uniform expression. In contrast, 3/11 (27%) of EnCa, 0/10 (0%) of PSCa were napsin A-positive. The lung-restricted marker, TTF-1, was positive in 0/12 (0%) of CCCa, 1/11 (9%) EnCa, and 1/10 (10%) PSCa, usually either rare cells positive or focally positive. The GYN-restricted marker, PAX-8, was positive in 9/9 (100%) CCCa, 9/10 (90%) EnCa, and 10/10 (100%) PSCa; all cases were uniformly positive. Conclusions: Napsin A is highly expressed in clear cell carcinomas of ovary, occasionally expressed in endometrioid adenocarcinomas and not expressed in serous papillary carcinomas. This unexpected fi nding suggests that napsin A may assist in separating CCCa from its mimics in GYN tract and could prove critical in the evaluation of metastatic carcinomas of unknown primary in which ovarian carcinoma is in the differential diagnosis. A potential pitfall, however, could be the rare case of TTF-1-positive/napsin A-positive endometrioid adenocarcinoma. These fi ndings underscore the importance of using a complete antibody panel to include multiple "organ-specifi c" markers in identifying carcinomas of unknown primaries. Design: A retrospective review of GA or MDA from the pathology databases of two institutions was performed. Using standard protocols, immunohistochemical (IHC) studies were performed on formalin-fi xed, paraffi n embedded tissue for CK7, p16, CK20, CDX2, p53, PAX8 and Her2/neu. Her2/neu expression was scored according to the ASCO/CAP guidelines (0 to 3+). All others were scored semiquantitatively as POS (>50%), NEG (0), FOC (any to 50%). Results: 16 cases with blocks available for staining were identifi ed. Results are summarized in Tables 1 and 2 . Four cases also had tissue from metastatic sites available for staining. Table 2 3+ (%) 2+ (%) 0/1+ (%) Her2/neu 1 (6) 1 (6) 14 (82) The metastatic tumors had similar staining patterns to the primary, except for 3 cases where CK20/CDX2 was either lost or focally gained. One case also lost PAX8 in the metastasis. Conclusions: Gastric type and minimal deviation adenocarcinoma are characteristically CK7 and many, but not all, are PAX8 positive as well. p16 is negative, further supporting HPV-independent tumorigenesis. A minority of tumors express focal "GI markers" CK20 and CDX2 but are usually negative. p53 is overexpressed in 19% of these tumors which may indicate presence of TP53 mutation. Her2/neu shows 2+ or greater expression in 12% of cases which may be indicative of Her2 amplifi cation. Results: 25 patients were identifi ed with (age 36-61 years). 16 patients had a history of colon carcinoma and 2 patients had a history of sebaceous carcinoma. Focal noninvasive FIGO grade 1 endometrioid ECs were detected in 2 patients, age 54 yrs (MSH2 mutation) and 56 yrs (MLH1 mutation). Focal complex atypical hyperplasia was seen in 2 patients, age 35 (MLH1 mutation) and 53 years (MSH2 mutation). One patient (44 year old with MSH2 mutation) showed a mixed endometrioid/clear cell OC and simple hyperplasia without atypia in the endometrium. The OC was adherent to the colon, but did not show distant metastasis. Other notable uterine fi ndings included mucinous metaplasia (MM) and increased lymphoid aggregates (LA). Conclusions: In our study, prophylactic uteri and ovaries in LS revealed incidental EC and/or EH in 20%, and OC in 4% of cases. The endometrial carcinomas were low grade, confi ned to endometrium and seen in patients older than 50 yrs. Prophylactic hysterectomy allows recognition of early lesions in LS which appear to be small, focal and not diffuse. MM and LA were also frequently noted in benign uteri. The most sensitive markers for DG were OCT4 (CS=11.6), D2-40 (CS=10.9), SALL4 (CS=9.6), NANOG and CD117 (CS=8.6) and PLAP (CS=6.8). Similarly in GBL, germ cell nests were best highlighted by OCT4 (CS=11.6), CD117 (CS=11. Background: In view of retrospective fi ndings on second opinion pathology in ovarian cancer, it seems certain that a considerable number of ovarian borderline tumors (BOTs) or metastatic non-ovarian primaries are being erroneously diagnosed as ovarian carcinomas. If BOTs are misdiagnosed as cancer, patients may not only suffer from non-benefi cial morbidity at unnecessary high cost but may have to cope with an incorrect diagnosis of cancer for the rest of their lives. In cases of metastatic disease mistaken for an ovarian primary, more adequate therapeutic modalities may be withheld from some patients. Finally, clinical trials may be biased through unintended disregarding of histological inclusion criteria. We hypothesized that 5% of all patients in clinical trials of ovarian carcinomas have lesions other than epithelial ovarian cancer, namely BOTs, non-epithelial or metastatic cancer. This is the fi rst such study with a prospective approach. Design: Patients who were enrolled into a chemotherapy trial of ovarian carcinoma were asked to consent to a translational subprotocol. Contributing pathologists were asked to submit all original slides as well as paraffi n material. Specialized central pathology review of all cases was performed by two experienced gynecopathologists. In cases of clinically relevant diagnostic discrepancies, the contributing pathologist was contacted. If a given discrepancy could not be resolved, a panel of experts was available for clarifi cation. Results: 454 patients with an outside diagnosis of ovarian epithelial cancer were recruited. In 6.8% (n=31), a major diagnostic discrepancy of potential clinical relevance was found. Most frequently (n=15), serous BOTs had been misdiagnosed as invasive cancer. Ovarian metastases constituted the second most frequent misdiagnosis (n=12). As minor discrepancies, a divergent histological typing of ovarian carcinomas was found in 28.2% (n=128).
Conclusions: This study clearly shows that central pathology review by experienced gynecopathologists is highly recommendable if overtreatment with chemotherapy of patients with BOTs and inadequate treatment of patients with ovarian metastases is to be avoided in the future. Specialized pathology review should become standard procedure in study protocols prior to randomization. In order to further optimize the quality of care, a high throughput infrastructure for specialized pathology review will have to be established. The authors propose a new internet-based ovarian cancer network, capable of providing specialized second opinion pathology within 10 working days. Background: Recently a single, recurrent somatic mutation (402C→G) in FOXL2 was identifi ed in almost all adult-type granulosa cell tumors (aGCT) but not other ovarian neoplasms. The histopathological features of aGCT can be mimicked by a variety of other tumors, making diagnosis of aGCT challenging. It has been suggested that molecular testing for FOXL2 mutation might be a useful tool in the diagnosis of aGCT. The aim of this study is to demonstrate how testing for the FOXL2 mutation can be used in a gynecological pathology consultation service.
Design: Immunohistochemistry (IHC) for FOXL2 was done using an anti-FOXL2 polyclonal antiserum. If IHC was positive, the FOXL2 mutation status was subsequently analyzed using a TaqMan PCR assay. In cases with a scattered growth pattern or minimal tumor only, laser capture of tumor cells was done prior to DNA extraction. Results: To date, 10 problematic cases have been assessed where the differential diagnosis after the initial investigations included aGCT. The differential diagnoses included: Sertoli Leydig cell tumor (SLCT), juvenile granulosa cell tumor (jGCT), endometrial stromal sarcoma (ESS). and follicular cyst. In all cases FOXL2 IHC was positive, however in only two samples was the FOXL2 mutation detected, thus confi rming a diagnosis of aGCT in these 2 cases. Conclusions: The analysis of the FOXL2 mutational status in clinical samples was a useful diagnostic tool in situations where the differential diagnosis was between aGCT and SLCT, jGCT, ESS and follicular cyst. The informative value of this test is limited to the question of whether a given tumor is an adult type granulosa cell tumor or not, but it is highly specifi c in this context. Background: With the growing certainty of future ovarian cancer treatment being type specifi c it becomes more and more desirable to reliably type ovarian carcinoma. Recently it has been shown, that the application of a set of nine immunohistochemical markers can objectively support the classifi cation of a tumor into one of the fi ve major types of ovarian cancer by entering immunoscores into the Calculator for Ovarian Subtype Prediction (COSP). It was the aim of this study to externally validate the nine-marker panel's prediction equation for the fi rst time. Design: A cohort of 408 cases which were derived from an international chemotherapy trial including all histological types was immunohistochemically stained for PR, p53, DKK1, WT1, p16, Vimentin, HNF1B, TTF3 and MDM2. Scoring was performed by one of the authors who was not previously involved in generating the original data for development of the COSP. In this validation experiment, two antibodies (HNF1B & MDM2) had to replaced for of lack of availability or quality reasons. Results: Of the 350 tumours that were assigned to the serous subtype, the COSP predicted 315 of these to be high-grade serous and 5 to be low-grade serous (table1). The overall concordance rate between the COSP preciction and specialized gynecopathology review is 87.7%. Conclusions: This experiment demonstrates the external validation of the COSP equation. The results are consistent with all internal validation exercises so far and suggest that this nine marker immunopanel can be used as an diagnostic adjunct in determining ovarian carcinoma cell type.
Successful External Validation of the Calculator for Ovarian Subtype Prediction in a Clinical
TP53 Mutations in Uterine Atypical Leiomyomas E Kuhn, A Yemelyanova, T-L Wang, RJ Kurman, I-M Shih. Johns Hopkins Medical
Institutions, Baltimore, MD. Background: Most uterine smooth muscle tumors can be broadly subdivided into two groups: leiomyoma (including variant subtypes) and leiomyosarcoma based on cytologic atypia, mitotic activity and coagulative tumor cell necrosis. A small number defi es classifi cation into unequivocally benign and unequivocally malignant categories and are classifi ed as "atypical leiomyoma" and "STUMP". These two latter tumor types generally behave in a benign fashion but some are malignant. Morphologic and immunohistochemical studies designed to identify the malignant subset have thus far been unsuccessful. Although p53 overexpression as determined by immunohistochemical staining has been reported in these tumors, it is uncertain whether atypical leiomyomas harbor TP53 mutations. We therefore performed a mutational analysis of atypical leiomyomas to determine their TP53 mutation status. Design: A total of 13 atypical leiomyomas were analyzed for TP53 mutations. In 7 cases marked cytologic atypia was diffusely present and in 6 it was focal. In tumors with focal atypia, manual microdissection was employed to separately dissect the atypical and conventional leiomyoma areas. DNA samples were sequenced and TP53 mutations were analyzed from exons 4 to 9. Results: TP53 mutations were detected in 8 (62%) of 13 atypical leiomyomas. Of the 8 tumors with mutations, 5 had morphologically distinct components composed of atypical and conventional leiomyoma areas. In three of these 5 cases, a TP53 mutation was detected in the atypical component but not in the conventional leiomyoma area. In addition, there were three atypical leiomyomas that were associated with conventional leiomyomas and of those, one atypical leiomyoma harbored a TP53 mutation and the concurrent conventional leiomyoma did not. The other two contained wild-type TP53 in both the atypical and conventional leiomyomas.
Conclusions:
The fi ndings in this study indicate that, as currently defi ned, the group of tumors designated "atypical leiomyoma" is heterogeneous at least based on the presence of TP53 mutations. It is tempting to speculate that those harboring TP53 mutations represent the subset of atypical leiomyomas that are malignant. As follow-up information was not available in this study we were unable to confi rm this hypothesis. Accordingly, future correlated molecular genetic and clinicopathologic studies in which follow-up information is available are necessary to clarify this important fi nding.
Brenner Tumors. A Mutational and Immunohistochemical Analysis of 39 Cases E Kuhn, T-L Wang, JD Seidman, I-M Shih, RJ Kurman. Johns Hopkins Medical
Institutions, Baltimore, MD; Washington Hospital Center, Washington, DC. Background: Benign Brenner tumors (BTs) are classifi ed as epithelial tumors of the ovary, based on the presence of nests of epithelial cells resembling urothelium. They are thought to be derived from Walthard cell nests because of their similar appearance. In addition, they have a prominent fi bromatous stroma. The aim of this study was to evaluate their immunohistochemical and molecular genetic features with the view that this might shed light on their pathogenesis. Design: A total of 39 BTs were retrieved from the Johns Hopkins Hospital and the Washington Hospital Center surgical pathology fi les. Immunohistochemistry (IHC) for WT1, ER, PR, calretinin, SF1 and alpha-inhibin was performed on FFPE tissue sections on 39 tumors. In addition, the nests of transitional-type epithelium from 20 tumors were laser-capture microdissected. The stromal component was manually microdissected in all cases as well. Genomic DNA was extracted for sequence analysis of BRAF, KRAS, PIK3CA, CTNNB1, HER2, PPP2R1A and FOXL2 mutations. Results: A somatic mutation of PIK3CA was detected in the stromal component in one tumor. No other mutations were detected in either the epithelial or the stromal component in the remaining tumors. IHC analysis revealed weak WT1 immunoreactivity in the epithelial nests in 3 cases. A similar IHC pattern of WT1 was found in the stromal cell component in 12 cases. In contrast, there was weak expression of ER in 28/39 (72%) and PR in 26/39 (67%), and strong expression of calretinin in 36/39 (92%), SF1 in 37/39 (95%) and alpha-inhibin in 34/39 (87%) in the stromal component. In contrast, expression of these biomarkers in the epithelial component was generally absent. Notably, calretinin, SF1 and alpha-inhibin showed particularly strong staining in the stromal cells that immediately surrounded the epithelial nests in the majority of the tumors. Conclusions: Our fi ndings suggest that mutation of the genes analyzed is unlikely to be a common molecular genetic aberration underlying the development of BTs. Moreover, the periepithelial IHC pattern of calretinin, SF1 and alpha-inhibin, markers of steroidogenic cells, suggests that the stroma is not a passive component but may play an important role in the pathogenesis of this tumor. It is conceivable that the stroma is responsible for inducing the epithelium or vice versa. Further studies are necessary to identify common molecular genetic aberrations in this tumor. We recently described a novel genetic fusion YWHAE-FAM22A/B resulting from translocation t(10;17)(q22;p13) in a subset of endometrial stromal sarcomas (ESS) which are histologically higher-grade and clinically more aggressive than JAZF1-rearranged ESS. We describe here the utility of cyclin D1 as a diagnostic immunomarker for YWHAE-FAM22A/B ESS. Design: Gene expression profi ling was performed by 3' end sequencing in 3 YWHAE-FAM22A/B ESS, 4 JAZF1 ESS and 4 uterine leiomyosarcomas. Signifi cance analysis of microarray data was used to identify genes (immunomarkers) substantially upregulated in YWHAE-FAM22A/B ESS. Immunomarker specifi city and sensitivity were evaluated in a series of YWHEA-FAM22A/B ESS and other uterine tumors. Results: The 3' end sequencing profi les demonstrated cyclin D1 overexpression in YWHAE-FAM22A/B ESS compared to JAZF1 ESS and leiomyosarcomas: this candidate immunomarker was selected for further evaluation because of its general availability in pathology laboratories. Immunohistochemically, > 70% of nuclei in the round cell/ epithelioid cell component of all YWHAE-FAM22A/B ESS (N = 10) demonstrated diffuse moderate-to-strong nuclear cyclin D1 staining (comparable to that seen in Mantle cell lymphoma) and such diffuse positivity was rarely seen (0.4%) in other uterine tumors (Table 1) . Other than YWHAE-FAM22A/B ESS, most uterine sarcomas (98%) displayed cyclin D1 straining in < 20% of tumor nuclei. Conclusions: These data demonstrate that GATA3, TFF1, TFF3, PAX8 and WT-1 are the most effective diagnostic panel for distinguishing breast carcinoma from ovarian serous carcinoma. Background: Endometrioid adenocarcinoma of the endometrium (EEC) is the most common histologic type of endometrial cancer; however few studies have evaluated the importance of patterns of myometrial invasion. Therefore, we were interested in evaluating this parameter in cases of grade 2 EEC and correlating it with clinical outcome. Design: 68 cases of grade 2 EEC (January 2002 -September 2009), with at least 2 years of clinical followup were retrieved from our fi les and reviewed to identify those with myoinvasion. Myoinvasion was subclassifi ed into the following patterns: infi ltrating glands (IG), broad front, adenomyosis-like, microcystic elongated and fragmented glands (MELF), and adenoma-malignum. Depth of invasion and presence/absence of lymphovascular invasion were confi rmed, and clinical follow up was obtained. Results: 56/68 (82%) cases of grade 2 EEC were myoinvasive. Of these, 11 (20%) were superfi cially invasive (<10% myoinvasion), 28 (50%) invaded 10-49%, and 17 (30%) invaded >50% into the myometrium. The invasive patterns consisted of IG (32; 57.1%), both IG and a second minor component of MELF (4, 7.1%), broad front (11; 19.6%), MELF alone (3, 5.4%), adenomyosis-like (6; 10.7%). No cases of adenoma malignumlike pattern of invasion were identifi ed. Lymphovascular invasion was noted in 21 cases (30.9%); 15 (71%) of which had IG. 11 (16.2%) cases contained cervical stromal invasion; 8 (72%) of which had IG. Six (8.8%) patients had hysterectomy and bilateral salpingo-oophorectomy while sixty-two (91.2%) also underwent a lymphadenectomy (LND). Forty-fi ve (66.2%) patients received adjuvant therapy (chemotherapy, radiation therapy, or vaginal brachytherapy). 6/62 patients with LND had metastases; 4/6 (66%) had IG. None of the cases without myoinvasion recurred while 8 (14.3%) cases with myoinvasion recurred (follow-up mean: 45 months). Of the patients with recurrence, all had an IG (including one case with a minor MELF component).
Cyclin D1 Is a Sensitive and Specifi c Diagnostic Immunomarker for YWHAE-FAM22A/B Endometrial Stromal Sarcoma
Histologic Patterns of Myometrial Invasion in FIGO Grade
Conclusions:
In this series, the majority of patients with grade 2 EEC had myometrial invasion (56/68; 82%) which is in distinct contrast to our previous study (Mod Path 24 (1), 2011; 264A, Abstract 1119) where 30% of Grade I cases were invasive. The presence of infi ltrative gland pattern of myoinvasion is associated with recurrence and other pathologic variables of poor outcome including LVI, cervical stromal invasion and lymph node involvement. Background: Although classifi ed as "ovarian cancers", the origin of high grade serous carcinomas in the pelvis has been controversial. Recent studies implicate the distal oviduct in a signifi cant percentage of these tumors by the presence of a serous tubal intraepithelial carcinoma (STIC). However, the magnitude of the role played by the fallopian tube remains unclear. We performed a detailed analysis of consecutive cases of serous cancer to determine 1) the maximum number of cases that could be assigned to a non-tubal source by exclusionary criteria and 2) if there was immunohistochemical evidence of an origin in the ovary. Design: Consecutive cases of high-grade carcinoma accessioned between 2005 and 2007 were analyzed. Reports were scrutinized for whether the distal fallopian tubes were completely analyzed. Cases containing STIC or in which the fi mbria could not be fully examined to exclude STIC, were placed in the non-exclusionary category. Cases in which the distal tubes were reported examined and were negative were systematically reviewed to confi rm this and exclude STIC. In a separate subset of cases in which both the fi mbria were visualized and STIC excluded, the ovaries were immunostained for PAX2 and p53 to identify normal PAX2 positive epitheium in continuity with adjacent p53 positive or PAX2-null cancers or putative precursor epithelium (either PAX2-null or p53 positive). Results: 203 cases of high-grade carcinoma were identifi ed of which 143 (70%) either reported a STIC or did not identify both fallopian tubes. Of the remaining 60, 34 were availble for review. Of these, 9 contained inadequate or no fi mbria in the tubal tissue blocs, 5 contained a STIC, and 16 contained negative fi mbrial histology from both the right and left fallopian tubes. Analysis of the ovaries from 20 cases with no clear tubal primary revealed PAX2-null and p53-positive surface serous carcinomas. However, in no case was a carcinoma detected in continuity with either normal or immunohistochemically altered (PAX2-null, p53+) mullerian epithelium, in keeping with surface implantation rather than de-novo neoplastic change.
In approximately 16% of high-grade pelvic mullerian carcinomas, both fi mbria can be identifi ed and both will be histologically benign. Analysis of the ovarian cortices do not implicate a source in the ovarian surface epithelium using the existing precursor models described for the fallopian tube. The possibility of other origins and the impact of meticulous sampling the oviduct will be discussed.
Re-Evaluation of Immunohistochemical Markers in Endometrial Adenocarcinomas
H Liu, H Yin, H Wang, F Lin. Geisinger Medical Center, Danville, PA; UCLA Medical Center, Los Angeles, CA. Background: When working on a tumor of unknown origin, a metastatic adenocarcinoma from the endometrium may present a diagnostic challenge because of the inconsistent data from the literature and complicated immunostaining profi les for endometrial adenocarcinoma (EAD). In this study, we re-evaluate the expression of an extensive panel of biomarkers in endometrial adenocarcinomas using a single immunostaining system (Ventana XT). Design: We immunohistochemically evaluated the expression of 1) epithelial markers (AE1/3, CAM5.2, CK7, CK20, CK17, CK19, CK903, EMA); 2) mucin gene products (MUC1, MUC2, MUC4, MUC5AC, MUC6); 3) tumor suppressor genes and transcription factors (ER, PR, p53, beta-catenin, ERG, GATA3, WT-1, CDX2, pVHL); and 4) tumor-associated proteins (TTF-1, napsin A, p16, HepPar1, glypican 3, SALL4, OCT4, PAX8, RCC, GCDFP15, mammaglobin, S100P, IMP3, maspin, MOC31, CEA, CA19-9, CD10, CD15, villin, and P504S) on 128 cases of endometrial adenocarcinoma endometrioid type (FIGO I 32 cases, FIGO II 58 cases, and FIGO III 38 cases) on tissue microarray sections. The staining intensity distribution was recorded. Results: The positive staining results from selected antibodies are summarized in Table  1 . Twelve of 128 cases (9.4%) showed diffuse (4+) and strong p16 positivity. All cases were negative for CK20, SALL4, OCT4, MUC2, HepPar1, villin, GCDFP15, and S100P. Conclusions: These data demonstrate that 1) mammaglobin and other tumor/organspecifi c markers can be positive in a signifi cant percentage of cases; 2) nearly all cases are positive for ER, PR and PAX8 regardless of tumor grade; 3) 10% of cases can be negative for CK7 and vimentin; and 4) caution should be taken when using p16 to differentiate endometrial primary from endocervical primary since close to 10% of cases are diffusely and strongly positive for p16. Background: Ovarian carcinoma (OC) is the leading cause of death among gynecological malignancies with a 46% overall 5 year survival. Lack of effective methods for its prevention/early detection (75% stage III/IV at diagnosis) and common development of resistance to fi rst line agents has launched studies to better understand its pathogenesis and identify targeted therapies. TP53 and KRAS are among the most frequently mutated genes while PIK3CA, although not as prevalent, is actively being investigated as promising therapeutic target. Recently, a multiplexed allele-specifi c assay (SNaPshot) has been developed to detect simultaneous somatic mutations in tumor DNA extracted from formalin-fi xed paraffi n-embedded specimens to obtain rapid/effective tumor genotyping and select patients that may respond to specifi c therapies. The aim of this study is to determine prevalence of mutant genes in resistant OC using this new assay. Design: The cohort included 63 tumors from 62 patients (1 with 2 different tumors) with resistant OC and ECOG 0-2 performance score. Samples were tested for common hotspot mutations using SNaPshot assay that detects mutations in 68 different loci as well as insertions and deletions from 15 cancer genes (AKT1, APC, BRAF, CTNNB1, EGFR, ERBB2, IDH1, KIT, KRAS, MAP2K1, NOTCH1, NRAS, PIK3CA, PTEN and TP53 (9) 16 (8) 18 (6) CIN 2 4 (10) 18 (11) 18 (6) CIN 3/MIC 7 (14) 15 (15) 17 (9) No differences in demographic data were statistically signifi cant between any subgroups. Conclusions: Our rate of HSIL in adolescents was 0.5%, consistent with other studies. However, our study did fi nd 56 (20%) CIN 3 lesions in the HSIL subgroup. CIN 3 behavior in adolescents has not been well described, but current guidelines from ACOG and the ASCCP states that CIN 3 lesions in adolescents should be ablated. This subset of adolescents was detected by cervical cancer screening and, in line with current guidelines, was treated with ablation. This study shows that the ACOG guidelines for adolescents may be reasonable for the majority of the adolescent population, but a subset of HRA with CIN 3 would be not be detected. The demographic data failed to identifi y a subgroup of adolescents at higher risk for CIN 3. We cannot suggest a way to select out the high-risk adolescents that would require CCS. Because there is a subset of HRA with CIN 3 lesions, we feel that more study is needed to create a process that can select out these high-risk adolescents for CCS.
Microcystic Stromal Tumor Is a Distinct Ovarian Neoplasm Characterized by ß-Catenin Alteration
The University of Tokyo, Tokyo, Japan; Osaka Rosai Hospital, Sakai, Japan; Kagoshima Municipal Hospital, Kagoshima, Japan; The University of Tsukuba, Tsukuba, Japan. Background: Microcystic stromal tumor (MCST) is a recently described subtype of ovarian tumor characterized by a prominent microcystic histological pattern and diffuse immunoreactivity for CD10 and vimentin. Descriptions regarding the histological features of MCST are limited, and the pathobiology remains unclear. Here, we report four cases of ovarian MCST in which we have performed extensive histological, immunohistochemical, and genetic investigations to determine its distinctiveness among ovarian neoplasms. Design: In addition to the morphological characterization of ovarian MCSTs, we performed immunohistochemical comparisons between ovarian MCSTs and a variety of sex cord-stromal tumors. Markers examined in this study include vimentin, CD10, β-catenin, WT-1, α-inhibin, calretinin, ER, PgR, EMA, and cytokeratin AE1/3. Further, two of the MCSTs were analyzed using direct sequencing for a mutation in exon 3 of the β-catenin gene.
Results:
The patients' ages ranged from 32 to 41 years. One patient had a past history of familial adenomatous polyposis (FAP). Microscopically, all four tumors showed similar histological features: generally bland tumor cells with round to ovoid nuclei growing in microcystic, macrocystic, and solid patterns. Intervening thick fi brous stroma were observed. Immunohistochemically, tumor cells were diffusely and strongly positive for CD10, vimentin, and WT-1, but negative for α-inhibin, calretinin, ER, PgR, and EMA. Cytokeratin expression was variable. Importantly, we detected aberrant nuclear expression of β-catenin protein in all four cases. In contrast, none of the sex cordstromal tumors examined showed nuclear expression of β-catenin. Mutation analyses performed in two of the non-FAP patient cases revealed the presence of the c.98C>G mutation in exon 3 of β-catenin. Conclusions: Our immunohistochemical analyses showed that MCST is a distinct ovarian neoplasm characterized by aberrant nuclear expression of β-catenin. The results of our immunohistochemical and mutation analyses, along with the presence of MCST in an FAP patient, strongly suggest that dysregulation of the Wnt/β-catenin pathway plays a fundamental role in the pathogenesis of ovarian MCST. Background: Diagnosis of ULMS is based on cytologic atypia, presence of coagulative tumor cell necrosis and mitotic index, all features with a variable degree of subjectivity. Frequently, no guidance or search plan is used when performing a mitotic count and a drop and run (linear) or drop and weave (random) search pattern is used. This study assessed accuracy and reproducibility in utilizing specifi c search patterns for mitotic fi gures in ULMS. Design: 11 cases of ULMS (chosen to assure abundant mitotic fi gures and desired tumor patterns) were culled from divisional fi les. Each case was evaluated at low power (4X) and examples of each tumor pattern were selected for counting. The tumor patterns were designated random, linear, along fascicles, fascicle cross-section, reactive (including areas near necrosis), hypercellular, and interface (tumor & normal). Slides were screened by 3 observers at 20X for the presence of mitotic fi gures, and, at the fi rst mitotic fi gure seen, one 40X mitotic count (10 high power fi elds) was performed for each available search pattern. The data was then compiled as an average count per pattern along with a maximum inter-observer range (MIR) for each case. Results: Counting in hypercellular areas and along fascicles yielded the highest counts, while fascicle cross section, linear, and random patterns yielded the lowest. 13 Non-diagnostic counts, i.e. less than 10 mitosis per 10 40X fi elds, were obtained (5 into fascicles, 3 random, 3 linear, 2 reactive\necrosis). Pattern based counting did not improve reproducibility based on MIR scores, with counting along the interface of ULMS and normal tissue faring the worst (see Conclusions: Mitotic fi gure assesment in hypercellular areas and along fascicles yields the highest number of mitotic fi gures. Mitotic activity should not be assessed in random or linear patterns and cross sections of fascicles should be avoided as counts may not reach the diagnostic threshold. As a diagnostic criteria, mitotic fi gure counting shows poor reproducibility, and, therefore, care should be used in selecting regions in which mitotic fi gure assessment will be made. Vulvar condyloma acuminatum is low-risk HPV (LRHPV)-related (most commonly types 6 and 11) and has virtually no risk of neoplastic progression. While infections with multiple high-and low-risk HPV types have been reported for cervical squamous intraepithelial lesions, coexisting vulvar condyloma and adjacent high-grade VIN have not been well-characterized. Design: Eleven cases of concurrent condyloma acuminatum and adjacent fl at high-grade VIN and four cases of high-grade VIN with prominent warty/condylomatous architecture were analyzed using immunohistochemical (IHC) analysis of p16 expression and in situ hybridization (ISH) for HPV detection (probes for HPV6/11, HPV16, and HPVWS [types 6, 11, 16, 18, 31, 33, 35, 45, 51, 52] 
MELF Pattern of Myoinvasion in Endometrioid Endometrial
Conclusions:
The restriction of LRHPV to condylomatous components and HRHPV to high-grade VIN components of adjacent lesions suggests these are independent and a result of infection with multiple HPV types. A diffuse pattern of p16 expression can highlight small foci of high-grade VIN which may be overlooked in more abundant condylomatous tissue from immunosuppressed patients. The presence of HRHPV in lesions with prominent warty/condylomatous architecture supports their classifi cation as forms of pure high-grade VIN and distinguishes them from condyloma acuminatum. 1) carcinoma. An antibody that was specifi c for the ARID1A encoded protein was used for immunohistochemistry. Complete loss was defi ned as absence of ARID1A immunoreactivity in all tumor cells whereas clonal loss was lack of the staining in a discrete tumor area(s) in the background of ARID1A positive tumor cells.
HPV73-Mediated CINII/III in a Gardasil
Results:
We found that 5 (14%) of 36 cases of CAH displayed clonal loss of ARID1A, but none showed complete loss of ARID1A expression. In contrast, complete and clonal ARID1A loss was detected in 13 (38%) and 2 (6%) of 34 high-grade endometrioid (FIGO 2 and 3) carcinomas, respectively. Among them, 8 cases had concurrent components of low-grade carcinoma. In the low-grade areas from those 8 mixed cases, complete loss of ARID1A was recorded in 2 (25%) and clonal loss in 5 (62.5%) of cases. In three of those 8 cases, ARID1A retention or clonal loss was observed in the low-grade component while complete loss was detected in the adjacent high-grade area. Conclusions: In summary, clonal loss of ARID1A was found in 14% of CAH but complete loss in 0%. In contrast, complete loss of ARID1A expression was found in approximately 25% of low-grade carcinomas and 38% of high grade carcinomas. These fi ndings strongly suggest that loss of ARID1A staining (presumably due to a mutation) plays an important role in tumor progression in endometrioid carcinoma which may have signifi cant implications to further understand the pathogenesis of uterine endometrioid carcinoma. Background: Metastasis of colorectal adenocarcinoma (ADC) to the ovary is not an uncommon occurrence. In particular, mucinous and endometrioid ovarian ADC phenotypes have proven to be diagnostically challenging in the differential diagnosis with metastatic colon ADC. From recent proteonomic studies that demonstrated signifi cant upregulation in colonic ADC relative to matched normal tissue, DiPeptidase-1 (DPEP1) has emerged as a potential diagnostic marker for colonic ADC. This fi nding has direct relevance to cases wherein the differential diagnosis predicament previously described are encountered, as DPEP1 may function to further help delineate metastatic colonic ADC from primary ovarian mucinous or endometrioid tumors. Design: Four cases of mucinous colonic ADC and ten cases of conventional colonic ADC from female patients were retrieved from archival fi les as well as 4 cases of endometrioid ovarian tumors, 6 cases of endometrioid uterine tumors, and 4 cases of mucinous ovarian tumors. All sections were subjected to immunohistochemistry with antigen retrieval using an antibody to DPEP1 (Sigma) at a titer of 1 : 1500.
DPEP1, a Useful Immunohistochemical Tool in Distinguishing Primary from Metastatic Endometrioid and Mucinous Ovarian Tumors
Results:
The conventional colonic ADC demonstrate diffuse, strong expression for DPEP1 in a polarized (apical/luminal centric) fashion. The mucinous colonic ADC showed some cytoplasmic staining with patchy apical/luminal staining. All four mucinous ovarian tumors were negative. Half of the ovarian endometrioid tumors expressed DPEP1, but in a punctuate fashion, with a circumferential pattern on the positive cells. Only 1 of the 4 endometrial endometrioid ADC cases expressed DPEP1, and in a manner similar to the ovarian endometrioid tumors. Conclusions: DPEP1 has utility in distinguishing colonic ADC from mucinous and endometrioid ADC of the ovary and is based on the presence of expression and the pattern of staining. The characteristic diffuse apical/luminal centric staining noted in the colonic ADC was only focal in the mucinous colonic ADCs, but still present in contrast to its complete absence in mucinous ovarian tumors. For those ovarian and endometrial tumors that did express DPEP1, the staining was focal and circumferential, in contrast to the apical/luminal staining pattern noted in colonic ADCs. Conclusions: EESS is commonly associated with endometriosis and tends to be indolent with a propensity for recurrence. 6/7 pts who DOD had bowel involvement and 1 had dedifferentiation. Unusual histologic features or presentation and the extrauterine location lead to an inaccurate dx in a signifi cant number of cases. We performed a retrospective review of records from January 1996-October 2010 of 217 women with a diagnosis of squamous or glandular cervical neoplasia in a cone biopsy. These subjects all subsequently underwent total hysterectomy within 11 years of the diagnosis (range: 2 days-11 years, median: 54 days, mean: 201 days). Results: Of the 217 women meeting the criteria, 13 had both squamous and glandular neoplasia and were counted in both categories. ECC was performed at the time of cone biopsy in 154 cases. Among patients with involved margins, residual neoplasia was found in 53% of those with squamous neoplasia versus 62% of those with glandular neoplasia. Among patients with negative margins, residual neoplasia was identifi ed more frequently in the glandular group (53%) than in the squamous group (31%). Stratifi cation based on the type of excision did not affect the outcome. Additionally, patients with neoplasia on concurrent ECC were 3.0 (squamous) and 1.7 (glandular) times as likely to have residual neoplasia compared to those with negative ECCs (p<0.01 and p=0.03, respectively). Among patients with negative ECCs, those with a diagnosis of glandular dysplasia on concurrent cone biopsy were 2.0 times as likely to have residual neoplasia compared to patients with squamous neoplasia (p=0.01). Lastly, among patients who had margin involvement by squamous neoplasia, those who also had a positive ECC were 3.8 times as likely to have residual neoplasia compared to those with a negative ECC (p<0.01). Conclusions: Our data is in accord with prior literature showing residual glandular neoplasia to be more frequent than residual squamous neoplasia despite negative margins on cone biopsy. Our study suggests that neoplasia found in a concurrent ECC is an important predictor of residual neoplasia and may ultimately prove to be of greater prognostic value than the cone biopsy margins. Finally, the modality of excisional biopsy did not signifi cantly affect the frequency of residual disease. Background: Neoadjuvant chemotherapy (NAC) followed by interval debulking surgery is an alternative approach in the management of patients with advanced stage epithelial ovarian carcinoma (EOC)/peritoneal carcinomas (PC) compared to the traditional debulking surgery followed by chemotherapy. Therefore, a tissue diagnosis for malignancy confi rmation is crucial. However, due to the wide differential histologic diagnoses, an accurate diagnosis could be challenging. Herein, we are planning to evaluate the utility of the transcription factor protein, PAX8, in the diagnosis of primary EOC/PC for patients eligible for NAC. Design: This is a retrospective study in which our database was searched for patients diagnosed with EOC/PC who received NAC followed by debulking surgery during a seven-year period (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) . Immunohistochemistry (IHC) was performed on paraffi n-embedded tissue from 96 cases (53 EOC/PC and 43 non-ovarian carcinomas). The IHC slides were blindly reviewed and the results of the PAX8 staining intensity were reported as positive (weak, moderate, and strong) or negative (no staining observed). Results: For EOC/PC cases, 36 cases were biopsy specimens and 17 cell blocks prepared from ascitic fl uid (n=10), pleural fl uid (n=4) and supraclavicular lymph node aspiration (n=3). The histology was as follows; 45 serous, 3 endometrioid, 3 mucinous, 1 clear cell and 1 carcinosarcoma subtypes. As for non-ovarian carcinomas, the tissue distribution was as follows; cell block from ascitic fl uid (n=1), whole section from metastatic adenocarcinoma to the ovary (n=12) and biopsies form various sites (n=30). Overall, PAX8 was positive in 53/96 (55%) cases and negative in 43/96 (45%) cases. 51/53 (96%) of EOC/PC were positive and 41/43 (95%) non-ovarian carcinoma cases were negative. The 2 non-ovarian carcinoma cases positive for PAX8 were renal cell carcinoma. The sensitivity and specifi city of PAX8 was 96% and 95%, respectively.
P504S (AMACR-alpha-
Conclusions:
The histologic distinction of EOC/PC from its mimics is clinically important yet not one single stain has been proven to be highly reliable. Our data clearly showed that PAX8 is very highly sensitive and specifi c in primary EOC/PC, especially on biopsy and cytology on cell blocks. Therefore, we highly recommend adding it to the immunohistochemical panel for the diagnosis of EOC/PC, especially in institutions where neoadjuvant is gaining popularity. (12) were assessed. Patients were 18 to 78 years old (mean 49) and 16 were premenopausal. The initial endometrial biopsy, treatment biopsies/currettages, and hysterectomy specimens (when available) were classifi ed by the WHO criteria for CAH and WDC. Applying the features used by Wheeler et. al, progesterone-related changes were assessed at 3-6 month intervals for the following features: gland:stroma, architectural abnormalities, mitotic activity, nucleus: cytoplasm, presence of nucleoli, nuclear chromatin quality, cytoplasmic metaplasia, and cytologic atypia (defi ned as coarse chromatin, prominent nucleoli, and irregular nuclear contours). Architectural abnormalities included increased gland:stroma ratio and gland confl uency (cribriforming/papillary). Outcomes were defi ned by diagnosis of the last available specimen as resolution (benign/inactive endometrium), regression (hyperplasia without atypia), persistence (CAH or WDC), or progression (CAH to WDC/WDC to poorlydifferentiated carcinoma). Results: Outcomes were: resolution (21 cases), regression (2 cases), persistence (3 cases), and progression (4 cases). Frequently early biopsies showed increased glandular crowding and cytoplasmic metaplasias (eosinophilic, secretory, and squamous) but this did not predict poor outcome. Resolution was most predictably detected by the complete absence of cytologic atypia in the six month post-treatment specimens. All cases with persistence or progression retained cytologic atypia for at least six months. Conclusions: Our study confi rms the results of Wheeler et al. Persistence of cytologic atypia after six months of therapy is a strong indicator of treatment failure. Since cytologic atypia is subjective, comparison to the patient's previous pre-and post-treatment biopsies is essential for proper assessment. Increased architectural complexity is common in early progesterone treatment and should not count as progression of disease. For the purpose of a triage of AGC cases, CA-IX appears to be a superior to HPV DNA testing and/or p16 cytochemistry since a subset of endocervical adenocarcinomas are high-risk HPV-independent as represented by gastric-type adenocarcinoma of the cervix. Design: Cases of lobular endocervical glandular hyperplasia (LEGH) (n=10), atypical LEGH (ALEGH) (n=6), and endocervical adenocarcinomas, including usual-type (n=3) and gastric-type (n=7, including 3 minimal deviation adenocarcinomas) were retrieved from the fi le. Using representative sections of the lesion, expression status of CA-IX was determined immunohistochemically, employing anti-CA-IX antibody (Abcam, MA, USA). Proportion of positive areas and staining intensity, ranging from 0 to 3+, were evaluated. Results: All 10 adenocarcinomas, including both usual and gastric-types, were positive for CA-IX, with 7 of 10 cases showing 3+ staining, and 6 cases showing positive areas exceeding 50% (3 cases; 100%, 1 case; 80%, 2 cases; 60%). Two adenocarcinomas showed only 30% areas with 2+ positivity, and one showing only 5% areas of 1+ staining. All 10 LEGH without atypia were positive for CA-IX, with all cases showing 50% or more positive areas, although only one case showing 3+ positivity, whereas 5 and 4 cases were 1+ and 2+ intensity, respectively. Five of 6 atypical LEGH were positive for CA-IX, with 4 cases showing 3+ positivity in 100% of areas. Normal endocervical glands, tunnel clusters, and non-specifi c endocervical glandular hyperplasias were negative for CA-IX, although reserve cell population was positive for CA-IX.
Carbonic Anhydrase Type IX Expression in Lobular Endocervical
Conclusions:
CA-IX appears to be a promising marker for the detection of gastrictype adenocarcinoma and ALEGH, and might play a crucial role in the HPV-unrelated pathway of carcinogenesis, as represented by LEGH-gastric-type adenocarcinoma sequence. From the point of view for practical use of this particular marker, it should be emphasized that; (1) CA-IX staining is rather heterogeneous in cases of adenocarcinoma, and (2) LEGH and ALEGH are also CA-IX-positive, and therefore, results of the staining should be combined with morphology.
Signifi cance of Alterations of the RB1 Pathway in High Grade Serous Carcinoma
A Milea, SHL George, H Berman, M Gauthier, PA Shaw. University Health Network, Toronto, Canada. Background: High grade serous carcinoma (HGSC) of the ovary/tube is characterized by a low prevalence of recurrent mutations, numerous DNA copy number changes and promotor methylation events. An understanding of the aberrant genes and pathways should lead to more effective targeted therapies. The mechanisms of one commonly deregulated pathway, the RB pathway, are not well understood and we hypothesize that different mechanisms may identify clinically distinct subgroups of HGSC. Design: All cases included for study were HGSC, controlled for grade, stage, and treatment, with followup data avalable. Snap frozen tissue samples from 75 cases were obtained for molecular profi ling, including RB1 loss of heterozygosity (LOH), gene expression analysis, and SNP and copy number analysis. Immunohistochemistry for RB1, CDKN2A, CCNE1, CCND1, CCND2 was completed using 102 cancer cases and 15 tubal epithelial precursor lesions. Correlations between RB pathway alterations were determined and prognostic signifi cance assessed. Results: RB1 LOH was frequent, seen in 76% of 42 cases, with RB1 hemizygous deletions present in 33% of 75 cases. CDKN2A hemizygous deletions were seen in 8%, and amplifi cation in 16% of cases. Immunohistochemistry for p16 showed a diffusely strong homogenous pattern of positivity in 51%, low or negative staining in 20%, and a heterogeneous pattern in 29%. RB1 staining was positive in 60%. RB1 LOH did not correlate with RB1 protein expression, but there was a strong correlation with p16 staining. Clinical outcome was predicted by three patterns of RB1/ p16 staining. The RB1+/p16 homogeneous pattern subgroup identifi ed 38% of tumors with the shortest recurrence free survival at 14 months, while the RB1+/p16 heterogeneous subgroup (30%) and the RB1-/p16 homogenous subgroup (32%) had an improved recurrence free survival of 22.5 months. Patterns of RB1/p16 staining seen in HGSC were identical in synchronous Tubal Intraepithelial Carcinomas. Conclusions: Deregulation of the RB pathway is frequent in HGSC, and occurs through various non-redundant mechanisms. A strong homogeneous pattern of CDKN2A protein expression identifi es a signifi cant percentage but not all of HGSC, and correlates with RB1 LOH. RB1 protein expression stratifi es CDKN2A staining into 3 clinically distinct groups, refl ecting differences in tumor biology which may have treatment implications. The presence of similar staining patterns in the immediate precursor lesion of HGSC suggests RB pathway abrogation is an early genetic alteration.
Signifi cance of Complement Split Product C4d Deposition in Paraffi n-Embedded Placenta of Systemic Lupus Erythematosus (SLE) and Pregnancy Induced Hypertension (PIH) S Minamiguchi, Y Mikami, Y Iemura, E Kondoh, K Tatsumi, I
Konishi, H Haga. Kyoto University Hospital, Kyoto, Japan. Background: SLE and PIH are both related to premature labor and intrauterine growth retardation (IUGR) with similar histological fi ndings of the placentas. The mechanism of placental injury of these different disorders, however, is still unclear. The purpose of this study was to investigate the utility of C4d immunostaining in placentas of SLE and PIH. Design: Immunostaining of C4d was performed on paraffi n-embedded tissue sections of placentas from 21 patients with SLE including 2 curettage cases because of uncontrollable clinical conditions, 21 with PIH, and 20 control cases. We used H-score for the evaluation of C4d immunoreactivity: The score was obtained by the formula: 3 x percentage of strongly staining trophoblasts plus 2 x percentage of moderately staining trophoblasts plus percentage of weakly staining trophoblasts, giving a range of 0 to 300. Clinical data were compared to H-score in both SLE and PIH. Results: Immunoreactivity of C4d was signifi cantly greater in villous trophoblastic membranes in SLE and PIH cases compared to control cases (P<0.05). Twelve (57%) of SLE including 2 curettage cases and 7 (33%) of PIH showed intermediate to strongreactivity of C4d, with an H-score ranging from 14-270 and 15-105, respectively. All H-scores of control cases were less than 4. Placentas with intermediate to strong reactivity of C4d showed signifi cantly low-placental weights (SLE, P<0.01; PIH, P<0.05), low-birth weights (SLE, P<0.01; PIH, P<0.05), and preterm birth in SLE (P<0.05) compared to low H-score (0-3) cases for each disorder.
Conclusions:
The degree of C4d immunoreactivity was associated with low birth and placental weight in both PIH and SLE, and with preterm birth in SLE. These fi ndings suggest that complement cascade is related to placental abnormality of both PIH and SLE. The evaluation of C4d in paraffi n-embedded placenta, including abortion and curettage specimens, may be important information for subsequent pregnancies in these patients.
Inadequate Endometrial Biopsies Follow-Up and Proposed
Adequacy Criteria M MoghadamFalahi, s Pokharel, H Alatassi. University of Louisville, Louisville, KY. Background: Endometrial biopsies and curettings are among the most common specimens received in the pathology laboratory. In several aspects, these specimens present a unique challenge for surgical pathologists, and one of them is the adequacy.
Since there is no defi ned criteria for adequacy, pathologists should exercise judgment in reporting adequacy based on the clinical information and age of the patient. Design: We reviewed all endometrial biopsies from January 2009 to August 2011 that were performed at our institution. We selected the cases that were diagnosed as insuffi cient or inadequate. The cases with the available follow up were reviewed. The fi nal diagnoses on these cases were evaluated in order to confi rm the inadequacy of the samples and to further categorize the causes of inadequate or insuffi cient diagnosis. Results: A total of 141 endometrial biopsies were found. 60 cases had available follow up biopsy or curetting. 41 (68%) of these patients were 45 years old or older. In the subsequent follow up, 17 cases (28%) had signifi cant fi ndings, which consisted of 2 cases of endometrial adenocarcinoma, 8 cases (13%) with complex hyperplasia with atypia, and 7 cases (11%) of endometrial polyp. The remainder of the cases revealed benign fi ndings mostly composed of atrophic endometrium in post menopausal status. From the above 60 cases, 39 cases (65%) showed no endometrial tissue. These biopsies consisted of blood, mucus and endocervical tissue. 15 cases (26%) showed superfi cial or minimal endometrial tissue and 6 cases (10%) were from the lower uterine segment mixed with endocervical glands. Conclusions: This study emphasizes the importance of avoiding diagnostic terms such as "no signifi cant pathological fi ndings" and the importance of appropriate description of the microscopic fi ndings. We strongly suggest that the endometrial biopsies be qualitatively and quantitatively evaluated. The absence of enough well preserved endometrial tissue from the body and fundus should be clearly transferred to the clinicians with the appropriate use of terms insuffi cient, inadequate or unassessable. In our experience the absence of the above mentioned statements in the fi nal report, can be interpreted as "negative for hyperplasia and malignancy" by some clinicians, and these patients will not be appropriately managed. In our study, the three most common instances which these statements should be used are: 1) No endometrial tissue present, 2) Scant endometrial tissue from the lower uterine segment, or 3) Only endometrial stroma with minute fragments of endometrial glandular strips. Background: Recent studies document a shared increased rate of ARID1A mutations in endometriosis and endometriosis associated carcinomas and a common endometriosiscarcinoma pathway has been proposed. However, the relative proportions, association with other histologic types, and site of origin (ovarian vs extra-ovarian) have not been well examined.
Design: We performed a retrospective, consecutive review of pathology reports to identify all malignancies associated with concurrent endometriosis in the past 10 years using the following parameters in our search criteria: "endometriosis", "endometriotic", "endometrioma" in association with the following: "carcinoma", "adenocarcinoma", "borderline", "low malignant potential", "sarcoma", "adenosarcoma", and "carcinosarcoma". In each case, the primary site and type of tumor was recorded in addition to the site(s) of endometriosis.
Results: 396 cases of simultaneous endometriosis and gynecologic malignancy were identifi ed. The most common site of malignancy was the ovary (67%), followed by uterus, fallopian tube, pelvis/peritoneum, and cervix. The 3 most common types of malignancies were endometrioid (45%), clear cell (23%) and serous carcinomas (13%). Analysis of the entire 10 year data set suggested the majority of endometriosisassociated ovarian carcinomas were endometrioid (53%), followed by clear cell (17.5%), and serous (15.6%). However, subanalysis of the ovarian cancers diagnosed in the last fi ve years (almost all of which were diagnosed by gynecologic pathologists using standard diagnostic criteria, often in conjunction with immunohistochemistry), showed a preponderance of clear cell carcinomas (37%) with fewer serous (16%) and endometrioid (33%) carcinomas. In contrast, extra-ovarian endometriosis-associated cancers were more commonly endometrioid (64% and 68%, 10-year and 5-year analyses). Extra-ovarian endometriosis-associated clear cell carcinoma was extremely rare (4% and 6%, 10-year and 5-year analyses).
Conclusions:
Clear cell carcinoma is the most common ovarian cancer associated with endometriosis when tumor classifi cation is based on uniform diagnostic criteria informed by immunohistochemistry and subspecialty-trained gynecologic pathologists. However, this subtype is extremely rare in extra-ovarian endometriosis associated cancer. These data suggest that the endometriosis-carcinoma pathway is non-uniform and differs depending on site of disease. The most common site of recurrence of low grade endometrial adenocarcinoma is the vagina; however, there is no clear explanation of how the tumor cells colonize the vagina. Design: In this multi-institutional study we compiled data from 113 patients from 1991-2011 with FIGO 1 and 2 endometrial adenocarcinomas with recurrence, and 187 control cases that did not recur and had similar follow-up time (44 and 59 months, respectively). We further stratifi ed this group and compared multiple risk factors for patients with vaginal recurrence, patients with recurrence in other sites, and control patients.
Results: There were no signifi cant differences in the age of patients, type of surgical procedure, gross appearance or grade of the neoplasm. There were signifi cant differences in many high risk factors associated with extravaginal recurrence compared with our control group and patients with vaginal recurrence. These include average tumor size, average depth of myoinvasion, presence of microcystic, elongated and fragmented (MELF) pattern of myoinvasion, presence of lymphovascular invasion (LVSI), documented cervical involvement, and death secondary to disease (DOD).
Risk factors in cases and controls:
Site of Recurrence Tumor Size (cm) Conclusions: 1. The known risk factors in low grade endometrial adenocarcinoma for patients with vaginal recurrence are similar to control cases, not to those of patients with recurrences in other sites. 2. The only parameter seen in patients with vaginal recurrence that is signifi cantly different than controls is the presence of cervical involvement (25% vs 8%). 3. Only 9.8% of patients with vaginal recurrence died of disease. This suggests that this site of recurrence is not an indication of aggressive behavior. 4. The presence of increased cervical involvement, but absence of other high risk factors and low incidence of mortality in patients with vaginal recurrence raises the hypothesis of contamination of the vagina during the surgical procedure. . The PTEN/AKT pathway is activated in EEC and induces deregulation of various FOXO proteins, a family of transcription factors that controls cell fate. FOXO1 which is involved in cell cycle regulation, apoptosis, and cell differentiation, is also controlled by miRNAs. For the fi rst time, we study the expression of miRNA signatures and FOXO1 in a series of non-invasive and invasive EEC. Design: miRNA expression signatures were studied in a series of 25 EEC and 5 normal endometria. Results, were validated in a series of 41 additional EEC by quantitative PCR for miR-27 and FOXO1, and immunohistochemistry for FOXO1 and active Caspase 3. Also PIK3CA and PTEN gene mutations were assessed by sequencing analysis for exons 9 and 20 of PIK3CA, and exons 1-9 of PTEN genes.
miRNAs Regulate Myometrial Invasion in Endometrioid Endometrial Carcinoma
Results:
In unsupervised hierarchical clustering analysis, normal endometria and non-invasive EEC were grouped together and separately from invasive and advanced stage tumors. A signature of 20 miRNAs was found to be differentially expressed in invasive and non invasive tumors (adjusted p value <0.001). One of them, miR27, was overexpressed in invasive carcinomas when compared to non invasive EEC (p=0.0013) and its expression increased linearly in each stage (p=0.001). Differences between non-invasive and invasive EEC were also observed in the validation group (p=0.045). Moreover, FOXO1, the main target of miR27, was downregulated in invasive tumors when compared to non-invasive tumors (p=0.033). Accordingly, we found that expression of active caspase 3 was higher in non-invasive than in invasive EEC (p=0.023). By immunohistochemistry, all tumors lacked FOXO1 immunoreaction whereas normal endometria were immunoreactive. In invasive tumors, miR27 overexpression (p=0.032) and FOXO1 downregulation (p=0.014) also occurred in unmutated PIK3CA tumors (n=27). Conclusions: Different miRNA signatures were found in invasive and non invasive EEC. The miR27-FOXO1 tandem inhibits apoptosis and represents an alternative mechanism of tumor cell survival in unmutated PIK3CA cases.
P16 Expression in Early Müllerian Serous Carcinogenesis
H Nafi si, Z Ghorab, N Ismiil, R Saad, V Dube, MA Khalifa, S Nofech-Mozes. University of Toronto, Toronto, Canada; Sunnybrook Health Sciences Centre, Toronto, Canada. Background: Mutation of tumor suppressor gene p53 is believed to be responsible for the initiation and progression of serous endometrial (ESC) and ovarian (OSC) carcinomas as well as their early/localized forms: endometrial intraepithelial carcinoma (EIC), tubal intraepithelial carcinoma (TIC) and the putative precursor p53 signature (p53S). In the majority of cases, p53 mutation is associated with p53 immunoreactivity; however, some molecular events do not result in p53 protein accumulation. Recent studies demonstrated P16 expression in ESC and OSC but data on its expression in early serous carcinogenesis is limited. We aimed to examine p16 immunoreactivity in EIC, TIC and p53S. Design: We studied p53 and p16 expression in EIC (n=27; 9 pure EIC and 18 with adjacent ESC), TIC (n=10) and p53S cases (n=11), using immunohistochemistry. Expression [percent staining (score 0-4) + intensity (score 1-3)] was assessed in the neoplastic epithelium and categorized as positive if the combined score was ≥5. Results: Among EIC cases, 22/27 (81%) were positive for p53 and 27/27 (100%) for p16. Among ESC cases 14/18 (78%) were positive for p53 and (17/18) 94% for p16. Among TIC cases, 9/10 (90%) were p53 positive and 10/10 (100%) were p16 positive. P53 was negative in 4 cases on both EIC and ESC components, one pure EIC and one TIC case. All p53 negative cases had typical morphologic features of serous/ intraepithelial carcinoma. P53 was positive in all 11 p53S by defi nition, while p16 was universally negative.
Conclusions:
We analyzed the gene products of p53 and p16 with pivotal role in cell cycle regulation and tumorigenesis. There is a high level of concordance between p53 and p16 expression in ESC and EIC component. These results suggest that p16 has a role in early müllerian serous carcinogenesis but is absent in non-committed lesions such as p53 signature. P16 immunohistochemistry is more sensitive than p53 in identifying early/localized forms of serous carcinoma and can be used as an adjunct confi rmatory tool in p53 negative cases.
Multiplex Short Tandem Repeat (STR) Genotyping of Complete Hydatidiform Moles: Analysis of Zygosity and Presence of Invasive Gestational Trophoblastic Disease at Presentation
N Nasseri-Nik, C DeScipio, KM Murphy, R Vang, BM Ronnett. The Johns Hopkins Medical institutions, Baltimore, MD. Background: The vast majority of complete hydatidiform moles (CHM) are androgenetic diploid, with most (>80%) arising from fertilization of an egg lacking maternal DNA by a single sperm that duplicates (monospermic/homozygous 46,XX) and a small subset arising via fertilization by 2 sperm (dispermic/heterozygous 46,XY or 46,XX). It remains controversial whether dispermic/heterozygous CHMs have a signifi cantly greater risk of persistent gestational trophoblastic disease (GTD). Analysis of zygosity of CHMs with and without invasive GTD at presentation has not been specifi cally addressed. Design: In a series of 390 products of conception specimens analyzed by p57 immunohistochemistry and STR genotyping for diagnosis and subclassifi cation of hydatidiform moles, 125 CHMs were diagnosed. Of these, 69 were genotyped (including all with invasive disease). Zygosity was compared between those with and without invasive GTD at presentation. Results: Of the 69 genotyped CHMs, 7 (10%) were invasive CHMs at presentation (in hysterectomy specimens); 2 of these were accompanied by choriocarcinoma in the uterus, 1 with pulmonary nodules consistent with metastatic GTD. 10 of 69 (14%) CHMs were dispermic (all XY) and 59 (86%) were monospermic (XX). 5 of 59 (8.5%) monospermic CHMs and 2 of 10 (20%) dispermic CHMs were invasive at presentation (p=0.27). The 2 invasive CHMs accompanied by pathologically documented choriocarcinoma were monospermic. Conclusions: Dispermic XY CHMs, which represent only ∼15% of CHMs, have a greater risk of being invasive at presentation but this difference did not reach statistical signifi cance. However, the 2 examples of invasive CHMs associated with choriocarcinoma were monospermic XX, indicating that this form is not without risk of signifi cant GTD. Follow-up analysis is required to assess the risk of persistent GTD in these 2 genetic types of CHMs. Background: Serous tubal intraepithelial carcinoma (STIC) is a non-invasive phase of pelvic serous cancer at risk for metastasizing. Because of its biologic signifi cance, its accurate distinction from non-malignant mimics is important. This can be achieved in part by the application of histologic criteria and immunostaining with biomarkers (p53, Ki-67). However, consistently distinguishing STIC from proliferative or expansile lesions with p53 mutations (p53 signatures) remains diffi cult. Loss of cell orientation is an important feature of STIC. Certain proteins, such as Ezrin-Radaxin-Moesin (ERM) are involved in cytoskelaton organization and when activated (phosphorylated or P-ERM) concentrate on the apical cytoplasmic membrane of polarized epithelia. We sought to determine if P-ERM would be useful in distinguishing STIC from its benign couterparts in oviductal mucosa. Design: A range of oviductal epithelia, including STICS (20), serous carcinomas (10), benign secretory outgrowths (SCOUTs) with (p53 signatures, 4) and without altered p53 staining (10), and expansile or proliferative p53 signatures (3) were immunostained with an antibody to P-ERM. Staining patterns were compared with attention to their location and intensity. Results: P-ERM staining was linear and luminal in normal mucosa, with weaker staining of the cell membranes. In STICS, the luminal staining was either lost or disrupted, producing a discontinuous pattern, with increased staining of individual cell membranes, a feature also seen in invasive carcinomas. Expansile or proliferative p53 signatures maintained the apical staining with variable cell membrane staining. Other SCOUTs and normal epithelium displayed a similar staining pattern. The intensity of P-ERM staining in the former was less but not accompanied by conspicuous staining of individual cell membranes. There was no apparent relationship between P-ERM staining and proliferation (MIB1).
P-ERM, a Marker of Cell
Conclusions:
We show, for the fi rst time, that an immunohistochemical correlate of cell polarity (P-ERM) shows an altered expression pattern in STIC that will distinguish it from its benign counterparts, including proliferative p53 signatures. If confi rmed this fi nding warrants further analysis of this and other indices of cell polarity as objective markers for diagnosis and mapping the evolution of early pelvic serous cancer. Background: Ovarian clear cell adenocarcinoma (CCA) is frequently associated with endometriosis, and less often with an adenofi bromatous component (AF). While one study suggested that AF might be a factor for less aggressive behavior, the other study showed contradictory results. We conducted a retrospective study to examine prognostic impact of AF in Stage I CCA. Design: Eighty-nine cases (age: 32-84yrs, average 54.9yrs) of Stage I CCA surgically treated between 2000 and 2007 were included in the study. All H-E slides of the ovarian tumors were reviewed for the presence of AF and endometriosis associated with carcinoma. The number of low-power (x40) fi elds (LPF) with AF was counted. Peritoneal cytology at the time of laparotomy was also reviewed. A multivariate Cox proportional hazards model was used to assess the association of potential prognostic factors (AF, endometriosis, peritoneal cytology) with disease-free survival. Conclusions: Carcinomas restricted to the LUS form a unique group of endometrial cancer characterized by younger age at presentation and more frequent undifferentiated histology. LUS tumors also trend towards high grade, non-endometrioid histology and more frequent association with Lynch syndrome, but this does not appear to be statistically signifi cant. N Ozeren, D Gumurdulu, B Guzel, H Zeren, M Ergin, MA Vardar, A Altintas. Cukurova University, Faculty of Medicine, Adana, Turkey. Background: Endometrial cancers are the most common cancers of the female genital tract that more than 80% of it consist of endometrioid type adenocarcinomas. In endometrial carcinomas, the underlying factors and their correlation with several histologic and clinical parameters are guiding the patients follow up and new treatment methods. In our study, CTNNB1 mutation, β-catenin and E-cadherin expressions are examined and their relationship with the prognostic parameters and survival are studied. Design: To the study, ninety three endometrioid adenocarcinoma, and fi fteen atypical endometrial hyperplasia cases were included and those cases were diagnosed at Cukurova University, Medical Faculty at the Pathology Department between the years 2002-2007. We have investigated the expression of β-catenin, E-cadherin by immunohistochemistry and CTNNB1 mutation by PCR in all cases. Results: In 93 endometrioid adenocarcinoma cases, membranous and cytoplasmic β-catenin expression was found in 74 cases, nuclear β-catenin expression was found in 14 cases, negative β-catenin expression was found in 5 cases. All of the 15 atypical endometrial hyperplasia cases displayed cytoplasmic and membranous β-catenin expression. In univariete analysis, β-catenin was found to have prognostic signifi cance with survival. In multivariete analysis, negative β-catenin expression was found as an independent prognostic factor. CTNNN1 mutation was found in 34 (36.6%) of 93 endometrioid adenocarcinoma, and it was found in 3 (20%) cases out of 15 atypical endometrial hyperplasia cases. There was a signifi cant correlation between CTNNB1 mutation and histologic grade. Decreased mutations were found in high grade tumors. There were statistical signifi cance between E-cadherin expression and tumor grade, lymphovascular invasion, and metastasis of lymph node. Conclusions: In this study, it has been shown that CTNNB1 mutation take a role early steps of carcinogenesis in endometrioid adenocarcinoma and negatif β-catenin expression was found to be an independent prognostic factor for survival. Design: The immunohistochemical expression of CYP27A1, the Vitamin D receptor (VDR), and 24-hydroxylase (CYP24, the enzyme that degrades vitamin D metabolites) was examined in tissue microarrays (TMA) from 80 samples of normal endometrium, and 157 endometrial carcinomas (ECs) with different histological types, FIGO grades, and pathological stages. Three EC cell lines (IK, RL95, HEC1A) were incubated with vitamine D3, and subjected to clonogenic assays. Results: In normal endometrium (NE), average CYP27A1 and VDR expression levels were lower in the proliferative phase compared to the secretory phase (p=0.06 and p< 0.000, respectively). Interestingly, CYP27A1 expression was signifi cantly higher in EC than in normal endometrium (p = 0.0002) suggesting an attempt by EC cells to compensate for the marked reductions in average VDR levels (EC: 90.7 vs. NE: 142.5; p = 0.0002). In fact, the functional relevance of local vitamin D activation by CYP27A1 in the control of cell carcinogenesis was demonstrated by a dose dependent reduction in the number of EC colonies formed upon a 48 h exposure of the human EC cell lines IK, RL95 and HEC1A to vitamin D3. Furthermore, CYP27A1 was signifi cantly decreased in FIGO grade III tumors (p = 0.072) and stage III carcinomas (p = 0.003). The expected reductions in the levels of CYP24 in parallel with those of VDR expression rule out a role for enhanced catabolism of vitamin D metabolites in EC carcinogenesis in vitamin D defi cient states. Conclusions: Defective local bioactivation of vitamin D, due to vitamin D defi ciency or reduced CYP27A1 expression, contributes to endometrial cell carcinogenesis through an impaired control of cell proliferation. Background: Endometrioid proliferations exhibit a wide variety of morphological variants, including spindled, corded, sertoliform, and microglandular. We have recently encountered a form of endometrial metaplasia that demonstrates morphology reminiscent of mesonephric hyperplasia in the uterine cervix, similar to that previously described as a deceptive pattern of cervical invasion by endometrial carcinoma. Herein we describe the features associated with this unique form of metaplasia. Design: A total of 14 cases featuring discrete proliferations of small, rounded and uniform tubules with cytologically bland nuclei were identifi ed by retrospective review of recent consultation fi les. H&E stained slides were reviewed and each case was classifi ed as simple metaplasia, hyperplasia, or carcinoma. In selected cases, immunohistochemical studies were performed to confi rm endometrial origin with a panel of 3 markers (ER, vimentin, p16) . Results: Of the 14 cases, 8 were associated with carcinoma, 3 were associated with hyperplasia and 3 were associated with benign processes. In each case, the characteristic glands were small, somewhat crowded in relation to the adjacent uninvolved endometrium, and round or tubular in contour. The gland lumens often contained pale staining, occasionally dense eosinophilic secretions. Nuclei were only mildly atypical, but mitotic fi gures were almost always present. The gland clusters tended to occur in the basalis of the endometrium or lower uterine segment, intermingling with normal uninvolved glands and sparing the superfi cial zone even when associated with an endometrioid carcinoma. Conclusions: Mesonephric-like endometrial glandular proliferations represent a unique form of metaplasia, often arising along the basalis of the endometrium. This predilection for basalis and lower uterine segment (which may refl ect a muted response to prevailing hormonal mileu) may account for the previously recognized unusual microglandular pattern of cervical spread by some endometrioid carcinomas. KJ Park, I Alvarado-Cabrero, G Rasty, SR Hong, JG Chanona-Vilchis, A Diaz De Vivar, B Arville, DA Barbuto, JKL Rutgers, AA Roma, R Ali-Fehmi, F Tabassum, N Teramoto, Y Mikami, EG Silva . MSKCC, New York; Mexican Oncology Hosp, Mexico City, Mexico; Univ Health Network, Toronto, Canada; Kwangdong Univ, Seoul, Korea; Inst Nacional de Cancerologia, Mexico City, Mexico; MDACC, Houston; Cedars Sinai Med Cnt, Los Angeles; Long Beach Memorial Hosp, Irvine; Cleveland Clinic, Cleveland; Wayne State, Detroit; Shikoku Cancer Cnt, Ehime, Japan; Kyoto Univ, Kyoto, Japan. Background: The treatment of endocervical adenocarcinoma (EAC) is largely based on tumor depth of invasion (DOI); however, this crucial prognostic parameter is pathologically diffi cult to measure accurately or consistently. Greater than 95% of lymph nodes (LN) resected in EAC are negative, yet such aggressive LN dissections cause signifi cant morbidity without obvious clinical benefi t to patients, many of whom are at a young age. Therefore, we investigated other pathologic parameters that may better identify patients at risk of developing LN metastases. Design: Cases diagnosed and treated as EAC from 12 institutions were reviewed. Clinical information and pathologic features were assessed, including: DOI, tumor size, LVI and pattern of tumor invasion using a newly devised system, defi ned as follows: Pattern A = well-demarcated glands, regardless of DOI Pattern B = early stromal invasion arising from well-demarcated glands Pattern C = diffuse, destructive invasion Results: 360 cases were identifi ed (stage IA1 to IVB). Ages ranged from 20 to 83 years (mean 44.9) and DOI ranged from 0.5 to >40mm (mean 7.7mm). LVI was present in 145 cases. Table 1 shows outcome data comparing the standard method of tumor evaluation (DOI) vs. the newly proposed pattern-based method: (GC) are diffi cult to interpret in the presence of secretory differentiation. We determined how often EIN and GC lesions with secretory differentiation are associated with background changes referable to circulating progestins. Design: We identifi ed all sequential cases over a 69 month interval in which the diagnostic report contained the descriptor "secretory" and either "EIN" or "gland crowding". 36 EIN and 24 GC cases had slides available. Morphologic features in lesional and background endometrium, and presence within a polyp, were recorded by two observers blinded to prior report diagnoses. All observations were analyzed separately for EIN and GC groups. Results: EIN patients studied averaged 45.2 years of age, and those with GC 46.6 years, both signifi cantly younger (p<0.01) than historical average (53 years) of all patients diagnosed with EIN at our institution. Background: Epithelial maturation traditionally is used to grade CIN in histologic sections. However, in some an immature epithelium displays atypia that is low in proportion to the level of epithelial maturity. Although MIB1 and p16ink4 are helpul in establishing the diagnosis of CIN in this setting, classifying such lesions can be problematic. We analyzed a subset of these atypias, and this study summarizes a correlation between morphology and p16 and MIB1 immunostaining. Design: Immature metaplastic atypias were divided into those with putative low (uniform nuclear spacing, minimal nuclear variation, absent or mild nuclear hyperchromasia) and high-grade (irregular nuclear spacing, heterogeneous nuclear morphology, increased nuclear chromasia) features. Immunohistochemical staining for p16 was classifi ed as patchy or diffuse (horizontally) and MIB-1 proliferation index was recorded as percentage of positive cells and location of elevated proliferative index as a function of basal, middle and superfi cial third of the epithelium. Staining patterns and histologic grade were correlated. Results: Forty-three cases were classified without knowledge of the immunohistochemistry. Immature metaplastic low grade CINs exhibited strong and diffuse staining for p16 and but unlike High grade CINs, the proliferating (MIB1+) cells were concentrated in the more basal 1-2 thirds of the epithelium and the proliferative index was less than 30%. Variable columnar differentiation was observed in some, with strong staining of both the columnar and squamous cells by p16.
CTNNB1 Mutation, ß-Catenin and E-Cadherin Expression and the Relationship with Clinical and Histopathological Prognostic Factors in Endometrial Adenocarcinomas and Hyperplasias
Downregulation of CYP27A1 Expression and Activity in Human
Endocervical Adenocarcinoma -Proposal for a New PatternBased Classifi cation System with Signifi cant Clinical Implications: A Multi-Institutional Study
Conclusions:
A distinct subset of immature CINs displays a uniform cell population and based on both cytology and proliferative index, warrants classifi cation as low grade CIN (CIN1). p16 immunohistochemistry, although helpful in the recognition of these lesions, will not distinguish them from higher grade CIN (CIN2/3). Attention to regularity in nuclear morphology with absence of noticeable differences in cell size and shape, combined with MIB1 staining, is helpful,. The presence of columnar differentiation, which also stains positive for p16 is consistent with bidirectional differentiation in the transformation zone epithelium. Further studies of this entity are warranted to precisely determine its biologic behavior. D Patel, SK Mohanty, K Singh, C Walsh, EG Silva. Cedars-Sinai Medical Correct classifi cation has a potential impact on therapy since not all lesions need adjuvant chemotherapy, and not all tumors respond equally to standard chemotherapy. The aim of this study was to determine interobserver agreement in the diagnosis of ovarian carcinomas between specialized gynecological (GYN) pathologists and general (GEN) surgical pathologists. Design: We selected 58 ovarian carcinomas surgically resected at SBUMC between 1/1/1999 and 6/1/2011, including 23 high grade serous carcinomas, 19 clear cell carcinomas, and 16 endometrioid carcinomas. All cases were reviewed by a senior GYN pathologist, and all diagnoses were confi rmed with immunostains for WT1, p53, ER, and hepatocyte nuclear factor 1-beta. Immunostains were done in tissue microarrays containing three random cores per tumor. Only cases in which all three cores had the same immunoprofi le were included in the study. One representative slide from each case was sent to 3 GYN pathologists and 3 GEN surgical pathologists, who were asked to classify the lesions according to their own criteria. The reliability of agreement between the pathologists was assessed using Fleiss' kappa value. Results: The reliability of agreement was "substantial" for the GYN pathologists (Fleiss' kappa value = 0.67), and "moderate" for the GEN pathologists (Fleiss' kappa value = 0.54). The most common problem was to confuse serous carcinoma with either clear cell carcinomas or endometrioid carcinomas. This happened in 13% of cases in the GEN group, but only in 0.7% in the GYN group. The accuracy rate for diagnosing serous carcinoma was 84.5% in the GYN group and 58.33% in the GEN group (p= 0.0003).
IMP3, EGFR and E-Cadherin in High Grade Ovarian Serous Carcinomas To Predict Disease Progression and Survival
Conclusions:
Interobserver agreement was better among GYN pathologists than general surgical pathologists. Diagnosis of ovarian carcinoma tumor type is more accurate when done by GYN pathologists than GEN pathologists. However, there is a small percentage of cases in which classifi cation by light microscopy alone is diffi cult even for GYN pathologists. If tumor type becomes an important factor in treatment decisions cases should be reviewed by a gynecological pathologist, and confi rmatory immunostains may be necessary when the H&E morphology is ambiguous. F Penault-Llorca, A Tchirkov, I Raoelfi ls, A Cayre, E Pierre, P Vago, G Chene. Centre Jean Perrin, Clermont-Ferrand, France; CHU, Clermont-Ferrand, France . Background: Through BRCA and P53 alterations, genetic instability plays an important contribution in ovarian carcinogenesis. We sought to study telomere shortening and surrogate markers of genetic instability in early and pre-invasive stages of ovarian cancer, serous tubal intraepithelial carcinoma (STIC) and tubo-ovarian dysplasia (TOD).
Genetic Instability in Serous Tubal Intraepithelial Carcinoma and Tubo-Ovarian Dysplasia from Prophylactic Oophorectomies for Genetic Risk
Design: 51 tubo-ovarian dysplasia from bilateral prophylactic oophorectomies (pBSO) with BRCA1 (36) or BRCA2 (15) mutation (defi ned by morphological score and immunohistochemical expression of p53, ALDH1 and gH2AX), 12 STICs, 53 ovarian high grade serous carcinoma and 36 control bilateral oophorectomies (nBSO) were laser-capture microdissected on formalin-fi xed paraffi n-embedded sections and analyzed by comparative genomic hybridization (CGH array) and for telomere length (T/S using quantitative real-time polymerase chain reaction based on the Cawthon technique (Nucleic Acid Res 2002 30:1-6)). Results: We found few subtle genomic alterations in dysplastic epithelium in opposition to the important genomic imbalances in STICs and ovarian cancers. STICs had the shortest telomeres followed by TOD in pBSO (respectively, T/S= 7.23 and T/S= 18.78).
Ovarian carcinoma (T/S= 30.68) had shorter telomeres than nBSO (T/S= 52.75) but longer than STICs and dysplasia.
All these differences were statistically signifi cant. When comparing telomere lenght in dysplasia from BRCA1 and BRCA2 pBSO, the shortest telomeres were observed in BRCA1 carriers. Conclusions: These fi ndings suggest that genetic instability occurs at early stages of ovarian and tubal carcinogenesis. Targeting genetic instability might be an option for prevention in high risk patients, but requires further studies. Immunohistochemical staining for CK20, CDX2 and SATB2 were performed and evaluated by two gyneco-pathologist. Results: Twenty-four mucinous tumors were identifi ed; 11 were classifi ed as metastatic according to clinical features (7 well-differentiated colon adenocarcinomas and 4 welldifferentiated adenocarcinomas of the appendix), the rest were catalogued as primary neoplasms of the ovary (at least 2 years of follow-up during which there were no carcinomatosis, pseudomixomas, or tumors at other sites). The primary neoplasms of the ovary were positive to CDX2 in 38% of cases, positive to CK20 in 92%, and all were negative to SATB2. The metastatic neoplasms were positive to SATB2 in 90% of cases, positive to CDX2 in 81%, and to CK20 in 100%. Specifi city SATB2 for differentiation of metastatic from primary was 96.4%, sensitivity 87.5%, PPV 95% and NPV90%, for CDx2 specifi city 61,5%, sensitivity 81,8%, PPV 64% and NPV 80%, CK20 specifi city 10%, sensitivity 95,8%, PPV 47,9% and NPV75%, respectively.
Conclusions: SATB2 appears to be a useful antibody in the differential diagnosis between primary and metastatic mucinous intestinal-type neoplasms, and highly sensitive in detecting lower gastrointestinal tract metastasis. Design: This is a multi institutional case-control study where 153 patients with LGEC and nodal disease were compared to 336 controls with negative lymph nodes. Studied variables included size and appearance of tumor, depth of myometrial infi ltration, cervical stromal and or lower uterine segment involvement (LUS), stromal reaction, intratumoral necrosis, LVI (divided as 0, 1 vessel, 2-5 vessels and more than 5 vessels), distance to LVI (adjacent to neoplasm and deeper than invasive front of tumor). Difference between mean estimates were evaluated by the student´s-T, Chi-square or We examined a consecutive series of EINs associated with EMPs to determine their likelihood of persisting or progressing to adenocarcinoma on followup sampling. Design: Consecutive cases coded as both EMP and EIN in the pathology fi les between 2009 and 2010 were identifi ed. Cases designated as arising in polyps were culled from this group, examined histologically and followup determined by a search of the pathology records. Results: Eighty-four cases coded as both EIN and EMP were identifi ed. Of these, the diagnosis of EIN occurring in EMP were confi rmed in 37. Followup endometrial sampling was obtained in 29 (78%). Of these 29, 13 (45%) showed no evidence of EIN, 12 (41%) contained persistent EIN, with or without a polyp and 4(14%) contained a well differentiated endometrioid adenocarcinoma. Conclusions: Close followup of women with EIN apparently confi ned to polyps will reveal the absence of EIN in nearly one-half of cases. Nevertheless, a nearly equal proportion will have persistence of their disease and 14% will be shown to have endometrial adenocarcinoma. Thus, while the possibility of complete removal of the EIN by polypectomy exists, the risk of persistence/recurrence requires close followup. The range of EIN morphologies seen in polyps will be illustrated.
Results: A pushing invasive pattern was seen in 24/34 (71%) metastatic cases with BRCA1 or BRCA2 abnormality, as compared with metastatic sites of negative BRCA1 germline or other high grade serous cases with no BRCA abnormality, which showed characteristically non-micropapillary, infiltrating invasion (89/89 cases, 100% Amplifi cation was present in 2,1% for HER-2 and 6,4% for EGFR. Overexpression of HER-2 corresponded to poorly differentiated tumors (p=0,0221), presence of vascular invasion (p=0,0314), recurrence (p=0,05) and death by cancer (p=0,0349). Lower survival rates were observed in tumors scored as 3+ for HER-2 (p=0,0445), but it was not signifi cant for EGFR. EGFR expression showed no association with the analyzed clinical and histological data. Conclusions: Our study shows a novel data regarding the 100% correlation between FISH and IHC for HER-2 and EGFR in vulvar carcinoma which allows the distinction between two entities of negativity (score 0, 1+ and 2+) and positivity (3+) of these oncogenes in vulvar cancer. Despite of the rare overexpression found for HER-2, it can possibly be associated with a more aggressive phenotype of the tumors. The lack of association between EGFR expression with the analyzed clinical and histological data may be due to the heterogeneity of the vulvar carcinomas. Still, the overexpression of both membrane receptors, although rare, could benefi t a small group of patients with therapy against these tyrosine kinase receptors. Background: Transitional cell tumors of ovary are a set of tumors that resemble tumors of the urothelium. They are relatively uncommon and comprise approx. 1-2% of all ovarian tumors. In rare instances one may have to differentiate these tumors from metastatic transitional cell carcinomas (TCC) to ovary. There has been recent interest in numerous markers, especially PAX8 and PAX2. The immunohistochemical profi le of these tumors is not well studied. Design: Paraffi n blocks from 15 cases of benign Brenner tumor were selected for staining. In addition, we studied 4 cases that were diagnosed in our institution as being transitional cell carcinomas (TCC) of ovary and one case that was a metastatic TCC from the bladder. Six immunostains were performed on these cases -PAX2, PAX8, CK7, CK20, p-63 and uroplakin. Immunostains were graded visually for extent of staining 0 (0%), 1+ (1-33%), 2+ (34-66%) and 3+ (>67%); and for intensity of staining as 1+ (weak), 2+ (moderate) and 3+ (strong). Results: Benign Brenner tumors showed positive staining with CK7 in 92% (12/13), p63 in 92% (11/12) and PAX8 in 7% (1/14). These tumors showed no staining with CK20 (0/12), uroplakin (0/8) and PAX2 (0/12). Cases of ovarian TCC showed positivity for CK7 and PAX8 in 4/4 cases; and p-63 in 1/4 cases. None of these cases stained with CK20, uroplakin and PAX2. One case of metastatic TCC from bladder showed positivity for CK7, PAX2, PAX8 and p63, with negative staining for uroplakin and CK20. Conclusions: Transitional cell tumors of ovary appear immunophenotypically different from transitional cell tumors of the urinary tract. Brenner tumors are CK7+/CK20-/p63-/ uroplakin-/PAX2-/PAX8-and do not share immunophenotype of urinary tract TCCs. PAX8 is known to be strongly positive in thyroid tissues and our one case of Brenner tumor that showed PAX8 positivity had concomitant struma ovarii. TCCs of ovary similarly are CK7+/PAX8+/CK20-/p63-/uroplakin-/PAX2-. The positivity noted with PAX8 stain likely refl ects the mullerian origin of tumor. These tumors were high grade and the possibility of admixed serous carcinoma is not excluded. The metastatic TCC showed an immunophenotype of its parent tumor and this is distinct from the staining pattern of all the other tumors. We did not have any cases of borderline and malignant Brenner tumors. Additional immunostains (ER and WT-1) are in process for further immunophenotypic characterization of these tumors. In-situ carcinomas of the cervix are exemplifi ed by endocervical adenocarcinoma in-situ (AIS) and high grade squamous intraepithelial lesions (HSILs). Both AIS and HSIL present histologically as hyperchromatic crowded groups of epithelial cells displaying loss of polarity and hyperchromatic nuclei with coarse chromatin. Occasionally, small strips of neoplastic epithelium can be diffi cult to precisely classify as glandular or squamous. Hence, we sought to investigate the expression of PAX8 and PAX2 in AIS and HSIL. Design: We identifi ed 66 cases of AIS from the pathology archive. In 18 of these 66 cases, concurrent HSILs were present. Immunohistochemistry for PAX8 and PAX2 were performed and nuclear expression of these markers were examined in all cases. Semiquantitative scores with respect to staining intensity (0, negative; 1, weak; 2, moderate; 3, strong) and extent of staining (0, no staining; 1, <25% cells positive; 2, 25-50% cell positive; 3, >50% cells positive) were recorded for benign endocervical glandular epithelium as well as foci of AIS and HSIL. For each, the two scores were added for a combined score of 0 to 6. A combined score of 2 or less was considered negative whereas a combined score greater than 2 was considered positive. Results: PAX8 positivity was observed in 64 (97%) of 66 cases of AIS. PAX2 was positive in 3 (5%) cases of AIS; PAX2 expression was lost in 63 (95%) of the 66 foci of AIS. In 62 of these 66 cases, benign endocervical glandular epithelium was present in the immunostained slides; PAX8 and PAX2 positivity was seen in 62 (100%) and 60 (97%), respectively. Seven (39%) and 0 (0%) of the 18 HSILs were positive for PAX8 and PAX2, respectively. The difference in PAX8 expression of AIS versus HSIL was statistically signifi cant (Fisher exact test, p<0.05).
Conclusions:
Immunohistochemistry for PAX2 is effective in confi rming the diagnosis of AIS, as benign endocervical glandular epithelium is typically PAX2(+) whereas neoplastic endocervical glandular epithelium is usually PAX2(-). The far majority of AIS lesions and a subset of HSILs are PAX8(+). With regards to the distinction between AIS and HSIL, a PAX8(-) immunophenotype is particularly predictive of high grade squamous dysplasia. is a growing tendency to treat advance ovarian cancers with neoadjuvant chemotherapy followed by debulking surgery. In these cases, the initial diagnosis is made on a biopsy, or cytological examination of the peritoneal fl uid. The aim is to minimize tumour volume and obtain optimal cytoreduction. Treatment effects in such resections are reported, however, these chemotherapy induced effects on ovarian carcinomas have not been well studied. We sought to 1) assess chemotherapy changes in ovarian serous adenocarcinomas by comparing pre-and post-chemotherapy samples; and 2) examine grading post-chemotherapy. Design: Archival cases of serous adenocarcinomas were reviewed, including: group a) pre-treatment biopsies (n=9); group b) subsequent post-chemotherapy resections of the same patients as in group a (n=9); and group c) resections without chemotherapy (n=18). We compared non-treated biopsies and resections (groups a and c) to post-chemotherapy resections (group b). Cases were evaluated for treatment effects (epithelial-stromal ratio, old hemorrhage, intratumoural lymphocytes, blood vessel proliferation, tumour necrosis, bizarre nuclei, giant cell reaction, foamy macrophages, ballooning and cholesterol clefts); treatment response (none, minimal or marked) and grading (Silverberg).
Results: The epithelial to stromal ratio was increased in all treated cases and correlated with the degree of treatment response (p=0.0005). Blood vessel proliferation (+2) and old hemorrhage and hemosiderin were signifi cantly increased in all treated cases (p=0.0005 and p=0.015, respectively). Intra-tumoural lymphocytes (p=0.0001), bizarre nuclei, cholesterol clefts, giant cell reaction and foamy macrophages were nearly exclusively seen in treated cases. Four cases showed lobular carcinoma-like features.
Post-compared to pre-chemotherapy grade remained the same or increased in 6/7 cases. Bizarre nuclei were a pitfall for nuclear atypia post-treatment. Conclusions: Our study highlights specific morphological changes in serous adenocarcinomas treated with chemotherapy, which may be linked to treatment response. We identifi ed three chemotherapy associated changes not reported previously, (epithelial to stromal ratio, blood vessel proliferation and intratumoural lymphocytes). Grading post-treatment was similar to pre-treatment (remains high grade 2 or 3). Conclusions: Possible sources of continued DUB include: coagulative necrotic debris, which may persist for years; superfi cial, congested blood vessels-persistent and viable even after the remainder of the endometrium is ablated; re-epithelialization of the endometrium via adenomyosis; endometriosis associated with proximal dilatation of the fallopian tube after ligation; and residual endometrium present due to spared cornual regions, ablated LUS only, or irregular ablation due to submucosal leiomyoma. All (11/11) of CCC were positive for HNF-1β and showed a diffuse pattern. None (0/11) of the SC showed immunoreactivity for HNF-1β. In the cases of MSC, both the serous and clear cell components were negative for HNF-1β.
PTEN Status and Frequency of Endometrioid Carcinoma and Its Precursors Arising in Functional Secretory
Conclusions:
HNF-1β appears to be a sensitive and specifi c marker for CCC and is not expressed in SC with clear cell change. The pattern of immunoreactivity of HNF-1β in tumors with both serous and clear cell changes supports the conclusion that MSC are SC with clear cells. Background: The JAZF1-JJAZ1 fusion transcript has been identifi ed in approximately 80% of endometrial stromal nodules, 60% of endometrial stromal sarcomas and 20% of undifferentiated uterine sarcomas. Because the malignancy of these sarcomas is believed to increase over time, with a subset of stromal nodules developing into stromal sarcomas, and a subset of these tumors developing into undifferentiated stromal sarcomas, early detection and diagnosis is crucial. Our hypothesis is that the fusion transcript may be present and identifi able in endometrial biopsy material years prior to the clinical presentation of a uterine mass. Design: Formalin fi xed paraffi n embedded tumor material was retrospectively identifi ed in the archives of the Karolinska University Hospital. Cases were included in this study if the JAZF1-JJAZ1 fusion transcript was identifi ed in the endometrial stromal tumor (EST) material and there was one or more prehysterectomy endometrial biopsy available for analysis. The fusion transcript was detected through real-time PCR. Results: Two patients were identifi ed where the fusion transcript could be detected in the EST (diagnosed at the time of hysterectomy) and where there was an earlier endometrial biopsy performed for another indication. H&E review of both biopsies revealed no histologic evidence for the presence of an EST. In one patient, an endometrial curettage was performed for dysfunctional uterine bleeding 5 years prior to the diagnosis of the EST. The JAZF1-JJAZ1 fusion transcript was identifi ed in this biopsy material. In the second patient an endometrial curettage was performed 6 years prior to hysterectomy for an EST. No fusion transcript was identifi ed in this material. Background: Pigmented lesions of the uterine cervix (UC) are rarely encountered and represent a wide spectrum of congenital, reactive and neoplastic conditions. Design: We conducted a prospective study of 2,118 consecutive hysterectomy specimens from 02/2010 to 08/2011which uncovered by routine gross inspection a total of 32 pigmented lesions of the UC. Results: Of the 32 grossly visible pigmented lesions of the UC, routine histology revealed 31 histologic correlates including 25 (81%) blue nevi, 1 (3%) lentigo / melanosis, 1 (3%) focal vasculitis, 2 (6.4%) previous biopsy site reactive lesions with hemosiderin-laden macrophages, 1 (3%) hemorrhagic Nabothian's cyst, 1 (3%) hemangioma, and 1 (3%) case of multinucleated giant cell reaction to India-ink like material. Almost one third of the cases required deeper levels to reveal the nature of the pigmented lesions (9/31). The overall incidence of blue nevus in the UC was 1.2 %. More than half of the patients were Caucasians (13/25, 52%). The mean age of the UC blue nevus patients was 47.4 years (range 31 to 64 years). The number of blue nevi per UC varied between 1 to 3 and the size ranged from 0.1 cm to 2 cm (mean : 0.68 cm). All UC blue nevi were located in the stroma of the endocervix. These blue nevi of the UC appeared to evolve through 3 distinct morphologic phases: 1-stromal melanocytic foci composed of fi ne spindle cells (9/25, 36%), 2-mixed phase with fi ne spindle, plump spindle, and epithelioid cells (15/25, 60%), and 3-nevus-like with epithelioid cells (1/25, 4%). Of note, all (100%) of UC blue nevi cases were not reported in the original hysterectomy surgical pathology report or were misinterpreted as biopsy site. Compared to blue nevus, lentigo of the cervix was signifi cantly less common and located in the squamous mucosa of the ectocervix. Lentigo of the UC was characterized by hyperpigmentation of the basal keratinocytes admixed with scattered slightly enlarged melanocytes. Conclusions: This study demonstrates that most grossly visible pigmented lesions of the UC are benign and have a histologic correlate. Therefore, careful macroscopic and microscopic examination, in many cases with the help of deeper levels, is required to characterize these pigmented lesions and facilitate the exclusion of a more ominous pathologic process such as UC malignant melanoma. Background: While single umbilical artery (SUA) has an overall incidence of 1%, isolated SUA (iSUA) occurs in only 0.37-0.5% of pregnancies. Isolated SUA is independently associated with fetal intrauterine growth restriction (IUGR), prematurity, multiple gestations, and maternal chronic (CHTN) or gestational hypertension (GH) and diabetes mellitus (DM). It is of questionable clinical signifi cance in the newborn period and has not been associated with long term, adverse growth and neurologic outcomes. However, we queried whether noninfectious placental pathologies seen with CHTN, GH, DM, and placental dysfunction, and/or those fetal conditions linked to adult onset cardiovascular and chronic renal diseases were more common with iSUA. Design: A retrospective review of all institutional placental and previable fetoplacental (gestational age <20 wk) surgical pathology accessions from 1/01/2006 to 12/31/2010 was undertaken. Patient demographics, obstetrical history and pathologic diagnoses were extracted from the medical records.
Results: There were 6534 cases with evaluable umbilical cords. Overall incidences of SUA and iSUA were 3.2% (n=211) and 1.9% (n=110) respectively, with iSUA significantly associated with multiple births (p=0.011), CHTN (p=0.0270), GH (p=0.032), DM (p=0.023), IUGR (p=<.002), low placental weight (p=<.002), and noncentral cord insertion (p=0.001) compared to normal cords. Chronic chorionic villous (CV) ischemia was signifi cantly more common in singleton placentas with iSUA versus 3-vessel cord cases (p=0.024); CV infarction was more frequent, but the difference was not signifi cant (19.4% versus 14.4%, p=0.178) . In singletons with non-central cord insertion and CHTN, DM, and/or GH, 82.4% of iSUA cases had CV ischemia versus 65.0% with 3-vessel cords (p=0.249) . No association with prematurity, fetal thrombotic vasculopathy (FTV), or villitis of unknown etiology (VUE) was found.
We confi rmed the association of iSUA with IUGR, multiple birth, CHTN, DM, and GH. We found signifi cant independent association between iSUA and chronic CV ischemia and an increased rate of CV infarction; however, no signifi cant association was found for preterm birth, FTV or VUE. The higher rate of CV ischemia after controlling for insertion site and CHTN, GH, and DM suggests that iSUA cord placentas may be more susceptible to ischemia than 3-vessel cord placentas. The higher association with CV infarction did not reach statistical signifi cance, possibly due to sampling. Background: Lynch Syndrome is associated with a >40% risk of developing endometrial carcinoma, with quite variable frequency of the different histologic subtypes reported, including high-grade endometrioid carcinomas (EEC), clear cell and serous carcinomas. Recently, an increased incidence of clear cell carcinomas (CCC) of the ovary has also been described in the setting of Lynch Syndrome. However, no large series of endometrial CCC have been studied. The goals of this study are to evaluate the overall incidence of loss of DNA mismatch repair (MMR) protein expression in a series of endometrial clear cell carcinomas and its potential association with Lynch Syndrome. Design: After IRB approval, 41 endometrial CCC were retrieved from our fi les from 1986 till 2010. All available H&E slides (2-12 per case) were reviewed by two gynecologic pathologists and clinicopathologic parameters were recorded. Immunohistochemical expression of MMR proteins (MLH1, MSH2, MSH6, and PMS2) was assessed. Results: The mean age of the patients was 67.8 years (range: 40-92; 5 patients < 50). Twenty patients were diagnosed at early stage (FIGO I and II) , and 21 at advanced stage (FIGO III and IV) . Combined loss of MLH1 and PMS2 expression was seen in 2 patients (40 and 59 years), while combined loss of MSH2 and MSH6 expression was seen in 2 other patients (46 and 48 years). A predominant solid growth was seen in 3/4 tumors (also present in 8/37 CCC with preserved MMR proteins) and abundant peri-and intratumoral lymphoplasmacytic infi ltrate in 2/4 (both with absent MSH2/ MSH6) (also seen in 9/37 CCC with preserved MMR proteins). All 4 patients were diagnosed with FIGO IA tumors, and had no evidence of disease with a mean followup of 148 months (range: 80-220). None of these 4 patients had metachronous ovarian or colorectal carcinoma. Eleven out of the other 16 patients with early stage CCC also had no evidence of disease with a mean follow-up of 96 months (range: 6-205). Two patients with a history of colorectal carcinoma had preserved MMR protein expression and advanced stage CCC. Conclusions: In this study, the overall frequency of DNA MMR protein abnormalities in endometrial CCC is relatively low (4/41; 9.8%) compared to a mean of 25% reported in EEC. Among patients aged ≤ 50 in our cohort, 3/5 (60%) showed loss of DNA MMR protein expression and they did not have high-stage tumors, however, clinical behavior was similar to patients without abnormal MMR protein profi le, and they had not developed other evidence of Lynch Syndrome. benign) were compared for mutation, ethnicity, age at RRSO, prevalence of breast CA, and age at diagnosis of breast CA. Results: 14(6.7%) of the 210 RRSO from BRCA+ women had OGC and 196 RRSO were benign. OGC was present in 13(6.7%) of 194 RRSO that had been serially sectioned and entirely submitted for microscopy and in 1(6.3%) of 16 RRSO that had routine sectioning and sampling. Women with OGC ranged from 43 to 76 years in age at RRSO, 10(71.3%) were of Ashkenazi Jewish descent, 12(85.7%) were BRCA1+ and 2(14.3%) were BRCA2+. The OGC included serous tubal intraepithelial carcinoma/STIC (8), invasive tubal CA (2), STIC and bilateral ovarian CA (1), ovarian CA [bilateral (1); unilateral (1)], and primary peritoneal CA (1). STICs were the most frequent tumors, measured up to 0.3 cm, and involved the distal tube/fi mbria. Most STICs were unifocal. All OGC were serous and high grade. The largest tumor was a 4 cm tubal CA. Post RRSO followup (4 to 114 mos) is available in 13 OGC cases;no followup is available in one case. Two women with stages II and III CA at RRSO had recurrent CA at 21 and 28 months, respectively. Of the 8 women who had only STIC at RRSO, 6 have had no recurrence, 1 returned with mullerian CA in an isolated celiac lymph node at 32 months, and 1 was diagnosed with stage 3 peritoneal CA at 42 months. In both cases, the adnexa had been entirely submitted for microscopy and the excised uterus/cervix were benign. When the OGC and the benign groups were compared, there was a signifi cant difference in the mean age at RRSO (55.9 vs 48.4 yrs, respectively p=0.0085). No signifi cant difference (p>0.05) was observed in the prevalence of BRCA1 mutation, Ashkenazi Jewish origin, or breast CA, or in the mean age at breast CA diagnosis between the two groups. Conclusions: -OGC was present in 6.7% of asymptomatic BRCA+ women who underwent prophylactic RRSO.
-STIC is the most frequent OGC diagnosed in these women.
-Women with OGC, even if confi ned to STIC when found at prophylactic RRSO, warrant ongoing surveillance for CA.
Evaluation of Histological Types of Endometrial Carcinomas:
Experiences from Endometrial Biopsies of 358 Consultation Cases J-J Wei, P Keh. Northwestern University, Chicago, IL. Background: Uterine serous carcinoma (USC, type II), accounts for 10% of all endometrial cancers, and is more aggressive than the endometrioid cancer (EMC, type I). Since USC has a higher propensity for lymphovascular invasion, extrauterine spread than EMC, meticulous staging is important. For this reason, accurate diagnosis of the tumor type for endometrial carcinomas in endometrial biopsies/curetting specimen is particularly valuable for surgical management. While consultation of endometrial neoplasm biopsies is a standard protocol in gyn-oncology practice, the value and importance of agreeing upon the type of endometrial carcinoma deserve further investigation. Design: A total of 358 biopsies of endometrial carcinomas were reviewed from the last three years of consultation records. The cases were from 49 hospitals, medical centers and private groups. Patients' ages ranged from 19 to 86 years old. For those cases with no agreement upon the type of endometrial carcinomas between the original diagnosis and consultation, one or more relevant immunomarkers were examined, including b-Catenin, CEA, cytokeratin, ER, PR, P16, P53, Vimentin, and WT1. Most cases with revised diagnoses for tumor types were further correlated with hysterectomy specimen. Results: Among the 358 endometrial carcinomas, original diagnoses of type I carcinoma accounted for 91% of cases (327/358) and type II carcinoma for 9% (31 cases). A total of 41 cases (11.5%) were questioned for tumor type based on histology alone. All 41 cases were further examined by immunohistochemistry. Of the 41 cases, 36 cases (10.1%) were reclassifi ed based on histology and immunohistochemistry (10 cases were changed from USC to EMC; 18 cases from EMC to USC; 8 cases resulted in various other outcomes (clear cell vs Secretory or squamous differentiation; Carcinosarcoma vs EMC with dedifferentiated; endometrial EMC vs cervical usual type) and 5 cases (1.4%) remained undetermined. Conclusions: Overall, 10% of endometrial carcinoma cases from our consultation were reclassifi ed. Interpretation of type I and II endometrial carcinomas remains a common problem in general practice. Common errors include: 1) lack of awareness of the importance of tumor types; 2) bias towards a single histologic feature, 3) sole reliance upon p53; 4) lack of examination of relevant immunomarkers. In addition, there are a small proportion of endometrial carcinomas that have a low grade 'endometrioid' appearance, aggressive growth behavior and inconclusive immunostains. Further clinical and molecular studies may help defi ne the nature of these tumors. Background: Diagnosis of EIN in a background of secretory endometrium (SE) is diffi cult due to gland crowding. In addition, a rare variant of EIN with secretory features has been suggested. In this study, we evaluated the histologic features of this uncommon and diffi cult to diagnose entity and evaluated the distinction between SEIN and other types of EIN from SE. Design: 77 endometrial biopsies diagnosed as hyperplasia (all types, WHO criteria) were evaluated using EIN criteria. We searched for cases of possible SEIN, as well as EIN associated with a background of SE. Histologic features (including luminal complexity and cytoplasmic and nuclear features) were evaluated in all cases. PAX2 staining was performed on all available blocks to investigate previous claims that PAX2 may aid in the diagnosis of EIN. PAX2 staining was defi ned as 3+ (strong nuclear staining, >90% nuclei), 2+ (weak nuclear staining, >50% nuclei), or 1+ (faint nuclear staining, <50% nuclei).
Results: Of the 77 cases, 3 (4%) were classifi ed as SEIN. The defi ning features included luminal complexity; vacuolated, voluminous cytoplasm; nuclear overlap and vesicular chromatin. SEIN is distinct from SE because the glands are larger, more complex, and haphazardly arranged. Three additional cases were classifed as EIN arising in a background of SE. These lesions were histologically distinct from SEIN because the neoplastic glands lack luminal complexity and resemble proliferative glands, but they arose in a background of SE. Luminal secretions were present in both types of EIN. Lesional EIN tissue was available for PAX2 staining in 5 cases. All cases of EIN showed altered PAX2 staining compared to background non-neoplastic glands, which are strongly PAX2 positive. Three cases showed negative PAX2 staining in EIN. One case showed increased EIN PAX2 staining compared to the background. The remaining case showed decreased EIN PAX2 staining (2+) compared to normal glands. Five of the six EIN cases were treated with hormones, with negative subsequent samples (rebiopsy or hysterectomy). On follow-up, all EIN cases had no evidence of disease (mean: 7 months). Conclusions: This is the fi rst detailed description of SEIN, which is an uncommon lesion distinct from traditional EIN, and its distinction from SE using both histologic criteria and PAX2 staining. All EIN (including SEIN) displayed altered PAX2 staining when compared to normal glands, primarily negative or decreased staining. Hormone therapy appears to be effective in treating EIN, although follow-up in this study is short. Background: FIGO grade 2 EEC carries a 88% fi ve year survival rate. They are defi ned by >5% but <50% solid epithelial component. A small subset may display <5% solid growth, but display marked nuclear atypia and are therefore designated grade 2. We compared tumor characteristics, staging, and clinical outcome of patients with architectural versus atypia defi ned grade 2 EEC. Design: 154 cases of grade 2 EEC were reviewed to confi rm grade; percent solid growth, and presence/absence of atypia. Only marked atypia (characterized by signifi cant nuclear pleomorphism identifi able at low power magnifi cation or a pattern of enlarged nuclei, 1.5-2 x normal, with irregular nuclear contours, dispersed chromatin and prominently enlarged nucleoli) increased the FIGO grade one level. Depth of invasion, tumor stage, lymph node status and clinical outcomes were then compared. Results: 154 cases were evaluated. 23 were eliminated based on review (6 to grade 3, 17 to grade 1). Of the remaining 131 FIGO II cases, 19 (15%) were grade 2 based on the presence of severe atypia and 112 (85%) met the architecturally defi ned criteria (Tables 1 & 2 Conclusions: Atypia defi ned vs. architecturally defi ned grade 2 ECC's show no signifi cant difference in stage and prognosis. An increase in grade based on presence of nuclear atypia stratifi es patients at increased risk since 89% of these patients have myoinvasion at the time of hysterectomy which is in distinct contrast to our previous study (Mod Path 24 (1), 2011; 264A, Abstract 1119) where 70% of Grade I cases were non-invasive. No signifi cant correlation between percentage of solid component and risk of recurrence was identifi ed in this study.
Negative Loop Electrosurgical Cone Biopsy Following a Biopsy
Diagnosis of High-Grade Squamous Intraepithelial Lesion: Frequency and Clinical Signifi cance BL Witt, RE Factor, EA Jarboe, LJ Layfi eld. University of Utah School of Medicine, Salt Lake City, UT; ARUP Laboratories, Salt Lake City, UT. Background: Loop electrosurgical excision procedure (LEEP) is a therapeutic option following a biopsy diagnosis of high-grade squamous intraepithelial lesion (HSIL). Most LEEPs confi rm the HSIL biopsy diagnosis but some will not show HSIL or carcinoma. Such negative fi ndings suggest the possibility of an incorrect biopsy diagnosis, removal of the lesion by biopsy or insuffi cient LEEP sampling. We studied a series of LEEPs to determine the frequency of negative LEEPs after HSIL biopsies and the clinical follow-up of these negative LEEPs. Design: The Department of Pathology's records were searched for all patients undergoing LEEP who had prior cervical biopsies and subsequent clinical follow-up. Results: Three hundred seventy-eight women were found who had index cervical biopsies, subsequent LEEPs and clinical follow-up. Clinical follow-up averaged 25.8 months. Three hundred seven women had HSIL on biopsy with 234 (76%) showing HSIL or carcinoma on LEEP and 73 (24%) LEEPs being negative or disclosing low-grade squamous intraepithelial lesion (LSIL) on LEEP. Thirty-two of 223 (14%) patients with the most superfi cial aspect of endometrioid carcinomas (EC) and impart the appearance of a 'maturational' phenomenon at the surface of the cancer. SECs typically show bland mucinous, syncytial, squamoid, and papillary features that mimic a variety of benign entities, particularly endocervical microglandular hyperplasia. Studies have reported SECs to be associated with approximately half of ECs many of which showed focal mucinous differentiation. Therefore, despite their morphologically benign histology, some workers have questioned whether the presence of SECs represents a 'marker' for an underlying malignancy. Since the biologic nature of SECs is unknown, we aimed to study the prevalence of K-ras gene mutations in SECs and the underlying EC from which they directly arise. Design: 14 cases with biopsy proven SECs and ECs in their subsequent hysterectomies were retrieved from our institutional archives. In 8 of 14 cases, only SECs were present in the endometrial biopsy but ECs were found in each uterine corpus after hysterectomy. 6 endometrial samplings showed concomitant SECs and ECs. All tumors associated with SECs were so-called 'type 1' ECs. Genomic DNA, derived from microdissected SECs and ECs to ensure >80% lesional cells, was extracted from formalin-fi xed paraffi n-embedded tissue sections. PCR amplifi cation for K-ras codons 12 and 13 was performed with subsequent sequencing by capillary electrophoresis. Results: K-ras codons 12 and 13 mutations were detected in 11 of 14 (78%) SECs and 11 of 14 (78%) ECs. 9 of 11 point mutations were identifi ed at codon 12 with the most prevalent mutation (4 of 9) being G12D (codon 12; GGT > GAT). Only 2 point mutations were seen at codon 13, both being G13D. All SECs had the same k-ras mutation as their underlying EC. Conclusions: 78% of cases with SECs had K-ras mutations, and in each case the mutation in the SECs was identical to that in the associated underlying ECs. These fi ndings strongly suggest that SECs, despite their bland appearance and varied histology, are neoplastic surface manifestions of the underlying EC. Therefore, their presence in endometrial biopsies/curettages, particularly in postmenopausal women, should raise suspicion for an associated EC.
1269 Array CGH Analysis Reveals Amplifi cation of Met and AKT2 in Clear Cell Carcinoma of the Ovary Y Yamashita, S Akatsuka, Y Yatabe, S Toyokuni. Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan. Background: Clear cell carcinoma of the ovary (OCCC) is a chemo-resistant tumor with relatively worse prognosis and is frequently associated with endometriosis. Frequent mutations of the ARID1A gene and activating mutations of the PI3CA gene are reported in OCCC, but positive array CGH results for specifi c gene amplifi cation have rarely been reported. Design: In this study, we performed an array CGH analysis using formalin-fi xed, paraffi n-embedded samples from 13 OCCC patients to comprehensively evaluate gene copy number changes in OCCC samples. We also performed Taqman gene copy number analysis, fl uorescence in situ hybridization, immunoblotting, and immunohistochemistry to confi rm the array CGH results. Results: Array CGH analysis revealed that Met gene amplifi cation was present in 4 / 13 OCCC patients and 2 / 8 OCCC cell lines. Amplifi cation of the AKT2 gene, which is a component of one of the downstream signaling pathway of Met together with PI3CA, was also detected in 3 / 13 OCCC patients and 2 / 8 OCCC cell lines. Totally 73 OCCC cases were examined by Taqman PCR for Met amplifi cation, and 37.0% revealed to have Met gene amplifi cation (>4 copies). Furthermore, stage 1 and 2 patients with Met gene amplifi cation had signifi cantly worse overall survival than patients without Met gene amplifi cation (p=0.037). Conclusions: We demonstrated for the fi rst time Met and AKT2 amplifi cation by array CGH in approximately half of the OCCC cases. Met amplifi cation was signifi cantly related to worse prognosis. Activation of the Met/PI3CA/AKT pathway may be one of the most important molecular events in OCCC carcinogenesis. Background: HPV L1 produces capsid protein to protect the viral genome and confer contagiosity. It is mainly expressed in the episomal stage and its expression is suppressed after HPV integrated in host genome. HPV L1 expression is inversely correlated with the expression of E6 and E7 oncoproteins. Elevation of E7 and subsequent degradation of pRb in turn triggers p16 overexpression. AIN is a precursor of the anal squamous carcinoma linked to HPV infection. Histopathologically, it is often challenging to accurately grade AIN. To investigate the role of HPV L1 and p16 in anal dysplasia, we studied the immunohistochemical co-expression patterns of HPV L1 and p16 in anal condyloma, AIN1 and AIN2-3 lesions. Design: Anal biopsies with condyloma and AIN were retrieved and histologically reviewed. Expression of nuclear HPV L1 was studied using combined immunohistochemistry and in situ hybridization technique from Advanced Medical. p16 immunohistochemistry was performed using Ventana antibody. Only diffuse, fullthickness nuclear and cytoplasmic p16 staining was considered as positive. Patch p16 cstaining was excluded in this study. Results: Co-expression of HPV L1 and p16 was analyzed in 53 anal lesions, including 10 condylomas, 21 AIN1 and 22 AIN2-3. There were 18 cases immunoreactive to HPV L1 and 23 cases showing p16 positivity. The immunostaining patterns of both HPV L1 and p16 are tabulated below. Briefl y, expression of HPV L1 and p16 diffuse staining pattern was mutually exclusive in all the cases except one, which showed focal high grade AIN2 in a background of extensive AIN1. Expression of HPV L1 but lack of p16 expression was seen in 70% condyloma and 47.6% of AIN1, but none of AIN2-3 lesions. In contrast, diffuse p16 expression with lack of HPV L1 staining was seen in all high grade AIN and only in 4.7% (1/21) of AIN2-3. None of the condyloma cases showed diffuse p16 staining. Lack of both HPV L1 and p16 expression was seen in 30% of condyloma and 47.6% of AIN1. Conclusions: Our study indicates that the expression of HPV L1 and p16 is mutually exclusive in a majority of anal condyloma and AIN. Expression of HPV L1 represents a biological episomal stage and usually seen in low grade lesions and diffuse p16 expression represents an integrated stage of malignant transformation. Our data suggests that application of both HPV L1 and p16 biomarkers can not only facilitate accurate grading of AIN, but also add risk assessment value of the anal lesion. Background: Two commonly used procedures in the assessment of abnormal uterine bleeding are dilation & curettage and biopsy. As the latter gradually gains in popularity, pathologists face the increasing challenge of making a diagnosis on minute material. In certain instances, the sample is so minimal that pathologists report it as "insuffi cient for diagnosis". Such report triggers either repeat sampling, follow-up, or even, hysterectomy. Alarmingly, a considerable percentage of patients are lost to follow-up and remain undiagnosed. Therefore, accurate triage of these patients is critical and yet remains problematic. Here we reporte the clinical outcome of 406 such patients at our institute over the past six years. Design: UMASS database (2005-2010) was searched. The patients' follow-up data extracted from medical records. Histological slides are reviewed.
Results:
Result details are showed in Figure 1 . A total of 10,800 endometrial biopsies and 4150 curettages were received. "Insuffi cient" or "nondiagnostic" was reported in 406 cases (3%), including 321 biopsies and 85 curettages. 212 patients were lost to follow-up. The remaining 175 patients repeated sampling. 60 (34%) remained undiagnosed. The other 115 (66 %) acquired a diagnosis: 108 (94%) benign, seven (6%) malignancy. Ninteen patients underwent hysterectomy directly. The outcomes were sixteen benign, three malignancy. In total, ten patients (5%) were found malignancy with additional procedures. Thirty-six cases reported "rare atypical cells" in additional to "insuffi cient tissue". Immunostaining (p53, Ki67) are performed but remain inconclusive. These resulted in 10 patients re-sampling; 12 hysterectomy; 12 lost to follow-up. The outcomes were seven (31%) benign, two (9%) atypical complex hyperplasia, one (4.5%) cervical adenocarcinoma, ten (45%) endometrioid adenocarcinomas, two (9%) serous carcinomas. Conclusions: Our results outline the potential outcomes of patients with non-diagnostic endometrial sample. A small but signifi cant portion of these patients has malignancy (5%). If rare atypical cells present, the chance of malignancy is signifi cantly higher (69%). For the adequate management of these patients, it is critical to be aware of the risk and to clearly communicate the uncertainty in these cases. 
